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Amyotrophic lateral sclerosis (ALS) is a devastating, progressive, and fatal 
neurodegenerative disease.  Despite the fact that ALS is the most common motor neuron 
disease in adulthood, there is no effective treatment for the disease.  Although most ALS 
cases (90-95%) are sporadic (sALS), the remaining cases (5-10%) are dominantly inherited 
and referred to as familial ALS (fALS). Because sALS and fALS show indistinguishable 
disease symptoms, a common disease mechanism has been proposed.  After the discovery of 
the link between fALS and mutants of cytosolic Cu/Zn superoxide dismutase (SOD1), over 
140 mutations in SOD1 have been identified to account for ~20% of fALS.  The location of 
these mutants are scattered throughout the primary and tertiary structures of the protein.  It is 
widely accepted that fALS-linked mutations in SOD1 result in a gain of toxic function to 
cause the disease, rather than a loss of physiological function, although the nature of the toxic 
mechanism remains unclear.  
SOD1 is a -rich, homodimeric metalloenzyme that catalyzes the dismutation of 
superoxide radicals to O2 and H2O2.  The protein is ubiquitously expressed and the mature 
form of SOD1 (holo SOD1) contains one catalytic Cu ion, one structural Zn ion, one intra-
molecular disulfide bond (between C57 and C146) and two free Cys residues (C6 and C111) 
per 153 residue subunit.  Analogous to many different human diseases in which protein 
aggregation is a hallmark, aggregation of Cu/Zn superoxide dismutase (SOD1) is implicated 
in the pathogenesis of ALS.  This thesis reports the first observation of aggregation of the 
most abundant form of SOD1 in vivo, the native, metallated (holo) dimer, under 
physiologically relevant conditions (37 °C and pH 7.8).  The medical relevance of aggregates 
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is demonstrated by structural and tinctorial analyses as well as the novel observation of 
binding of an anti-SOD1 antibody that specifically recognizes pathological aggregates in 
ALS.  Additionally, ALS-associated SOD1 mutations promote aggregation but are not 
required, supporting a common mechanism in familial and sporadic ALS.  The aggregation is 
characterized by a lag phase, which is diminished by self- and cross-seeding where 
heterogeneous nucleation is the underlying mechanism.  Moreover, multiple pathways of 
aggregation are elucidated including dimer dissociation and metal loss.  It is shown that if 
holo SOD1 loses more Zn ions than Cu ions, the aggregation profiles have shorter duration 
and lower final intensity, whereas when holo SOD1 loses more Cu ions than Zn ions, the 
aggregation profiles have longer duration and higher intensity.  Taken together, the data in 
this thesis establish a valuable system for understanding SOD1 aggregation and toxicity 
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1.1 Cu/Zn Superoxide Dismutase (SOD) 
1.1.1 SODs 
Reactive oxygen species (ROS), such as superoxide and hydroxyl radicals have been 
shown to be toxic due to their high reactivity due to the presence of unpaired electrons.  
Therefore, it is crucial for a living cell to regulate ROS homeostasis (Lenaz, 1998).  
Superoxide is formed mainly on the matrix side of the inner mitochondrial membrane as a 
byproduct of respiration (Fridovich, 1986).  In addition, superoxide can be formed 
enzymatically by enzymes such as xanthine oxidase, aldehyde oxidase, dihydrorotic 
dehydrogenase, and flavoprotein dehydrogenases (for a review see (Fridovich, 1975)).  To 
prevent cellular damage arising from superoxide reactivity, cells have evolved a number of 
defense mechanisms to limit the levels of superoxide.  One such mechanism involves 
conversion of superoxide (O2
-
) into diatomic oxygen (O2) and hydrogen peroxide (H2O2), a 
reaction that is catalyzed by superoxide dismutases (SODs).   
SODs exist in both prokaryotic and eukaryotic cells where they perform the same 
function but possess different catalytic cofactors.  These include: Cu/Zn SOD (Cu
2+
 is the 
metal involved in catalytic reactions), Mn SOD, Fe SOD, and Ni SOD.  Mn SOD is found 
mostly in the matrix of mitochondria in eukaryotic cells and in bacteria (Barondeau et al, 
2004).  Although Mn SODs from bacteria and eukaryotic cells bind the same metal, the 
tertiary structure of the proteins are different; the former is dimeric with a molecular weight 
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of 40 kDa, while the latter is tetrameric with a molecular weight of 80 kDa.  SOD2 refers to 
Mn SOD in the matrix of mitochondria from eukaryotic cells (Zelko et al, 2002).  The theory 
that mitochondria developed from a prokaryote that entered into an eukaryotic cell is 
powerfully supported by this finding (Fridovic.I, 1974).  Fe SOD is found in the cytosol of 
cyanobacteria, in the periplasmic space of bacteria, and in the chloroplast stomata of most 
eukaryotic algae (Grace, 1990).  Cu/Zn SOD found in the cytosol of eukaryotic cells is called 
SOD1.  Recently, Cu/Zn SOD has also been identified in the extracellular matrix of 
eukaryotic cells, and has been referred to as SOD3.  The sequences of SOD1 and SOD3 are 
homologous but the structures differ in that SOD1 is a dimeric protein, whereas SOD3 is a 
tetramer (Zelko, Mariani & Folz, 2002).  In addition, Cu/Zn SOD is also found in bacteria 
(Puget & Michelso.Am, 1974).  However, the structure of Cu/Zn SOD from Escherichia coli 
(E. coli) is monomeric, resulting from the substitution of hydrophobic residues with charged 
residues at positions located in the dimer interface of the human enzyme (Battistoni, 2003).  
Most recently, a completely distinct third SOD class, hexameric Ni SOD was  discovered in 
Streptomyces (Youn et al, 1996) and cyanobacteria (Plakoutsi et al, 2005).  To summarize, 
humans have three different SODs: SOD1, SOD2, and SOD3 which vary in location but all 
act on superoxide (Zelko, Mariani & Folz, 2002).  The focus of this thesis is SOD1, which 




1.1.2 SOD1 structure 
SOD1 is a homodimeric metalloenzyme with a molecular weight of 32 kDa, in which 
each subunit contains 153 residues, one Cu ion, one Zn ion, two free cysteines (C6 and 
C111), and one intramolecular disulfide bond between C57 and C146.  Human SOD1 
(hSOD1) was crystallized in 1986, and the structure was determined at a resolution of 2.0 Å 
(Parge et al, 1986; Parge et al, 1992).  In 2003, the structure was solved to a higher resolution 
of 1.78 Å (Strange et al, 2003).  More recently, the crystal structures of various hSOD1 
mutants, including A4V, I113T, G37R, H46R, S134N and G85R (Antonyuk et al, 2005; Cao 
et al, 2008; Hart et al, 1998; Hough et al, 2004b) and solution structures of S143N, G93A 
and G37R have also been determined (Banci et al, 2003; Banci et al, 2005; Banci et al, 
2007a; Shipp et al, 2003).   
Fig. 1.1 illustrates key structural features of SOD1.  These features include: a Greek 
key domain, two long functional loops, the active site, and the dimer interface.  Each subunit 
is composed of eight antiparallel β strands that form a Greek key motif (Fig. 1.1b) 
resembling a flattened cylinder.  Seven loops connect the strands:  Loop I, residues 12–15; 
loop II, residues 23-28; loop III, residues 38-40; loop IV, residues 47-82; loop V, residues 
90-93; loop VI,  residues 102-114; and loop VII, residues 121-143 (Parge, Hallewell & 
Tainer, 1992).  Loop IV and VII play central roles in enzymatic function.  Loop IV is 
composed of three different sections that are defined as follows: the dimer interface section 
(residues 49-54), the disulfide bond section (residues 55-61) and the Zn binding section 
(residues 62-82) (Hornberg et al, 2007).  Loop VII is called the electrostatic loop and is 
involved in guiding the superoxide substrate into the active site (Getzoff et al, 1992a).  These 
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loops (loop IV and VII) also contain residues that form salt bridges which help maintain the 
native structure. For example, salt bridges form between residues Asp 76 and Lys 128, Asp 
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Figure 1.1 Structure of human Cu/Zn SOD1   
(a) Ribbon representation of dimeric Cu/Zn SOD1 (pdb code 1SOS) was made using Molmol 
(Koradi et al, 1996).  Eight β-stands are represented by cyan arrows and labeled β1 – β8, 
whereas short helical structures within loops are represented in red.  5 loops (loop I-III, V, 
and VI) connecting the β strands are colored gray and labeled in Roman numerals.  Loop IV 
is composed of three different regions: the dimer interface region (residues 47-54); the 
disulfide bond region (residues 55-61); and the Zn binding region (residues 62-82).  These 
regions are coloured magenta, red, and blue, respectively (Hornberg, Logan, Marklund & 
Oliveberg, 2007).  The electrostatic loop, loop VII (residues 121-144) is coloured dark 
orange. The overall shape of each subunit resembles a flattened cylinder.  Cu and Zn ions are 
shown as orange and black spheres, respectively.  The intra-subunit disulfide bond between 
C57 and C146 is indicated by red spheres.  The image is based on the crystal structure of the 
C6A/C111S recombinant hSOD1, which exhibits a very similar structure with the wild type 
of hSOD1 (Lepock et al, 1990; Parge, Hallewell & Tainer, 1992).  (b) The Greek-key motif 
of a monomer SOD1 is shown using 8 arrows to represent the 8 β strands.  The strands are 
labeled β1-β8 and the loops connecting the strands are labeled with Roman numerals (I-VII).  




The Cu and Zn binding sites in hSOD1 (Fig. 1.2) are close in space and share an 
imidazolate ligand (His 63).  In addition to His 63, the Zn ion is coordinated in an 
approximately tetrahedral geometry by His 71, His 80, and the aspartyl side chain of Asp 83.  
The Cu ion is coordinated in an irregular five coordinate geometry by His 46, His 48, His 
120, a water molecule, and the shared His 63 ligand.  In addition, a secondary hydrogen bond 
network stabilizes and interconnects the metal binding regions of the electrostatic loop via 

















Figure 1.2 The active site of hSOD1 
An illustration of the structure of hSOD1, made using pdb code 1SOS in Viewerlite 5.0, is 
shown with the active site (a).  The box in (a) is expanded in (b).  The residues (black) that 
are involved in the coordination of Cu (orange sphere) and Zn (blue sphere) ions are shown.  
The interaction between the metals and the various amino acids are represented in dots 
(magenta).  4 residues (His 80, His 71, His 63 and Asp 82) coordinate the Zn ion, whereas 
the Cu ion is coordinated by 4 residues (His 46, His 48, His 63, His 120) and a water 
molecule (not shown).  His 63 acts as a bridge between Cu and Zn ions.  The image is based 
on the crystal structure of the C6A/C111S recombinant hSOD1.  
 
Within the dimer, the forces contributing to the strong dimer interface are 
hydrophobic interaction and hydrophilic interactions, which include hydrogen bonding 
between two subunits and a number of hydrophilic residues interacting through bridging 
water molecules (Getzoff et al, 1986; Getzoff et al, 1989).  Overall the dimer interface is 
formed by 10 β strand residues and 12 loop residues, with the N and C termini of each 
monomer juxtaposed near the dimer interface (Getzoff, Tainer & Olson, 1986; Getzoff et al, 
1989) (Fig.1.1).  The highly conserved residues in the dimer interface, Cys 57 and Cys 146, 
form an intramolecular disulfide bond stabilizing the dimer interface section of loop IV by 
covalently joining it to the β barrel.  Thus, one can expect that reduction of the disulfide bond 
would weaken the dimer interface, and this has been observed experimentally (Lindberg et 
al, 2004).  Additionally, Gly 51 and Gly 114 stabilize the dimer interface through the 
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hydrogen bonding to Ile 151 in the opposite subunit, so that these three residues form all four 
of the hydrogen bonds across the dimer interface (Getzoff et al, 1989).    
All of the elements described in this section: stable β domain, salt bridges, 
intramolecular disulfide bond, metal cofactors, and the strong dimer interface contribute to 
the stability of this protein.  As a consequence, SOD1 is highly resistant to denaturants, 
extreme pH and high temperatures.  For example, the enzyme is not denatured by even 8M 
urea or 1% of sodium dodecyle sulfate (SDS) (Lyons et al, 1999). SOD1 has been shown to 
be stable in the pH range of 6-11 (Senoo et al, 1988), and exhibits a high melting temperature 
that exceeds 80 °C (Lepock, Frey & Hallewell, 1990; Rodriguez et al, 2005).  Stability 
analysis of bovine SOD1 (bSOD1) shows that the dimer remains intact in 8M urea or 4% 
SDS, and the functional activity remains normal in 4% SDS or 10 M urea (Forman & 
Fridovic.I, 1973; Malinowski & Fridovich, 1979).  However, despite the stability of its native 
structure, aggregation of human SOD1 has been implicated in the pathogenesis of the 
neurodegenerative disease, amyotrophic lateral sclerosis (ALS) (see section 1.2). 
 
1.1.3 SOD activity 
As an antioxidant enzyme, SOD1 protects the cell by catalyzing  the conversion of 
superoxide into oxygen and hydrogen peroxide in the active site, where Cu
2+
 is bound 




   +   O2
–




    Eq 1.1 
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where E represents the enzyme with bound Zn
2+
.  First, the substrate is delivered to Cu
2+
 (Eq 
1.1) then the Cu
2+ 
becomes reduced to Cu
+
 through transfer of one electron from superoxide 
(Eq 1.2).  Reduction of the Cu ion changes the Cu binding site geometry from a distorted 
square pyramide to a nearly trigonal planar orientation.  This involves protonation of His 63 
which no longer coordinates Cu
+
 (Banci et al, 2002), and release of the water molecule 
involved in copper binding from the active site (for reviews see (Miller, 2004; Valentine, 
Doucette & Zittin Potter, 2005)).  In the other half of the reaction, the Cu
+
 is reoxidized when 
a second superoxide molecule is reduced and takes up two protons to form hydrogen 
peroxide (Klug et al, 1972).  Therefore overall O2 and H2O2 are produced from two 
superoxide molecules reacting with two protons at the SOD1 active site.  The hydrogen 
peroxide formed in this reaction can be disproportioned into water and oxygen by other 
enzymes including peroxiredoxins, catalase, and glutathione peroxidases (Rhee et al, 2005).  
The observed dismutation of superoxide is a first order reaction with respect to the 
concentration of superoxide.  Therefore, the reactions shown in Eq 1.2 and 1.4 are effectively 
irreversible as written. The first reaction (Eq 1.1) is rate limiting and occurs with a rate 






.  In other words, the dismutation of superoxide by SOD1 is 
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limited by the diffusion of superoxide into the SOD1 active site (Getzoff et al, 1992b; 
Getzoff et al, 1983; Klug, Fridovic.I & Rabani, 1972).   
It has been proposed that the conserved, positively charged residues in the 
electrostatic loop (loop VII) promote enzyme-substrate interaction by attracting the 
negatively charged superoxide substrate to the highly positive catalytic binding site at the 
bottom of the active site channel (Getzoff et al, 1992b; Getzoff et al, 1983).  These 
conserved residues include Lys 136, Glu 132, Glu 133, and Arg 143.  Lys 136 and Glu 132 
direct the long range approach of superoxide by forming a hydrogen bonding network while 
Glu 133, located close to the substrate binding pocket between Thr 137 and Arg 143, plays a 
role in positioning the substrate and preventing other anions from entering the binding pocket 
(Getzoff et al, 1992b; Getzoff et al, 1983).   
 
1.1.4 SOD Metallation 
The intracellular concentration of free copper has been proposed to be less than one 
free copper ion per cell (Rae et al, 1999), which suggests that copper is not inserted into 
metalloenzymes from an intracellular pool of free copper ions.  This theory is further 
supported by the fact that free copper ions are cytotoxic (Rae et al, 1999).  The involvement 
of a copper metallochaperone for the in vivo copper insertion into SOD1 was first discovered 
by Lyons et al. in 1998 (Lyons et al, 1998), in which the studying yeast mutants lacking 
LYS7 expressed a form of SOD1 that contained a single zinc ion per dimer of SOD1 .  After 
this discovery, the human copper chaperone for SOD1, CCS, was quickly cloned and 
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identified (Culotta et al, 1997).  It is worth noting that additional copper chaperones have 
been identified, including COX17 for delivery of copper to mitochondrial proteins, and 
cytochrome oxidase, HAH, and ATOX1 for copper delivery to the Golgi (for a review see 
(O'Halloran & Culotta, 2000)). 
 The largest copper metallochaperone identified to date, CCS, folds into three domains 
(Lamb et al, 1999; Schmidt et al, 1999a) and delivers a single copper ion.  The first domain 
(domain I) of CCS is near the N terminus and has a copper binding site, while the central 
domain (domain II) of CCS is homologous to its target protein, the SOD1 monomer, and 
facilitates interaction with SOD1 during copper insertion (Casareno et al, 1998; Hall et al, 
2000; Schmidt et al, 1999b).  The C terminal domain III of CCS is highly conserved among 
CCSs from different species and is positioned close to the N terminal domain I, such that 
these two domains can bind a copper ion together (Lamb et al, 1999).   
A recent study proposed mechanistic details of CCS involvement in Cu insertion and 
intramolecular disulfide bond formation during SOD1 maturation (Furukawa et al, 2004).  
Upon copper binding, CCS undergoes a conformational change in order to bind SOD1 with a 
higher affinity (Lamb et al, 1999).  The Cu-bound CCS and a disulfide reduced, Zn bound 
monomer of SOD1 form a heterodimer through interaction of domain II.  In this state, Cu
+
 is 
coordinated by two Cys residues in domain III and two Cys residues (C57 and C146) in 
SOD1, which replace the ligands from CCS domain I.  In the next step, O2 attacks the Cu
+
 
ion bound to the CCS-SOD1 complex, resulting in formation of an intermolecular disulfide 
bond between CCS and C57 of SOD1.  Additionally, the oxidation of Cu
+
 (i.e., formation of 
Cu
2+
) occurs and Cu
2+
 is transferred into the active site of the SOD1.  Next, C57 in SOD1 
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, which was bound at the outset of the reaction, is released from the 
CCS.  Due to the proper positioning of the dimer interface residues as a result of disulfide 
bond formation and metallation, the monomers released from CCS will readily form dimers.  
The proposed mechanism for the Cu insertion of SOD1 has been widely accepted, but it 
should be noted that other mechanisms may also occur (e.g., with no bound Zn (Furukawa, 
Torres & O'Halloran, 2004)).  In addition, an alternative mechanism for activating SOD1 in 
the absence of CCS is also proposed, in which the reduced form of glutathione (GSH) plays a 
key role for the insertion of copper ions (Carroll et al, 2004).  However, it remains unclear 
whether or not the copper-binding process requires zinc-bound SOD1 monomers. 
 
1.2 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a term used to cover the spectrum of 
neurodegenerative syndromes characterized by fatal and progressive muscular paralysis 
resulting from the degeneration of motor neurons in the primary motor cortex, brainstem and 
spinal cord (Boillee et al, 2006a; Wijesekera & Leigh, 2009).  The features of ALS were first 
described by French neurologist Dr. Jean Martin Charcot in 1869 (Charcot & Joffoary, 
1869).  Because of this, ALS is more commonly called Charcot’s disease in Europe.  In 
North America, it is more commonly known as Lou Gehrig’s disease, after the American 
baseball player who developed the disease in the 1930’s.  Approximately two thirds of 
patients with typical ALS show symptoms related to muscle weakness in the upper and lower 
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limbs.  Most patients go on to develop bulbar symptoms and eventually respiratory failure 
(Wijesekera & Leigh, 2009).   
 ALS occurs in sporadic (sALS) and familial (fALS) forms.  The incidence of sALS in 
the 1990’s was close to 1.9 per 100,000 people in North America.  Typically, males are 
affected more than females, with a ratio about 1.5:1, suggesting that some hormones may 
affect ALS (Worms, 2001).  The mean age of onset for sALS has been reported to be 
between 55-65 years.  Most cases of ALS are sporadic while the remaining ~10% have a 
genetic component (fALS), which is characterized by high penetrance and an autosomal 
dominant pattern of inheritance (Wijesekera & Leigh, 2009) .  Importantly, sALS and fALS 
are clinically indistinguishable, implicating similar disease mechanisms (Boillee, Vande 
Velde & Cleveland, 2006a).  Geographically, Western Pacific countries have 50 – 100 times 
higher prevalence of ALS than the rest of the world.  These countries include Guam and 
Marianas Islands (Steele & McGeer, 2008).  A recent review suggests that smoking may be 
an exogenous risk factor associated with development of ALS, while other factors such as 
occupation are not related to prevalence of ALS (Sutedja et al, 2007).  
 
1.2.1 Human ALS neuropathology 
Generally, sALS and fALS share a common essential pathological feature, which is 
the loss of both upper and lower motor neurons.  Analysis of the affected motor neurons shows 
that they contain inclusions in the perikarya, dendrites, and axons that are characteristic of 
sALS and fALS (see below).  These inclusions are complex structures that contain a number 
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of different proteins (Kato, 2008).  From this observation, one can expect the toxic 
mechanisms that give rise to ALS to also be complex.  However, the reasons why differing 
inclusions (see below) arise and how they are related to disease development remain unclear.  
The following sections describe the differences and the components within each 
characteristic inclusion found in sALS and fALS patients.   
 
1.2.1.1 sALS neuropathology 
Bunina bodies, skein-like inclusions (SLIs) and round hyaline inclusions (RHIs) are 
characteristic inclusions of sALS.  Bunina bodies are small inclusions (1-3 µm in diameter) 
and appear either as a single inclusion or arranged in small beaded chains.  It is important to 
note that Bunina bodies are never reported in SOD1-associated fALS and transgenic mice 
models expressing SOD1 mutants (for a review see (Kato, 2008)).  SLIs and RHIs are 
filamentous and granular structures, and it has been hypothesized that SLIs evolve to form 
RHIs.  Both inclusions stain positively for ubiquitin, but negatively for phosphorylated 
neurofilaments (NFs) and SOD1s (Kato, 2008; Kato et al, 1996).  It is important to note that 
there are some sALS cases where SOD1 was detected in inclusions that resembled Lewy 
body-like hyaline inclusions (Shibata et al, 1996; Shibata et al, 1994). 
 
1.2.1.2 SOD1-associated fALS neuropathology 
The inclusions in SOD1-associated fALS are characterized as Lewy body-like hyaline 
inclusions (LBHIs) in motor neurons and hyaline inclusions in astrocytes (Ast-HIs). Both 
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inclusions are highly immunoreactive to SOD1, NF and ubiquitin, (Kato, 2008; Kato et al, 
1997; Kato et al, 2000; Kato et al, 1999; Kato et al, 2001; Shibata et al, 1994).  Also, both 
WT and mutant SOD1 are detected in the inclusions of fALS patients (Bruijn et al, 1998).  
The structure of LBHIs and Ast-HIs are described as 15-25 nm granule-coated fibrils that are 
occasionally blended with NF.  In addition to LBHIs, the NF conglomerate is another 
characteristic inclusion in SOD1-associated fALS, which is less common in patients with 
sALS (Ince et al, 1998).  In a previous study, immunohistochemical analysis using various 
antibodies revealed that the LBHIs and Ast-HIs are composed of a mixture of different 
proteins, including synaptophysin, neuron-specific enolase, and astrocyte-specific proteins 
such as αβ-crystallin, metallothionein, glutamine synthetase, and S-100 protein.  
Furthermore, the modification of SOD1 with advanced glycation end product (AGE) is 
identified in inclusions.  It is worth noting that AGE is considered as cytotoxic, owing to the 
fact that it prevents protein digestion systems such as ubiquitination and lysosomal 
degradation (Kato et al, 2001).  These results suggest that cellular defense mechanisms are 
closely involved in fALS toxicity.   
 
1.2.2  Pathogenesis in ALS 
The exact molecular mechanism causing motor neuron degeneration in ALS is 
unknown; however, a number of factors, described in the following section, are likely to be 




1.2.2.1 Genetic factors 
Several mutations leading to ALS-like motor neuron diseases have been identified 
and the cases have been classified as ALS1 to ALS8 (Boillee, Vande Velde & Cleveland, 
2006a).  The primary known cause of ALS1, typically called ALS (from the next section 
onwards, ALS refers to ALS1), is mutation in the SOD1 gene located on chromosome 21, 
which accounts for ~ 20 % of all cases of fALS (Boillee, Vande Velde & Cleveland, 2006a).  
The effect of SOD1 mutants on ALS will be discussed further in section 1.3.   
Genes responsible for other ALS cases have also been identified.  These mutations 
are located on various chromosomes.  Mutations in the genes responsible for ALS2, ALS4, 
and ALS5 cause severe juvenile ALS.  Although mutations linked to ALS1 to ALS8 have 
been identified, only some of the encoded proteins and their functions have been 
characterized.  Briefly, SOD1 for ALS1, Tau protein for ALS with frontotemporal dementia 
coupled with Parkinson’s disease (ALS-FTDP) and vesicle-associated membrane proteins B 
(VAPB) for ALS8, are a few of the proteins that have been identified.  Whether loss of 
function by mutation for ALS-associated proteins, except for SOD1 (see below for details),  
is the cause of toxicity is not clear at this time (for reviews see (Boillee, Vande Velde & 
Cleveland, 2006a; Bruijn et al, 2004)).   
 
1.2.2.2 Mitochondrial dysfunction 
Mitochondrial damage is a common feature of many neurodegenerative diseases, 
including ALS (Boillee, Vande Velde & Cleveland, 2006a).  sALS patients show 
abnormalities in mitochondrial function (Siklos et al, 1996; Wiedemann et al, 1998) as well 
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as show an accumulation of mutations in mitochondrial DNA (Ro et al, 2003).  Furthermore,  
SOD1 transgenic mice models of ALS show vacuolated mitochondria within spinal motor 
neurons very early in the disease development (Dalcanto & Gurney, 1994; Kong & Xu, 1998; 
Wong et al, 1995a).  Moreover, vacuolated mitochondria have been proposed to result from 
expansion of the mitochondrial intermembrane space due to aggregation of SOD1 mutants 
(Higgins et al, 2003).  Thus, mitochondrial damage may be an important component in the 
toxic mechanism of ALS.  However, the idea that vacuolated mitochondria are a pathological 
feature in the disease development has been disputed because mice models expressing WT 
SOD1 do not develop the disease but show vacuolated mitochondria.  Additionally, other 
mice models with SOD1 mutations develop the disease without vacuolated mitochondria (for 
a review see (Boillee, Vande Velde & Cleveland, 2006a)).  However, there is further 
evidence suggesting that mitochondria are involved in disease development.  Mitochondria 
play a key role for neuronal death because cytochrome c, which activates the cascade of 
apoptosis is released through the permeability transition pore.  To support this notion, 
Caspase-3 was found to be responsible for the final apoptotic mechanism in mutant SOD 
mice models, implying a role of mitochondrial apoptosis activation (Li et al, 2000).  
Interestingly, a recent study found that caspase-3 activation inactivates the glutamate 
transporter EAAT2, which can lead to excitotoxicity (Boston-Howes et al, 2006) 
(excitotoxicity will be discussed as a disease mechanism in section 1.2.2.5).  Taken together, 
mitochondrial damage may be an important factor in the progression of some ALS cases, but 
further studies are required before a clear connection between the damage of mitochondria 




1.2.2.3 Impaired axonal transport 
Motor neurons have a very distinctive shape that is different from other cell types: 
extreme asymmetry (up to one meter long) and large volume (up to 5000 times that of a 
typical cell) (Boillee, Vande Velde & Cleveland, 2006a).  Impaired axon transport appears to 
be a common pathological features in ALS, supported by the observation of alterations in 
axonal structure in both sALS and fALS (Hirano et al, 1984) and in mice models (Bruijn et 
al, 1998).  Importantly, SOD1 transgenic mice models of ALS show evidence of impaired 
axonal transport months prior to disease onset (Williamson & Cleveland, 1999), implying 
that  impaired axonal transport is an early event in the disease process.   
 
1.2.2.4 Astrocytes and excitotoxicity 
Astrocytes have been suggested to play a significant role in the pathogenesis of the 
disease, since histopathological features of fALS include astrocyte inclusions ((Kato, 2008; 
Kato et al, 1997; Kato et al, 2000; Kato et al, 1999; Kato et al, 2001; Shibata et al, 1994) and 
references in (Kato, 2008)).  There are many studies to support the involvement of astrocytes 
in ALS.  When SOD1 mutants are expressed exclusively in either motor neurons (Lino et al, 
2002) or in astrocytes (Gong et al, 2000) of ALS mice models, the mice do not show 
degeneration of motor neurons.  Furthermore, when the mutant SOD1 is expressed in motor 
neurons which are surrounded by astrocytes expressing WT SOD1, the ALS-affected mice 
have an extended lifespan, whereas when motor neurons with WT SOD1 are surrounded by 
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astrocytes with mutants of SOD1, motor neuron damage is accelerated (Clement et al, 2003).  
Therefore, communication between motor neurons and astrocytes may be an important 
component of ALS toxicity, although the expression level of mutant SOD1 may affect the 
sensitivity of these results (Van Den Bosch & Robberecht, 2008).  This hypothesis is 
supported by another study, which showed that the amount of mutant SOD1 in astrocytes is a 
critical factor in controlling disease duration (Boillee et al, 2006b).  Another study proposed 
that astrocytes can be a source of extracellular mutant SOD1 to trigger microgliosis and 
eventually motor neuron death (Urushitani et al, 2006).  This neural death is thought to result 
from the mutants of SOD1 co-localizing with components of neurosecretory vesicles from 
asctrocytes (Urushitani et al, 2006).  These results reinforce the hypothesis that an interaction 
between motor neurons and astrocytes is a significant contributor to the disease.     
Generally, a major role of astrocytes is to protect motor neurons by providing 
neurotrophic factors and maintaining extra-neural concentrations of glutamate by scavenging 
glutamate using a glutamate transporter such as EAAT2 (Van Den Bosch & Robberecht, 
2008).  High concentration of extra-neuronal glutamate may lead to motor neuron death by 
over-stimulating the glutamate receptor; this event is called excitotoxicity (Van Den Bosch et 
al, 2006).  It is likely that excitotoxicity is involved in ALS because of the reduced density of 
EAAT2 detected in both sALS and fALS (Shaw et al, 1994).  Taken together, there is strong 
evidence that non-cell autonomous processes and excitotoxicity contribute to ALS, even 




1.3 SOD1 in ALS 
Mutation in the gene for SOD1 is the most common known cause of ALS and is by 
far the most studied.  Since 1993, when Rosen et al. discovered a link between SOD1 
mutations and fALS (Rosen, 1993), over 140, mainly missense, mutations in the SOD1 gene 
have been reported to cause fALS (Turner & Talbot, 2008) (Fig.1.3).  These disease-
associated mutations are located throughout the protein structure including the dimer 
interface and metal binding sites (Valentine, Doucette & Zittin Potter, 2005).  The structural 
diversity of fALS-associated mutations in SOD1 suggests that this disease occurs as a result 
of a general toxic mechanism, but not a site-specific mechanism.  Most mutants exhibit a 
dominant pattern of inheritance, with the exception of N86S, D90A, and D96N.  Furthermore, 
individuals with fALS-associated SOD1 mutations are heterozygous and exhibit a disease 
onset and duration that is characteristic of each mutation (Table 1.1) (Turner & Talbot, 2008). 
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Figure 1.3 ALS-associated point mutations in hSOD1 
Schematic diagram of the hSOD1 primary sequence with exons.  The 8 β strands and 7 loops 
are shown with Roman numerals.  The metal binding residues (Cu and Zn), intramolecular 
disulfide bond, and mutations linked to fALS are also indicated 
(http://alsod.iop.kcl.ac.uk/misc/sod1MutationsDiagram.aspx).  Insertion, deletion and silent 
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mutations represent a small fraction of ALS-associated mutations in SOD1, thus they are not 
shown here, but can be found at 
(http://alsod.iop.kcl.ac.uk/misc/sod1MutationsDiagram.aspx).  
 
Table 1.1 Disease duration and age of onset for selected
a












(# of patients) 
A4S < 3 (0) 34 (1) 
A4T 0.5 (21) 45.3 (26) 
A4V 1.2 (205) 47.7 (212) 
H43R 1.8 (12) 49.3 (14) 
H46R 17.6 (49) 45.6 (70) 
H48Q 1.2 (4) 43.6 (4) 
G85R 6.0 (11) 55.5 (11) 
G93A 3.1 (16) 46 (15) 
G93D 8.8 (7) 39.3 (10) 
G93S 8.6 (11) 51.6 (15) 
G93V 6.0 (2) 46.0 (3) 
I113T 4.3 (38) 56.3 (43) 
I149T 2.7 (15) 37.6 (14) 
SALS 2.5 (269) 58.4 (359) 
 
a The selected mutants are based on the ones characterized in this thesis, which are described in  chapter 2 and 3.  
b The information in Table 1.1 is from Wang et al. (Wang et al, 2008) as well as the references therein. 




1.3.1 Oxidative stress vs. Protein aggregation 
The initially proposed pathogenic mechanism of fALS-associated SOD1 mutants was 
loss of the superoxide detoxifying activity.  However, a number of studies have shown that 
the simple loss-of-function does not result in motor neuron death.  Firstly, SOD1 knockout 
mice do not develop the disease (Reaume et al, 1996).  In addition, the mice models 
expressing mutants of SOD1 with varying activity levels, including similar to wild-type, 
develop comparable disease pathologies to those seen in fALS patients (for a review see 
(Kato, 2008)).  Taken together, a gain of toxic function by mutation, not a loss of function, is 
thought to be responsible for the disease.  Two main hypotheses have been put forward to 
explain how fALS-associated SOD1 mutants may confer toxicity to the affected neural cells. 
The first suggests that aberrant copper-dependent oxidative damage occurs and causes motor 
neuron degeneration, while the second hypothesis proposes that SOD1 aggregation is the 
cause of toxicity.  The following sections discuss each hypothesis in detail. 
 
1.3.1.1 Aberrant copper-dependent oxidative chemistry  
Extensive research indicates that oxidative stress plays an important role in ALS 
(Simpson et al, 2003).  Transgenic mice expressing SOD1 disease mutation G93A show 
enhanced levels of free radicals in the spinal cord (Liu et al, 1998).  Furthermore, the levels 
of oxidatively damaged proteins in G93A mice models are twice as high as the levels found 





 bound to the mutants in which the active site is ―loosened‖ and so can 
more easily catalyze aberrant reactions.  In other words, abnormal substrates have easier 
access to the active site in mutants of SOD1 where they can react with Cu
2+
.  The products 
from the Cu-mediated aberrant chemistry can then damage amino acid residues near the Cu 
binding sites in SOD1 (see below for details).   
Three harmful and abnormal substrates for SOD1 have been proposed: nitric oxide 
(NO), peroxynitrite (OONO
-
) and hydrogen peroxide (H2O2).  Nitric oxide (NO) is produced 
by nitric oxide synthase to help modulate synaptic plasticity by interneurons that surround 
motor neurons (Valtschanoff et al, 1992) and is also produced as a response to neuron injury 
(Wu et al, 1995).  SOD1 mutants with disruptions in their active site pockets (e.g., A4V) can 
allow greater access of nitric oxide (NO) to the active site (Beckman et al, 1993; Estevez et 
al, 1999).  The nitric oxide (NO) can react with superoxide more rapidly than the Cu
2+
 bound 
to the active site (Huie & Padmaja, 1993).  Peroxynitrite (OONO
-
) is formed by the reaction 
between nitric oxide (NO) and superoxide in the active site or freely in cytosol.  The 
peroxynitrite (OONO
-
) formed in the SOD1 active site can react with the Cu
2+
 bound to the 
active site, resulting in nitration of tyrosine residues (Beckman, 1996; Beckman et al, 1992).  
This hypothesis is strongly supported by the identification of increased levels of free 3-
nitrotyrosine in mice models as well as sALS and fALS patients, although there is no 
evidence of increased levels of nitrotyrosine bound to proteins in ALS (Abe et al, 1995; 
Bruijn et al, 1997a; Chou et al, 1996; Ferrante et al, 1997; Strong et al, 1998).  Moreover, 





, resulting in apoptosis in cultured motor neuron cells 
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(Estevez et al, 1999).  Therefore, Estevex et al. proposed Zn-deficient SOD1 (i.e., aberrant 
copper-dependent oxidative chemistry) as the critical species in the disease.  However, there 
is reason to question whether this mechanism describes the primary event in the neuron cell 
death pathway in all ALS, because survival of ALS-affected mice is independent of nitric 
oxide synthase expression, even though peroxynitrite related toxicity should be dependent on 
nitric oxide (NO) and therefore on nitric oxide synthase.  This suggests that aberrant copper-
dependent oxidative chemistry cannot be the only critical component of disease pathology 
(Son et al, 2001).   
Hydrogen peroxide has been proposed as another harmful abnormal substrate for 
SOD1.  The interaction of bovine SOD1 (bSOD1) with hydrogen peroxide can induce 
enzyme inactivation in vitro via rapid reduction of Cu
2+
 by hydrogen peroxide.  Furthermore, 
the reduced Cu ion (Cu
+
) and hydrogen peroxide can generate harmful hydroxyl radicals via 
a Fenton reaction mechanism (Hodgson & Fridovich, 1975).  fALS-associated mutants also 
show a greater ability to produce hydroxyl radicals. (WiedauPazos et al, 1996).  The 
hydroxyl radicals can react with copper ligands (His 46, His 48, and His 120 as well as Pro 
62, which is adjacent to His 63) in vitro, resulting in oxidation of these amino acids at the 
active site of SOD1 (Kurahashi et al, 2001; Uchida & Kawakishi, 1994).  There is, however, 
no evidence for enhanced production of hydroxyl radicals throughout the disease progression 
in fALS mice models.   
Although aberrant copper-dependant oxidative chemistry has been extensively 
studied and proposed to be the underlying toxic mechanism through which fALS-associated 
mutants of SOD1 cause the disease, there is significant in vivo result that disputes this claim.  
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First of all, mutant SOD1 that lack all four copper coordinating His residues still cause 
progressive motor neuron degeneration, indicating that the disease is developed without the 
copper-mediated reaction discussed above (Wang et al, 2003).  In addition, transgenic mice 
lacking CCS in motor neurons show no difference in onset and progression of the disease, 
even though the mice show a significant reduction in the amount of properly copper loaded 
mutant SOD1 (Subramaniam et al, 2002).  These two observations suggest that an alternative 
mechanism must exist to give rise to the gain-of-toxic function seen in ALS, discussed next.   
 
1.3.1.2 Protein aggregation 
Protein aggregation has been implicated in the pathogenesis of many different 
neurodegenerative diseases including Alzheimer’s, Parkinson’s, Huntington’s, and prion 
disease (Chiti & Dobson, 2006; Ross & Poirier, 2004).  Similarly, SOD1-containing 
aggregates have been found in sALS and fALS patients (Kato et al, 2001; Okamoto et al, 
1991; Shibata, Asayama, Hirano & Kobayashi, 1996; Shibata et al, 1994) and ALS-SOD1 
transgenic mice models (for reviews see (Kato, 2008; Turner & Talbot, 2008)).  However, 
whether protein aggregation itself is toxic or a harmless byproduct of oxidative damage has 
been debated.  Several lines of evidence support the theory that a gain-of-toxic function 
arises as a result of a mutation in SOD1, which predisposes the protein to form toxic 
aggregates.  In support of this theory, it has been found that high molecular weight 
complexes containing mutant SOD1 are detectable in spinal cord extracts from transgenic 
mice before motor neuron pathology is apparent (Johnston et al, 2000).  Additionally, a 
recent study investigated the appearance and abundance of mutant SOD1 aggregates 
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throughout the disease course in SOD1  fALS mice models (G93A, G37R and H46R/H48Q) 
(Karch et al, 2009).  This work reported that small aggregates (e.g., soluble oligomers) form 
in the early stages of the disease but larger aggregates of mutant SOD1 form primarily in the 
later stages of the disease, concurrent with the appearance of rapidly progressing symptoms 
(Karch et al, 2009).  Taken together, small aggregates of mutant SOD1, rather than large and 
mature aggregates, appear to be more toxic.  However, the mechanisms that connect SOD1 
aggregation to motor neuron toxicity still remain unknown.  There are various hypotheses to 
explain the toxicity of aggregation including: aggregate-mediated inhibition of the 
proteasome machinery; impaired chaperone activity; and deregulation of organelle function 
such as mitochondria, and microglia (Boillee, Vande Velde & Cleveland, 2006a).  Each 
hypothesis is discussed in detail.   
Misfolded proteins are targeted for disposal via the proteasome.  Therefore, the 
proteasome machinery can be adversely affected by accumulation of ubiquitinated and/or 
misfolded proteins.  In the case of ALS, ubiquitinated proteins have been confirmed as part 
of the inclusions found in patients (see section 1.2.2), implicating that impaired proteasomal 
machinery is prominent in ALS.  More specifically, the insoluble forms of mutant SOD1 in 
the spinal cords of G93A mice models clearly show both mono- and oligo-ubiquitinated 
proteins (Basso et al, 2006).  Additionally, Dorfin, a RING finger type E3 ubiquitin ligase, is 
an abundant component in inclusions in both fALS and sALS (Niwa et al, 2002).  
Furthermore, Dorfin enhances degradation of mutant SOD1, but not WT, in vitro, and 
overexpression of Dorfin (Niwa et al, 2002) protects against motor neuron degeneration and 
reduces the levels of intracellular protein inclusions.  While proteasome malfunction has 
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been implicated in motor neuron death, contradictory results have been reported; Shaw et al. 
found that the most abundant proteins recovered from aggregates in transgenic mice models 
were full length unmodified (i.e., no ubiquitination) SOD1 polypeptides (Shaw et al, 2008).  
Misfolded and aggregates of SOD1 can also interact improperly with folding chaperones, 
abolishing their normal functions.  In fact, inclusions from sALS and fALS patients, and  
transgenic mice models, have been shown to contain CCS (Watanabe et al, 2001), Hsp 70 
(Watanabe et al, 2001) and Hsp 25 (Wang et al, 2003).  Thus, it can be postulated that 
mutants of SOD1 may devastate the cells’ defense mechanism through diminishing the 
protective effects of the proteasome and chaperone mechanisms, thereby causing the disease.   
 There is growing evidence that SOD1 mutants cause ALS by interfering with a 
different cell type and organelles, the mitochondria (Velde et al, 2008) and microglia 
(Urushitani et al, 2006).  Misfolded SOD1 has been found to be associated with the 
cytoplasmic face of the outer mitochondrial membrane in spinal cord tissues, but  not other 
tissues, of mice models (Sturtz et al, 2001).  Velde et al. proposed that the mutant proteins 
bound to mitochondria might be responsible for the malfunction of protein import, ionic 
homeostasis, mitochondrial mobility, mitochondrial fission/fusion, or mitochondrial 
regulation of apoptosis (Sturtz et al, 2001).  However, detecting misfolded SOD1 in mice 
models may have limited relevance to disease because the mice models have a higher 
possibility of containing mismetallated or misfolded proteins due to overexpression of SOD1 
and insufficient amounts of CCS for full metallation, for example, G93A mice ( either 25 
copies (Gurney, 1997) or 8 copies (Chiu et al, 1995)), G37R (12 copies) (Wong et al, 
1995b), and G85R (between 2 and 15 copies) (Bruijn et al, 1997b).  Additionally, there is 
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significant experimental evidence to indicate that WT and mutant SOD1 can be secreted 
through secretory pathways in the transgenic mice models, even though  SOD1 is a cytosolic 
protein without a specific translocation sequence (Turner et al, 2005; Urushitani et al, 2006).  
The extracellular SOD1 mutant may trigger microgliosis, which can lead eventually to motor 
neuron death (Urushitani et al, 2006). 
There has been significant research on the topics of protein aggregation and oxidative 
damage in ALS.  As seen above, neither mechanism can completely explain the toxic 
mechanism of SOD1 mutations.  Current research indicates that the two hypotheses may not 
be mutually exclusive, because there is evidence to show that oxidative damage to SOD1 
enhances aggregation of the protein (Rakhit et al, 2002), and that aggregates from patients 
contain oxidative modifications (Kato et al, 2000). Thus, further research should consider 
both possible toxic mechanisms. 
 
1.4 Protein misfolding and aggregation 
1.4.1 Protein folding 
Following synthesis on the ribosome, each polypeptide must fold into its native 
conformation in order to enable properly function. Often in vivo the protein folding process is 
aided by a variety of chaperones (Hinault et al, 2006).  However, a polypeptide can also 
reach its correctly folded structure in vitro in the absence of any chaperones under 
appropriate conditions, suggesting that the primary amino acid sequence contains the folding 
information (Anfinsen, 1973).  In order to achieve the native state, a protein must find a 
 
 32 
pathway to the correctly folded structure, rather than one of the countless alternatives, 
because it would take an  infinite amount of time for even a small polypeptide to search all 
possible conformations, yet real proteins can fold into the native state within 1 sec (Karplus, 
1997).  The concept of an energy landscape has emerged in attempt to describe protein 
folding pathways (Bryngelson et al, 1995).  In this approach, the unfolded state of a given 
peptide folds along an energy landscape towards the compact native state (Fig 1.4).  As the 
size and complexity of the protein increases, so does the complexity of the folding process.  
Therefore, intermediates with partially formed structures can be populated and have 
significant life times.  Additionally, during the search for the stable native conformation 
between residues, non-native interactions may take place, which is generalized by the term 
―misfolding‖.  In vivo, molecular chaperones can provide some protection for these undesired 
events (Hinault, Ben-Zvi & Goloubinoff, 2006).  Nevertheless, misfolded or partially folded 
species that arise in the cell can participate in further undesired events (e.g., aggregation) that 
can cause diseases.  Indeed, an increasing number of diseases are linked to protein misfolding 
and aggregation (see Table 1.2 for selected examples).  Thus, in recent decades, many 
researchers have been making efforts to understand protein folding, misfolding, and 


















Figure 1.4 Schematic diagram of a folding and aggregation energy landscape 
The surface represents a multitude of conformational states during folding of a polypeptide 
into its native conformation, or partially folded intermediates and soluble oligomers that lead 
to aggregate formation. The lowest energy states in the protein folding (left) and protein 






Table 1.2 Protein misfolding diseases 
a
 
Human Disease Protein Involved 
Cystic fibrosis cystic fibrosis transmembrane regulator 
Sickle cell anemia hemoglobin 
Alzheimer’s disease β amyloid 
Spongiform encephalopathies prion protein 
Familial amyloidoses transthyretin or lysozyme 
Parkinson’s disease  α-synuclein 






 Table 1.2 is modified from Thomas et al.(Thomas et al, 1995) and Dobson (Dobson, 2001b) . 
 
1.4.2 Amyloid and human diseases 
A significant number of proteins readily fold into not only their native structures but 
also have the ability to fold into an alternative structure, known as amyloid (Jahn & Radford, 
2008b).  Thus, an energy landscape should also include the unfolding pathways that lead to 
aggregate formation, thereby connecting unfolding/aggregation pathways to the native 
protein folding pathways (Fig. 1.4).  A given protein can maintain its native structure most of 
the time in a living cell because the kinetic barrier associated with partial unfolding provides 
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protection, even though the aggregated state may be thermodynamically more stable than the 
native state (Dobson, 2001a).  Thermodynamic stability of protein aggregates is typically 
attributed to increased entropy.  The entropy increase is a result of the water molecules that 
are initially bound to the unfolded protein being released upon aggregation (Oosawa, 1975).  
The aggregation component of an energy landscape may contain many different species, 
including amyloid, amorphous aggregates, and soluble oligomers.  Their existence  is 
supported by in vitro experiments, in which a multitude of  aggregate morphologies have 
been identified simultaneously under the same solution conditions (Jahn & Radford, 2008b).   
Many protein misfolding diseases are classified as amyloidoses (Sunde et al, 1997).  
Amyloidosis is defined as a disease involving the extracellular deposition of insoluble protein 
complexes, amyloid (Tan & Pepys, 1994) (see Table 1.3 for selected examples).  Many 
neurodegenerative diseases are included in Table 1.3.  Many of the amyloidoses occur both 
in sporadic and familial forms.  One of the striking characteristics of the amyloid diseases is 
that protein aggregates possess very similar properties and appearance (Sunde et al, 1997).  
The fibrils are typically smooth and bind the dye, Congo red, and exhibit green-gold 
birefringence under polarized light.  Also, they are composed of very extensive β-sheet 
structures, in which the β strands are oriented perpendicular to the fibril axis to generate what 
is described as a cross β structure (Fig. 1.5) (Sunde et al, 1997).  This commonality of the 
aggregate structures is very surprising, because the precursor proteins in different diseases do 
not share sequence homologies or native structures (Jahn & Radford, 2008b).  With regards 
to the toxicity of amyloid, precursor amyloid oligomeric species are found to be substantially 
more toxic than the mature amyloid (Ross & Poirier, 2004).  Support for this is that soluble 
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oligomers of Aβ correlate better with the severity of Alzheimer’s disease than insoluble 
fibrillar deposits (Kuo et al, 1996).  Additionally, Kayed et al. found that an antibody that 
specifically recognized the oligomeric state of Aβ can neutralize the toxicity of soluble 
oligomers (Kayed et al, 2003).  This antibody also  recognized other soluble oligomers that 
formed from a wide variety of amyloidogenic proteins including α synuclein, islet amyloid 
polypeptide, polyglutamine, lysozyme, insulin and prion peptide (Kayed et al, 2003).  This 
finding indicates that amyloid oligomers likely share common structural features regardless 
of their precursor protein sequences.  Therefore, it is possible that amyloidoses can share a 
common mechanism of toxicity via the primary toxic species, the soluble oligomer (Kayed et 












Figure 1.5 Cross-β structure of an amyloid fibril, modeled by the peptide GNNQQNY 
A total of 8 peptide molecules in Fig.1.5 form 4 β-sheets.  Amyloid fibril grows along the y-
axis (red arrow).  One peptide from the top layer and one from the bottom layer (stacked 
along the z axis) form an anti-parallel β sheet.  Each β-strand is parallel to the x axis (i.e., β 
strands run perpendicular to the long axis of the fibril).  Side chains are colored blue, and two 
blue arrows represent the orientation of β strands in the top and bottom layer, respectively.  
The figure was made using pdb code 1YJP (Nelson et al, 2005) in Molmol (Koradi, Billeter 
& Wuthrich, 1996).  
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Table 1.3 Human amyloid diseases and their related fibril components 
a
 
Human Disease Fibril Components 
Alzheimer’s disease Aβ peptide, 1-42, 1-43 
Spongiform encephalopathies full length prion or fragments 
Familial amyloidotic polyneuropathy I transthyretin variants and fragments 
Senile systemic amyloidosis WT transthyretin and fragments 
Familial amyloidotic polyneuropathy II β2 microglobulin 
Type II diabetes fragments of islet-associated polypeptide 









 Table 1.3 is modified from in Sunde et al. (Sunde et al, 1997). 
b
 amyloid formation is involved in the diseases but the deposit is intracellular instead of extracellular. 
 
A great deal of research in vitro has been conducted to provide detailed insight into 
molecular mechanisms for amyloid formation.  In vitro, amyloid has been generated from 
disease-related proteins under a range of solution conditions.  Additionally, proteins with no 
known connection to disease, for example apo myoglobin (Fandrich et al, 2003a), are also 
found to be converted into amyloid under appropriate conditions.  This finding suggests that 
amyloid formation can occur under appropriate conditions from any protein (for a review see 
(Dobson, 2001b)).  Furthermore, amyloid formation in vitro is promoted by adding seeds 
(preformed aggregates).  For example, mutant-specific cross seeding ability has been shown 
for prion propagation (Sparrer et al, 2000).  Strain-specific behavior has been reported, in 
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which the morphology of final aggregates resemble that of the seeds (Sparrer, Santoso, Szoka 
& Weissman, 2000).   
As for proposed SOD1 aggregate toxicity mechanisms, impaired cellular defense 
systems against protein aggregation are related to amyloid diseases.  For example, prion 
protein oligomers and α-synuclein protofibrils inhibit the 26S proteasome (Kristiansen et al, 
2007; Zhang et al, 2008).  Thus, some research into possible treatment for amyloidoses has 
focused on decreasing the accumulation of amyloid in the affected tissue or enhancing its 
clearance using antibodies or small molecules.  Using an antibody that recognizes toxic 
oligomers, a vaccination approach has also been investigated (Holtzman, 2008).  Small 
molecules that can prevent protein unfolding or stabilize partially unfolded species against 
aggregation have strong potential for therapeutic strategies.  Thus, understanding aggregation 
in more detail and developing ways of controlling aggregation has profound medical 
implications.  Furthermore, understanding protein aggregation can further our knowledge of 
the physical properties of proteins that facilitate proper folding in normal cellular processes.  
 
1.5 Thesis outline 
1.5.1 hSOD1 pseudo wild-type (pWT) 
Our lab has been investigating the thermodynamic stability and kinetic stability of 
SOD1.  In all experiments from our lab, a well established pseudo wild-type (pWT) 
background was used in which the free cysteines at positions 6 and 111 are mutated to 
alanine and serine, respectively.  Using pWT allows us to carry out an accurate 
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thermodynamic analysis of protein denaturation since it should be fully reversible.  
Moreover, the pWT has very similar structure, dynamics, stability and activity to wild-type 
SOD1, but aberrant disulfide bond formation by oxidation of the free cysteines is eliminated 
(Lepock, Frey & Hallewell, 1990; Parge, Hallewell & Tainer, 1992).  All the experiments in 
this thesis were also performed using pWT in order to make use of accumulating 
thermodynamic and kinetic data from our lab.  Furthermore, recently Borchelt, et. al. 
reported that intermolecular disulfide bond via the free cysteines have a minor effect on the 
disease (Karch et al, 2009).  This supports the notion that pWT is a valid model to study the 
pathogenesis of ALS. 
 
1.5.2 Outlines 
Aggregation has been emerged as one of the leading hypotheses for the toxic gain of 
function associated with ALS (Valentine, Doucette & Zittin Potter, 2005).  Thus, many 
research labs have studied the aggregation mechanism of SOD1 (Banci et al, 2007b; 
Chattopadhyay et al, 2008; DiDonato et al, 2003; Furukawa et al, 2008; Khare et al, 2004; 
Oztug Durer et al, 2009; Rakhit et al, 2002).  Nevertheless, toxic aggregation mechanisms 
remain poorly understood at a molecular level and the diseases have very limited treatment 
options (Wijesekera & Leigh, 2009).  In most studies of protein aggregation, the solution 
conditions used were quite extreme (e.g., extreme pH or temperature, strongly oxidizing 
conditions).  Aggregation is favoured in such scenarios, making it easier to characterize 
experimentally; however, the biological relevance is often questionable, or unclear.  In 
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contrast, aggregation under mild, physiological conditions has received very little attention, 
although such conditions are frequently relevant to disease.  All previous studies of 
aggregation for SOD1 have used either harsh, non-physiological solution conditions, or 
various immature or aberrant forms of the protein  (Banci et al, 2007b; Chattopadhyay et al, 
2008; DiDonato et al, 2003; Furukawa et al, 2008; Khare, Caplow & Dokholyan, 2004; 
Oztug Durer et al, 2009; Rakhit et al, 2002; Stathopulos et al, 2003), whereas the native, 
fully metallated (holo) state of SOD1 has been thought to be unaffected by aggregation due 
to its very high stability.   
Based on preliminary experimental observation on aggregation of holo SOD1, our lab 
has developed the hypothesis that pathological aggregates of SOD1 do form in complex 
ways, such that multiple species (e.g., the least stable form of SOD1, reduced apo SOD1 and 
the most stable form of SOD1, holo SOD1) form mixed aggregates during the disease 
process.  In other words, no single form of SOD1 is responsible for aggregation and global 
stability is not the only factor of aggregation propensity.  This thesis presents an in-depth 
analysis of holo SOD1 aggregation in pathologically relevant conditions.  Structurally and 
chemically different mutants of SOD1 are used in order to characterize the effects of 
mutations on the aggregation and elucidate a possible aggregation mechanism.   
Chapter 2 will report that SOD1 readily aggregates from the holo state under 
physiologically relevant conditions.  General mechanisms (dimer dissociation and metal loss) 
of in vitro holo SOD1 aggregation and their relevance to in vivo aggregation have been 
elucidated, based on experimental evidence obtained using light scattering, atomic force 
microscopy (AFM), mass spectrometry, dye binding assay and an ALS specific antibody 
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assay.  These findings have valuable implications for understanding disease mechanisms in 
ALS and other neurodegenerative diseases, as well as other diseases where aggregation may 
occur from the native state.   
In chapter 3, the aggregation mechanism is further characterized in detail, using 
methods such as metal content analysis and various spectroscopy techniques including 
ultraviolet-visible spectroscopy (UV), Fourier transform infrared (FTIR) spectroscopy, 
circular dichroism (CD) spectroscopy, and fluorescence.  Holo SOD1 can lose either more 
Cu or more Zn ions relative to the other metal during aggregation, resulting in different 
durations and final intensities of the aggregation profiles.  However, the significance of these 
two aggregations mechanisms needs to be studied further.   
Previously, our lab published the effect of sonication on the formation of amyloid, 
(Stathopulos et al, 2004).  This finding has significant implications since protein aggregation 
and amyloid have been implicated in many human diseases, including Alzheimer’s 
Huntington’s, Parkinson’s and prion disease.  Chapter 4 will report further details on the 
effects of sonication as influenced by cycle settings, temperature, and free radical scavenger.  
Other types of protein damages (backbone cleavage and non-physiological dimer formation) 
were investigated using various proteins including bovine serum albumin (BSA), myoglobin, 
β-lactoglobulin, SOD1, hisactophilin, and lysozyme.  These findings provide important 
evidence of necessity of proper controls when sonication is employed in various fields such 
as food processing and medical applications.   
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In chapter 5, general implications of the findings of this thesis, and avenues for future 





Pathological aggregation from the holo state of Cu/Zn superoxide 
dismutase in ALS 
2.1 Introduction 
Amyotrophic lateral sclerosis (ALS) is a devastating, rapidly progressive, and 
invariably fatal neurodegenerative disease, characterized by motor neuron degeneration and 
paralysis (Boillee, Vande Velde & Cleveland, 2006a).  Approximately 10% of ALS cases are 
familial, the remaining cases being sporadic.  The familial and sporadic diseases are 
clinically indistinguishable and so have been proposed to share common disease mechanisms 
(Boillee, Vande Velde & Cleveland, 2006a).  The main known cause of ALS is mutations in 
SOD1, which accounts for ~20% of familial disease (fALS).  It is generally accepted that 
fALS-linked SOD1 mutations result in a gain of toxic function, rather than a loss of function 
(Boillee, Vande Velde & Cleveland, 2006a).  Recently, much attention has focused on toxic 
protein aggregation as a cause for ALS, analogous to pathogenic protein aggregation in other 
neurodegenerative diseases, including Alzheimer’s, Huntington’s, Parkinson’s, and prion 
diseases (Boillee, Vande Velde & Cleveland, 2006a; Chiti & Dobson, 2006; Kato et al, 2001; 
Shibata, Asayama, Hirano & Kobayashi, 1996; Shibata et al, 1994).  SOD1 is present in 
aggregates in motor neurons of SOD1-linked fALS patients (Kato et al, 2001; Okamoto et al, 
1991) and mice models (Johnston, Dalton, Gurney & Kopito, 2000; Karch et al, 2009; Kato 
et al, 2001; Rakhit et al, 2007; Urushitani et al, 2007), and in some sporadic ALS (sALS) 
patients (Shibata, Asayama, Hirano & Kobayashi, 1996; Shibata et al, 1994).  In mice models, 
 
 45 
mutant SOD1 oligomers/higher molecular weight complexes appear well before the onset of 
disease symptoms (Johnston, Dalton, Gurney & Kopito, 2000; Karch et al, 2009), 
implicating small aggregates of the protein as a cause of the disease; however, the molecular 
mechanisms for this are not clear.  This chapter will discuss a possible aggregation 
mechanism that might be responsible for disease: aggregates formed from holo SOD1s under 
physiologically relevant conditions, pH 7.8 and 37 °C.  The following sections will describe 
the background and rationale for the studies presented in this chapter. 
 
2.1.1 Abundance of SOD1 in motor neurons 
SOD1 is ubiquitously expressed in aerobic cells.  Expression levels have been studied 
in many different tissues, including the liver, kidneys, stomach, muscles and cerebral cortex 
(Valentine, Doucette & Zittin Potter, 2005).  Comparisons of the concentrations of SOD1 in 
different tissues suggest that SOD1 has a higher level of expression in the nervous system 
(Valentine, Doucette & Zittin Potter, 2005).  The cellular distribution of SOD1 in motor 
neurons has been also studied using immunocytochemistry (Pardo et al, 1995).  An 
abundance of SOD1 was identified in the perikarya, dendrites, axons, cytoplasm, and 
peroxisomes of the motor neurons.  The concentration of SOD1 has been reported as 10 µM 
in erythrocytes (Rakhit et al, 2004), based on the normal values for the amount and volume 
of hemoglobin and the known ratio of SOD1 to hemoglobin in erythrocytes (0.95 ± 0.07 µg 
of SOD1/mg hemoglobin) (Kurobe et al, 1990).  Since the brain contains approximately 4.5 
times more SOD1 than erythrocytes (Kurobe, Suzuki, Okajima & Kato, 1990), the 
concentration of SOD1 in the brain has been estimated to be 45 µM (Rakhit et al, 2004).  The 
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concentration of cytoplasmic SOD1 in motor neurons tends to be higher than the average 
concentration in the brain (Kurobe, Suzuki, Okajima & Kato, 1990).  Thus, 100 µM is 
typically accepted as the concentration of SOD1 in motor neurons and this value has been 
used in previous in vitro experiments (Banci et al, 2008; Banci et al, 2007b; Rakhit et al, 
2004) as well as the current study.  It is worth noting that those parts of the nervous system 
that are affected by ALS are not always parts that are abundant in SOD1.  Therefore, the 
apparent abundance of SOD1 in motor neurons is only partially related to motor neuron 
degeneration in ALS, rather than the primary toxic properties SOD1 in the disease (Pardo et 
al, 1995).   
 
2.1.2 Rationale 
This section provides an overview of previous studies of SOD1 aggregation related to 
ALS and shows how they relate to the research reported in this chapter.  Many previous 
studies have attempted to correlate ALS disease characteristics (such as survival times and 
disease onset) with SOD1 biophysical properties (e.g., aggregation propensity and/or protein 
stability); however, no universal trends have been identified (Wang, Johnson, Agar & Agar, 
2008).  Biophysical properties that have received particular attention include protein stability, 
charge and aggregation propensity.  Owing to the very high stability of holo SOD1 
(Stathopulos, 2005), many studies have focused on the stability of less mature and less stable 
forms of the protein (e.g., those lacking bound metals or the intra-subunit disulfide bonds).  
An initial claim was that all mutations decrease the apparent melting temperatures of 
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unmetallated (apo) SOD1s (Lindberg et al, 2002).  Later, this was refuted when it was 
discovered that the melting temperatures of various mutants that are located at the metal 
binding sites were similar or even slightly higher than wild-type (Rodriguez et al, 2005).  
The change in net charge of the protein has been investigated as a common trend between 
fALS associated mutants of SOD1.  Based on analysis of 100 fALS-linked SOD1 mutants, a 
preference to reduce the net negative charge of the protein is observed; however, there are 
exceptions, V7E, G41D, N86D, G93D, R115G and G141D (Sandelin et al, 2007).  Recently, 
there has been some success in correlating ALS disease duration with properties of SOD1 
mutants by combining apo protein stability with predicted aggregation propensities of the 
mutant proteins (Wang, Johnson, Agar & Agar, 2008).  More specifically, SOD1 aggregation 
propensities were calculated using an equation developed by Dobson and coworkers for 
prediction of aggregation propensity of the amyloid forming protein, acylphosphatase and its 
mutants (Chiti et al, 2003a).  The equation was derived empirically by examining how three 
physicochemical properties, hydrophobicity, secondary structure (including loss of α helix 
and gain of β sheet) and protein net charge, contribute to aggregation propensity for the 
proteins.  Wang et al. showed that combining calculated aggregation propensity with 
experimental data on apo SOD1 stability accounted for 69% of the varied disease duration of 
mutant-SOD1 associated fALS (Wang, Johnson, Agar & Agar, 2008).  The remaining 
variation may be due in part to limitations in patient data and in mutant protein 
characterization.  Consideration of additional data, such as stability of the native, fully 
metallated (holo) form of SOD1, which has received relatively little attention, may be 
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essential in giving more clarity to the roles of mutant SOD1 in disease (Meiering, 2008; 
Wang, Johnson, Agar & Agar, 2008) 
The holo form of SOD1 has been thought to be incompatible with aggregation 
because of its high stability, although the majority of cellular SOD1 is in the holo form 
(Shaw & Valentine, 2007; Valentine, Doucette & Zittin Potter, 2005).  Furthermore, 
aggregation has been reported mostly for immature or aberrant forms of the protein, often 
under highly destabilizing conditions which generally favor aggregation (DiDonato et al, 
2003; Rakhit et al, 2004; Stathopulos et al, 2003).  However, the relevance of these 
aggregation studies to human disease is not clear.  It is not known which forms of SOD1 may 
give rise to or be present in aggregates in patients to date (Hayward et al, 2002).  There is 
some nuclear magnetic resonance (NMR) evidence for increased association of holo S134N 
(Banci et al, 2005), and partially metallated forms have been found to form fibrillar 
assemblies in crystals (Hough et al, 2004a; Shipp et al, 2003).  Recently, evidence has been 
accumulating for pathological aggregation of various other disease-associated proteins under 
mild solution conditions via states that are close to the native (Chiti & Dobson, 2009).  For 
example, β2-microglobulin in dialysis-related amyloidosis (Chiti & Dobson, 2009) and serpins 
in serpinopathies, early-onset dementia, emphysema, and thrombosis (Yamasaki et al, 2008) 
have been shown to aggregate from the native protein.  Thus, it may be necessary to look 
beyond the immature forms of SOD1 to determine how SOD1 may be involved in disease 




2.1.3 Chapter overview 
This chapter shows that aggregates can form from the native, holo form of SOD1, 
with or without ALS-associated mutations, under physiologically relevant solution 
conditions.  The similarity of the aggregates to those observed in vivo is demonstrated by 
structural and tinctorial analyses as well as the novel observation of binding of an anti-SOD1 
antibody that specifically recognizes pathological aggregates in ALS.  ALS-associated SOD1 
mutations can promote aggregation but are not required, suggesting that SOD1 aggregation 
may be a common mechanism in familial and sporadic ALS.  The SOD1 aggregation is 
characterized by a lag phase, which is diminished by self- and cross-seeding, and 
heterogeneous nucleation.  Metal loss and/or dimer dissociation promote aggregation. This 
establishes a valuable system for understanding SOD1 aggregation and toxicity mechanisms, 
and ultimately developing urgently needed therapeutic strategies targeting protein 
aggregation. 
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2.2  Materials and Methods 
2.2.1  Expression and purification of pWT and mutant SOD1 and SEDI antibody 
The plasmid, pHSOD1Lac1
q
, was used for expression of human cytosolic Cu/Zn 
SOD1 in E. coli cells.  The plasmid contains a human SOD1 gene joined to the leader 
sequence of Photobacterium leiognathi Cu/Zn SOD (Getzoff et al, 1992b), the ampicillin 
resistance gene, and the lacI
q
 gene in a pBR322 derivative containing the tac1 promoter.  The 
leader sequence directs the translated protein to the periplasm (Getzoff et al, 1992b).  The 
synthetic SOD1 gene contains the mutations, C6A and C111S, and the resulting protein is 
referred to as pWT.  The strain employed in this study (derived from QC779) is deficient in 
bacterial SODs, Mn SOD and Fe SOD by mutation (SOD (-/-)) and resistant to kanamycin 
and chloramphenicol (Farr et al, 1986; Natvig et al, 1987).   
 SOD (-/-) E. coli were transformed with pHSOD1Lac1
q
 by electroporation.  1 µg of 
the vector DNA was added to 40 µL of electrocompetent cells in 10 % (v/v) glycerol and 
then placed into an electroporation cuvette (0.1 cm gap, BioRad Laboratories, Inc.).  A high 
electric field, 1.80 kV for 1 sec, was applied to the cell/DNA mixture (E.coli Pulser, BioRad 
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Laboratories, Inc.).  The electroporated cells were grown for 1 hr at 37 °C in 1 mL of a 
medium (containing 0.4 % (w/v) glucose, 20.0 g tryptone, 5.0 g yeast extract, 0.5 g NaCl, 
and 0.01 M MgSO4 per liter).  The cells were then plated on Luria Bertani (LB)-agar plates 
containing ampicillin (100 µg/mL), kanamycin (30 µg/mL) and chloramphenicol (30 µg/mL) 
and then incubated overnight at 37 °C.  A single colony was selected and grown overnight in 
50 mL of LB medium.  Next, 10 mL of the LB culture was used to inoculate 1 L of 2TY rich 
medium (containing 16.0 g tryptone, 10.0 g yeast extract, and 5.0 g NaCl per liter) at 37 °C 
with constant shaking at 200 rpm.  In addition, the medium contained three antibiotics: 0.1 
mg/mL ampicillin, 0.03 mg/mL kanamycin, and 0.03 mg/mL chloramphenicol.  When the 
cultures reached an optical density between 0.6 and 0.8 at 600 nm, isopropylthiogalactoside 
(0.25 mM, final concentration) was added to induce expression of human SOD1.  At the time 
of induction, CuSO4 and ZnSO4 were also added to final concentrations of 0.5 mM and 0.01 
mM, respectively.  The growth medium was further incubated at 37 °C for 8 hrs from the 
time of induction.  Cells were harvested by centrifugation (4500g for 15 min) and if 
necessary, stored at – 80 °C. 
 Human SOD1 was obtained from the periplasm of cells by osmotic shock.  The 
following procedures apply to a cell pellet obtained from 1 L flask of culture.  Cells were 
resuspended in 50 mL of sucrose solution (20 % (w/v)) containing 15 mM 
ethylenediaminetetraacetic acid (EDTA) and 10 mM tri(hydroxymethyl)aminomethane 
hydrochloride (Tris-HCl), pH 7.5.  The resuspended cells were gently agitated on ice for 20 
minutes and then centrifuged to collect pellets (4000 g for 30 min).  The cell pellets were 
lysed by osmotic shock with the addition of 20 mL of ice-cold deionized water obtained from 
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a milliQ water system (Millipore Ltd.).  Centrifugation was performed (4500 g for 45 min) 
and the soluble fraction from the periplasm was collected.  The solution from osmotic shock 
was stored in – 80 °C if needed. 
 Heat treatments were performed to remove unwanted proteins after osmotic shock.  
The final solution from osmotic shock was diluted to 0.8 mg/mL using 20 mM Tris-HCl, pH 
7.8 and milliQ water.  The used volume of Tris buffer is twice more than the volume of 
water.  The diluted solution was heat-treated at 70 °C for 20 min in the presence of 1.4 mM 
CuSO4 as the final concentration.  The pH of this solution was adjusted to 6.7.  This step 
helps Cu ions bind to human SOD1 and removes thermally unstable proteins.  The soluble 
fraction was obtained by centrifugation (4000 g for 10 min).    
Purification of human SOD1 was carried out by hydrophobic interaction 
chromatography.  (NH4)2S04 was added to the supernatant from heat treatments to a final 
concentration of 3 M.  All the solutions to be used in the chromatography column: the highly 
saturated protein solution, 3 M (NH4)2S04, and 20 mM Tris-HCl, all at pH 7.8, were filtered 
through 0.45 micron low protein binding filter.  Then, the solutions were degassed for at least 
20 min.  Appropriate aliquots of the protein solution were subsequently loaded onto a Waters 
column (2.2 cm diameter x 10 cm length, Waters), packed with Poros 20 micron HP2 
(polystyrene-divinylbenzene).  The typical gradient used was 65 % (v/v) of 3 M (NH4)2S04 
against 20 mM Tris-HCl, pH 7.8 and decreased to 40 % (v/v) of 3 M (NH4)2S04 against 20 
mM Tris-HCl, pH 7.8 over 4 column volumes.  It is worth noting that the gradient was very 
subjective to the mutant of interest and the concentration of the prepared (NH4)2S04.  When 
the column purification was complete, the holo form of SOD1 was collected and pooled 
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together.  The final solution was extensively dialyzed with milliQ water at 4 °C using a 
dialysis membrane to remove salt.  The reservoir water was changed at least three times after 
at a minimum of 8 hrs incubation each time using 10000 Da cutoff cellulose membranes, 
(Spectrum Laboratories, Inc.).  The protein was concentrated using an Amicon ultrafiltration 
device with a regenerated cellulose membrane (YM10 Amicon untrafiltration, Millipore 
Ltd.).  The purified and concentrated protein was examined for purity, metal status and 
concentration using differential scanning calorimetry (DSC), enzymatic activity assays, 
inductively coupled plasma- atomic emission spectroscopy (ICP-AES), mass spectroscopy 
(MS), and Lowry assays (Lowry et al, 1951).  The concentrated solution was once again 
filtered using a 0.45 micron low protein binding filter and then aliquoted into various 
volumes and stored in -80 °C until it was used.   
Mutant genes were prepared and were provided from Kristin Dimmick for current 
work.  SOD1 Exposed Dimer Interface (SEDI) antibody was generously provided by Dr. 
Janice Robertson from University of Toronto and its preparation is described in reference 
(Rakhit et al, 2007). 
 
2.2.2  Holo SOD1 aggregation 
Samples for aggregation experiments were prepared by concentrating by 
ultrafiltration (Nanosep 3K Omega, PALL Corporation) and then diluted to the desired final 
protein concentration, which was generally 10 mg/mL (317 µM) unless otherwise stated, in 
20 mM 4-(2-hydroxyethyl)-1-piperazineethanefulfonic acid (HEPES), pH 7.8.  Except for the 
experiment to determine the effect of filtration, samples were then filtered using 20 nm filters 
 
 54 
(Anotop 10 Plus, Whatman) to remove any dust particles and preformed aggregates.  
Samples were incubated without agitation at 37 °C in 4 mL glass vials (VWR) sealed with 
parafilm to minimize evaporation.  Samples were measured 2 times per day during the lag 
time, 3 times per day during rapid growth phase, and 1 time per day at the plateau phase.  
 
2.2.3  Light scattering measurements 
Time average light scattering was measured using a 90Plus particle sizer 
(Brookhaven Instruments, Inc.) or a Zetasizer Nano-ZS (Malvern) and the two instruments 
gave comparable results.  However, since the detectors of the two instruments are located at 
different angles (90° and 173° for the 90Plus and Nano-SZ, respectively), the total counts are 
higher for Nano-SZ (van Holde Kensal E. et al, 1998).  The reported light scattering values 
are the averages of 3 measurements, each consisting of 10 (5) consecutive 30 (10) second 
data accumulations by the 90Plus (Nano-SZ) instrument.  For restart experiments, samples 
were monitored until they reached the plateau phase, aggregates were removed by 
centrifugation (2000 g, 10 min) and filtration (20 nm filters, Anotop 10 Plus, Whatman).  
Then, samples were then incubated at 37 °C and monitored by light scattering.  
 
2.2.4  Activity of soluble SOD1 during aggregation 
Activity of remaining soluble SOD1 during aggregation time courses was determined 
by removing a sample aliquot, diluting this to a suitable concentration for activity 
measurement, centrifuging (14,000 g for 8 min) to remove aggregates, and determining the 
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activity of SOD1 samples by the inhibition of pyrogallol autooxidation activity assay 
(Marklund & Marklund, 1974).  The protein concentration after centrifugation was 
determined by the Lowry assay (Lowry, Rosebrough, Farr & Randall, 1951), and used to 
calculate specific activity.  To minimize activity assay variability, a specific activity was also 
determined in parallel for control unaggregated pWT, and sample activity determined as the 
ratio of aggregated sample to unaggregated pWT specific activity.   
 
2.2.5  Data fitting for protein aggregation profiles 









YY        Eq. 2.1 
  
where and  are the initial and average plateau light scattering intensity, respectively,  
is the time of half completion, and  is the time constant (Nielsen et al, 2001).  The lag time 
for aggregation was calculated from the fitted parameters as: 
 




To gain insight into the aggregation mechanism, the initial 10-20 % of the light scattering 
aggregation time course data was fit as described by Ferrone et al. (Ferrone, 1999) for 
primary nucleation, described by a cosine function: 
 
fractional completion = │A│{1-cos(│Bt│)}     Eq. 2.3 
 
and secondary nucleation, described by a hyperbolic cosine function: 
 
fractional completion = │A│ {cosh(│Bt│)-1}    Eq. 2.4 
 
where A is the fitted amplitude, B is an effective rate, and t is time (Ferrone, 1999).   All the 
fits were performed in Origin 7.5, and reported R
2
 values are from the fitting.  The two tailed 
Student’s t-test was used for obtaining reported P-values. 
 
2.2.6  Seeding effects 
Aliquots of preformed aggregates were added to freshly prepared holo SOD1 samples 
(10% (w/w)), and aggregation was monitored by light scattering as above.  The aliquots 
contained either ―early‖ or ―late‖ seeds obtained at the end of the lag phase or the plateau 
phase, respectively. Cross-seeding experiments were performed by adding early seeds from 




2.2.7  Atomic force microscopy (AFM) 
Aliquots of aggregation samples at various time points were diluted in MilliQ water 
to a suitable concentration for AFM imaging (~0.5 g/mL) and then centrifuged (10,000 rpm, 
6 min).  Diluted unaggregated (control) and aggregated (pellet from the centrifuge tube) 
protein solutions were applied to freshly cleaved mica, then rinsed with MilliQ water, and 
air-dried overnight.  Imaging was performed at room temperature using a PicoScan
TM
 atomic 
force microscope (Molecular Imaging) using the tapping mode.  All images were acquired 
using a 225 m silicon single-crystal cantilever (NCL type) with a typical tip radius of 10 nm 
and resonance frequency of ~170 kHz.  A scanner with the maximum scan size of 6×6 m
2
 
was used.  Images were obtained at a resolution of 512×512 pixels on a scale of 1 m × 1 
m.   
To obtain the size of a protein particle, an image analysis program (Scion Image, 
Scion Corporation) was used.  An individual particle was selected and its width and height 
were measured.  To remove tip effects on the determination of the real width of objects 
probed by AFM, the measured widths were converted using the following equation (Fung et 
al, 2003): 
 
          Eq. 2.5 
 
where W* is the actual width, W is the observed width, H is the observed height, and Rc is 
the radius of curvature of the tip (10 nm).  The volume of the particle was calculated using 
 
 58 
the converted width and measured height assuming the particle has a circular cylinder shape.  
The calculated volume was divided by the volume of the native dimer SOD1 (ellipsoidal 
dimensions of ~30 x 40 x 70 Å) (Parge, Hallewell & Tainer, 1992) in order to get the number 
of dimers within the particle.  This approach assumes the association creates no significant 
volume change. 
 
2.2.8 In-torch vaporization inductively coupled plasma atomic emission 
spectroscopy (ITV-ICP-AES) 
Ultra high sensitivity ITV-ICP-AES was used to analyze the amounts of Cu, Zn and S 
in aggregated and unaggregated SOD1.  The ICP-AES system with attached rhenium-cup 
ITV is described in detail elsewhere (Badiei & Karanassios, 1999).  Calibration curves for Cu, 
Zn, and S were made using standard solutions (ICP-mass spectroscopy grade, SCP Science).  
Aggregates were prepared by centrifuging plateau phase samples (2000 g for 15 min).  The 
pellets were washed using 1 mL of MilliQ water followed by centrifugation (2000 g for 15 
min), 5 times, and then resuspended in MilliQ water for analysis.  Each sample was measured 
in triplicate and the amounts of Cu, Zn, and S determined using the calibration curves.  [S] 
was used to determine the concentration of the SOD1 polypeptide based on 2 S per 
polypeptide chain from the 2 cysteine residues.  The values of [Cu]/ [Zn] in unaggregated 




2.2.9 Electrospray ionization-mass spectrometry (ESI-MS) 
The molecular weight of SOD1 before and after aggregation was analyzed using a 
Micromass Q-TOF Ultima Global (Waters).  Aggregate pellets were prepared as described 
for metal analysis (see Materials and Methods, section 2.2.8).  Supernatants were prepared 
for analysis by exchanging the sample from HEPES buffer into MilliQ water by 
ultrafiltration (Nanosep 3K Omega, PALL Corporation) by 15 rounds of ~10-fold 
concentration (8700 g for 8 min) at 13°C.  The prepared supernatants were diluted to a final 
concentration of 1 µM with 50/50 (v/v) methyl cyanide (MeCN)/H2O containing 0.2 % (v/v) 
of formic acid (FA) prior to the measurements.  The prepared pellets were dissolved in 20 µL 
of 50/50 (v/v) MeCN/H2O containing 0.2 % (v/v) of FA prior to the measurements.  Samples 
were infused by electrospray ionization, and measured in positive ion mode.  The capillary 
voltage and cone voltage were 3 kV and 80 V, respectively.  The signal was accumulated for 
at least for 1 min and the average of m/z data from the accumulated signal was reported.  
Prior to mass measurements, 1% of phosphoric acid solution in 50/50 of MeCN in water was 
used for m/z calibration.   
 
2.2.10 Thioflavin T (ThT) fluorescence 
6.8 μL of pWT aggregation sample prepared at either 8.7 mg/mL or 3.2 mg/mL were 
diluted to 1.00 or 0.36 mg/mL, respectively, in 0.17 mM ThT and 20 mM HEPES at various 
time points.  Fluorescence emission spectra were obtained immediately (unless otherwise 
stated) using an excitation wavelength of 440 nm.  The slit widths for excitation and emission 
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were 1 and 5 nm, respectively.  Fluorescence spectra were obtained using a Fluorolog3-22 
spectrofluorometer (Jobin Yvon-Spex, Instruments S.A., Inc.) at 25 °C.   
 
2.2.11  Anilinonaphthalene sulphonic acid (ANS) fluorescence 
A solution of 680 μM ANS was prepared by dissolving ANS in water and the 





(Lai et al, 1996)).  3.1 μL of aggregation samples prepared with either 8.7 mg/mL or 
3.2 mg /mL of pWT and 62.5 μL of the prepared ANS solution were mixed and then 
fluorescence emission spectra (400 – 600 nm) were obtained immediately (unless otherwise 
stated) using an excitation wavelength of 410 nm.  The slit widths for excitation and emission 
were 2 and 4 nm, respectively.  Fluorescence spectra were obtained using a Fluorolog3-22 
spectrofluorometer (Jobin Yvon-Spex, Instruments S.A., Inc.) at 25 °C.   
 
2.2.12  Competition enzyme linked immunosorbent assay (ELISA) 
Competition ELISA assays for unaggregated (control) and aggregated pWT were 
conducted in parallel to ensure accurate comparison.  Competing C-terminal peptide (see 
Fig.2.1b) was added to the plate (0.05 μg/well), incubated for 1 hour at RT, then the plate 
was washed a total of 5 times, 3 times using phosphate buffered saline (PBS, this solution 
contained 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, and 0.24 g of KH2PO4 per liter, pH 
7.4) containing 0.05 % (v/v) of Tween 20 (PBST) followed by 2 washes with PBS solution.  
Next, blocking solution (1% (w/v) BSA in PBS) was added to the plate, which was incubated 
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overnight at 4 C.  The plate was washed a total of 5 times, 2 washes using PBST followed 
by 3 washes using PBS solution.  Meanwhile, a polyclonal antibody preparation from rabbit, 
SEDI antibody was diluted (1000 times) in blocking solution.  Then, this was combined with 
either aggregated SOD1 from the plateau phase or with unaggregated SOD1, and incubated 
for 2 hours at RT with gentle shaking.  The final concentration of SOD1 in the SEDI solution 
was 180 nM.  Control solutions of SEDI solution with no added SOD1 were also prepared.  
These solutions were added to the plates (50 μL/well), incubated for 35 min at RT with no 
agitation, and then washed a total of 7 times, 5 washes using PBST followed by 2 washes 
using PBS solution.  Horseradish peroxidase (HRP)-conjugated anti-rabbit IgG secondary 
antibody (Pierce) was diluted in blocking solution (1:2000) and then added to the plate, 
incubated for 80 minutes at RT, and the plate washed for a total of 7 times, 5 washes using 
PBST followed by 2 washes using PBS solution.  For visualization, 100 µl/well of 2-2'-
azino-di-(3-ethylbenzthiazoline sulfonic acid (ABTS) substrate (Pierce) was added, 
incubated for 30 minutes at RT, and read at 405 nm using a plate reader (Spectramax 
Plus384,Molecular Devices).  For a given experiment, samples for SEDI with/without 
unaggregated pWT were prepared on one plate and samples for SEDI with/without 
aggregated pWT were prepared on the other plate.  Each sample was prepared in 3 wells.  
Three independent SEDI binding experiments were conducted, and the average and standard 
deviation of the 3 experiments were obtained.  The reading from the samples of SEDI with 
either unaggregated or aggregated pWT was normalized against the reading from the sample 




2.3  Results 
2.3.1 Aggregation is formed from the holo form of SOD1. 
Aggregation from the holo form of SOD1 was followed using light scattering to 
measure particle formation in solution as a function of time.  The experiments were 
conducted at close to physiological conditions of temperature (37 °C), pH (7.8) and protein 
concentration (100 – 1000 µM, 3-30 mg/mL) (Rakhit et al, 2004).  Diverse ALS-associated 
mutations were studied: G85R, which disrupts metal binding (Cao et al, 2008); A4V, A4T, 
A4S, and I149T, in the dimer interface; and G93V, G93S, and G93D, at a mutational hotspot 
in a loop (Fig. 2.1).  Proper metallation and folding of holo SOD1 preparations were 
confirmed by ICP-AES, DSC and pyrogallol activity assay prior to aggregation 
measurements (see Materials and Methods, section 2.2.1).   
Remarkably, all of the SOD1s (A4T, A4S, I149T, G93D, G93V, and G85R) 
including pWT, exhibit a sigmoidal-like increase in light scattering intensity with time (Fig. 
2.2).  Previously, sigmoidal aggregation profiles were reported for A4V and G93A 
(Stathopulos, 2005).  The aggregation time courses resemble those of many other disease-
associated proteins (Morris et al, 2008).  The observation of aggregation for pWT supports 
the hypothesis that SOD1 aggregation can also contribute to the pathology of sALS (Shibata, 








Figure 2.1 Structure of Cu/Zn SOD1 
(a) Ribbon representation of dimeric holo pWT (Parge, Hallewell & Tainer, 1992) (pdb code 
1SOS).  Cu and Zn ions are shown as orange and black spheres, respectively.  The 
intrasubunit disulfide bond between cysteines 57 and 146 is shown in yellow space filling 
representation.  The two active site loops, electrostatic loop VII (residues 121-142) and loop 
IV (residues 49-82), are colored blue and green, respectively.  Loop IV is composed of three 
regions: the dimer interface region (residues 49-54); the disulfide bond region (residues 55-
61); and the Zn binding region (residues 62-82) (Hornberg, Logan, Marklund & Oliveberg, 
2007).  Sites of fALS mutations characterized here are colored red and labeled.  (b) The 
epitope (residues 143-151, red) for the SEDI antibody is buried in the dimer form of SOD1 
(left) and exposed in the monomer form (right).  The dimer view is the same as in (a) but the 
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monomer is rotated to clearly show the epitope.  The figure was made using Molmol (Koradi, 
Billeter & Wuthrich, 1996) and Pymol for (a) and (b), respectively.   
 

































































































































Figure 2.2 Representative sigmoidal aggregation profiles for holo SOD1s monitored by light 
scattering.   
(a) pWT, (b) A4T, (c) A4S, (d) I149T, (e) G93D, (f) G93V, (g) G93S, and (h) G85R.  
Dashed lines show the fit of the data to an empirical sigmoidal equation for aggregation, Eq. 
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2.1 (Nielsen et al, 2001) (see Materials and Methods, section 2.2.5).  R
2
 values from the 
fitting are 0.986, 0.844, 0.969, 0.990, 0.984, 0.994, 0.969, and 0.978 for (a) to (h), 
respectively.  Plotted values (●) and error bars are the means and standard deviation for 3 
light scattering measurements per sample at each time point (see Materials and Methods, 
section 2.2.3).  Some error bars are smaller than the symbols.   
 
2.3.1.1 Differences from previous studies of holo SOD1 aggregation  
Previous studies generally have reported lack of aggregation for holo SOD1 (Banci et 
al, 2007b; Chattopadhyay et al, 2008), although recently WT and A4V in the pWT 
background were reported to aggregate (Oztug Durer et al, 2009) and there is also evidence 
for aggregation from holo SOD1 in other studies (Banci et al, 2005; Rumfeldt et al, 2006).  
The differences between some of the previous studies (Banci et al, 2007b; Chattopadhyay et 
al, 2008) and the results here may be due to various experimental factors.  The previous 
studies monitored aggregation primarily using ThT binding, a probe of amyloid formation 
(LeVine, 1995).  The aggregates from holo SOD1 reported here do not bind ThT, nor do they 
have other characteristics of amyloid (see Discussion, section 2.4.1).  Light scattering used 
here is sensitive to the formation of any larger particles (Lomakin et al, 1999).  An additional 
experimental difference is the increased number and/or longer time course of measurements 
here, enabling observation of aggregation from the holo state of SOD1 even though this is 
less favourable than aggregation from other states (Chattopadhyay et al, 2008; Furukawa et 
al, 2008; Oztug Durer et al, 2009; Shaw & Valentine, 2007; Stathopulos et al, 2003).  When 
we incubated identical holo SOD1 samples in parallel, with one sample being measured as 
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usual and the other not, aggregation occurred more quickly for the regularly measured 
sample, suggesting that the process of sample measurements and mixing promotes 
aggregation (Fig. 2.3).  This is consistent with other studies that show sample agitation can 
promote aggregation of SOD1 and other proteins (Chattopadhyay et al, 2008; Furukawa et 
al, 2008; Khurana et al, 2001; Oztug Durer et al, 2009; Souillac et al, 2003).  In order to 
facilitate comparisons among mutant holo SOD1s, a consistent frequency of measurements 
was used for all samples (see Materials and Methods, section 2.2.2).  In addition, the results 
obtained here are not inconsistent with numerous previous studies characterizing holo SOD1 
reported by our group and others since, based on activity and aggregation restart experiments 
(see below), considering that the majority of SOD1 in solution (>80%) does not aggregate.  
Furthermore, this is similar to the extent of aggregation observed for other proteins (Huang et 












































Figure 2.3 Sampling effect on aggregation of holo pWT 
Aggregation profiles of pWT (10 mg/mL) were monitored by light scattering measurements.  
(●, ○) symbols represent light scattering intensity of the sample with and without daily 
measurements, respectively. The plotted values and error bars are the average light scattering 
intensity and s.d. from the 3 replicates of 10 measurements for 30 sec.  The sampling effect 
on aggregation was observed in two other cases, where no aggregation was observed after 
over 2 weeks incubation.   
 
2.3.1.2 Quality check of holo SOD1 aggregation 
Aggregation is very sensitive to environmental factors (e.g., agitation and head 
volume (Kiese et al, 2008; Sasahara et al, 2008; Sluzky et al, 1991)) as well as varying 
solution conditions (pH, ionic strength, and temperature (Glabe, 2008)).  Therefore, great 
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caution is required for sample preparation, especially with protein concentration and filtering 
steps, which can cause the proteins to unfold or form oligomers.  For aggregation, samples 
were filtered using a 20 nm cut off filter prior to sample incubation and initially did not 
contain detectable aggregates based on light scattering measurements.  It should be noted that 
light scattering is extremely sensitive to the presence of larger species owing to the 
dependence of scattering intensity on the 6
th
 power of the radius of the scattering species 
(Lomakin, Benedek & Teplow, 1999).  For example, considering a hypothetical mixture 
containing only 5 and 50 nm diameter species in solution and the 50 nm diameter species 
account for only 0.1 % of the total proteins in solution by mass, 99% of the scattering 
intensity will come from this species.  The initial light scattering measurements clearly show: 
(1) consistently low light scattering intensities at ~2 kcps (from a Brookhaven 90 plus 
particle sizer); and (2) a single exponential autocorrelation function for all samples, 
indicating that the solutions are monodisperse, i.e., consist of a single species with 
hydrodynamic radius of ~5 nm as expected for a protein the size of the SOD1 native dimer 
(Wilkins et al, 1999) (Chapter 3 will discuss this in more detail).  In contrast, samples that 
were not filtered showed shorter lag times consistent with a previous study from the Meiering 
laboratory (Stathopulos, 2005).  It is important to note that some of the filtered SOD1 
aggregation profiles show quite short or no appreciable lag times (Fig. 2.4), suggesting that 
some aggregates or seeds may sometimes be present initially and facilitate further 
aggregation.  Fig. 2.4c shows the aggregation profile of a ―pre-seeded‖ holo SOD1 sample, in 
which the sigmoidal fit using Eq. 2.1 (see Materials and Methods, section 2.2.5) does not 
give a reasonable Yi value (the fitted value for Yi is negative instead of the expected ~1.9 
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kcps).  It is important to mention that the light scattering intensity is not noticeably higher at 
t=0h even in the case of Fig. 2.4c.  57 % of total aggregation experiments show similar case 
of pre-seeded aggregation profiles.  Only profiles with good fits where a fitted value for Yi is 
within 35 % variability of a measured Yi, such as Fig. 2.4a were used for lag time comparison 
(Fig. 2.5) as well as log AB
2
 and log B
2
 comparison (see chapter 3).   
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Figure 2.4 Examples of the various goodness about fits of aggregation time courses to the 
sigmoidal equation (Eq. 2.1) 
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(a-c) The plotted values are the average light scattering from the 3 replicates of 10 
measurements for 30 sec (a and c) and 5 measurements for 10 sec. (b), and fits are shown as 
red lines (—).  It is worth noting that the y-axis scales are different because the data were 
collected using different light scattering instruments (see Materials and Methods, section 
2.2.2).  The criterion for the goodness of the data fit is how well Yi and Yf in Eq. 2.1 agree 
with the measured values for the initial and the average plateau intensities, respectively.  (a) 
The aggregation profile fits well to the sigmoidal equation (Eq. 2.1).  (b) The fitting result of 
Yf does not represent the average plateau reading.  This is probably due to the premature end 
of data collection.  (c) The fitted value for Yi does not match the initial intensity.  This is 
likely due to pre-seeding of the sample (i.e., the presence of aggregates at t=0).   
 
2.3.1.3 Aggregation is facilitated by dimer dissociation.   
The aggregation time courses were fit to an empirical equation for a sigmoidal curve, 
and fitted parameters used to calculate lag times and apparent rate constants (Nielsen et al, 
2001).  An approximate comparison of aggregation for different SOD1 mutants was made by 
averaging fitted values obtained from multiple independent aggregation time courses, 
excluding time courses from samples that appeared to be ―pre-seeded‖ (Fig. 2.4c).  There are 
no clear trends in the aggregation time course parameters with respect to protein stability or 
ALS characteristics (data not shown).  This is reasonable because aggregation can depend on 
various protein properties, including global and local instability and charge, in complex ways 
that are not well understood (Chiti & Dobson, 2009; Chiti et al, 2003a; Rodriguez et al, 
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2005; Shaw & Valentine, 2007).  It is noteworthy that sALS had a similar disease duration to 
many fALS cases, typically ~3-5 years.  Also, different mutant SOD1-fALS tend to have 
characteristic disease durations, for example the dimer interface mutant A4V has a 
particularly short duration of ~1 year (Wang, Johnson, Agar & Agar, 2008).  Interestingly, 
the lag times for the dimer interface mutants tend to be shorter than for pWT and other 
mutants (Fig. 2.5), suggesting that aggregation from holo SOD1 involves dimer dissociation.  
This is further supported by the protein concentration dependence of aggregation and 































Figure 2.5 Aggregation lag times for holo SOD1s 
The lag times were calculated using Eq. 2.1 (see Materials and Methods, section 2.2.5).  The 
presented values are means ± s.d. for 17, 6, 4, 3, 1, 4, 7, 5, and 5 independent experiments for 
pWT, A4V, A4T, A4S, I149T, G85R, G93D, G93V and G93S, respectively.  (†) indicates 
error estimate from the fitting program for this single experiment.  Symbols indicate 
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statistical significance of each lag time value with respect to that of pWT (*, P < 0.001; **, P 
< 0.065; ***, P < 0.05; and ‡, P > 0.1), determined using the two tailed Student’s t-test. 
 
2.3.1.4 Aggregation involves changes in metal binding. 
We further checked that aggregation occurs from the holo form of SOD1, and not 
from misfolded or mismetallated SOD1, by measuring specific activity during aggregation as 
well as conducting restart aggregation experiments.  SOD1 activity absolutely requires Cu 
and is sensitive to protein mismetallation or misfolding (Valentine, Doucette & Zittin Potter, 
2005).  Thus, if samples initially contain some misfolded or mismetallated SOD1 with lower 
activity than the holo form, aggregation of the lower activity protein should cause the 
specific activity of the remaining unaggregated protein to increase with time.  Fig. 2.6 
illustrates that the specific activity instead decreases as aggregation proceeds.  These 
decreases may be caused by altered metal binding and/or formation of soluble aggregates 
































































Figure 2.6 SOD1 specific activity decreases as a function of incubation time 
(a) pWT, (b) I149T, (c) G85R and (d) G93V.  Closed circles (●) represent the normalized 
ratio (see Materials and Methods, section 2.2.4).  Ratios were calculated from the average 
values for 3-5 activity measurements, and then normalized to 1 at t=0 (see Materials and 
Methods, section 2.2.4).  The vertical error bars are the s.d. from the replicate measurements.  
The arrows indicate the end of the lag phase from light scattering measurements conducted in 
parallel with activity measurements.  Some error bars are smaller than the symbols.   
 
Furthermore, if aggregation originates from a pre-existing pool of mismetallated or 
misfolded SOD1, no further aggregation should be observed if aggregates are removed after 
the plateau phase of the time course is reached.  Instead, a previously published study from 
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the Meiering laboratory showed another sigmoidal aggregation time course of pWT, A4V, 
G85R, and G93V occurs even after removal of the aggregates (Stathopulos, 2005).  This 
experiment was repeated with other mutants of SOD1, G85R and I149T, and showed the 
same results.  Together these results strongly support that aggregation arises from the holo 
protein.   
The metal content of aggregates was determined using ITV-ICP-AES.  The data 
clearly show that aggregates contain bound metals, but the protein is not fully metallated 
(Table 2.1).  Measurements of absorbance during aggregation time courses further support 
that changes in metal binding occur with time (details in chapter 3).  Thus, aggregation arises 
from the holo protein but involves some, though not complete, loss of metals. 
 











pWT 0.25 ± 0.03 0.44 ± 0.32
G85R 0.23 ± 0.08 0.11 ± 0.05




Calculated as the ratio of [Cu]aggregate/[S]aggregate to [Cu]native/[S]native and 
b 
calculated from [Zn]aggregate/[S]aggregate 
and [Zn]native/[S]native, where aggregate represents aggregates and  native represents fresh unaggregated protein 
solution.  
The values are means ± s.d. for 4 (pWT and G85R) and 2 (G93V) independent aggregation time courses, for 





2.3.2 SOD1 in aggregates is not significantly oxidized. 
Oxidative damage arising from aberrant Cu-mediated chemistry has been proposed to 
be a toxic function of mutant SOD1.  In order to investigate whether this is involved in the 
observed aggregation from holo SOD1 samples, ESI-MS was performed to try to detect 
oxidative modifications: 13 samples including pWT, G85R and I149T from the plateau phase 
of aggregation, were analyzed. In general, no changes in mass are observed except for one 
sample (out of 13 analyzed by MS); the protein species with increased mass by 16 mass unit 
(+ 16 adduct) was observed (Fig. 2.7).  The +16 adduct may be occurring from the oxidation 
of histidine residues (e.g., 2 oxo-histidine) near the Cu binding site, as seen in a previous 
study where aggregation of holo wild-type SOD1 was induced by the addition of Cu and 
ascorbate (Rakhit et al, 2002; Uchida & Kawakishi, 1994).  The results suggest that most 
aggregation occurs without Cu mediated aberrant chemistry and Cu mediate aberrant 
chemistry is not the primary toxic mechanism of disease since the +16 Da adduct was 





Figure 2.7 Mass spectrum of pWT before and after aggregation 
Molecular mass of pWT before aggregation (a) and supernatants (b) and pellets (c) of pWT 
after reaching plateau was determined. Symbols (*, **) represent +96 adducts and +26 
adducts, respectively.  These adducts probably come from sulfate ion and sodium ions.  The 
+98 adducts are frequently observed since ammonium sulfate is used for SOD1 purification 
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2.3.3 Holo SOD1 aggregation is less concentration dependent than typical 
aggregation. 
In protein aggregation reactions, lag phases occur because the initial nucleation event 
is unfavorable, and this is followed by relatively favorable and rapid aggregation (Harper & 
Lansbury, 1997).  For various disease-associated proteins, the lag phase has been found to 
depend on protein concentration, since the nucleation step requires association of protein 
subunits (Harper & Lansbury, 1997).  The concentration dependence of aggregation was 
determined for both pWT and the fALS associated mutant, G93V (Fig. 2.8).  For all samples, 
again a sigmoidal-like time course was observed.  The lag phase for both proteins decreases 
with increasing protein concentration (Fig. 2.8), as expected for a protein association 
reaction, though the concentration dependence is quite moderate (Ferrone et al, 1980; 
Nielsen et al, 2001).  One likely explanation is that SOD1 aggregation involves dissociation 
of the native dimer to monomers.  Similarly, increased formation of native dimer relative to 
aggregation-prone monomer at increased protein concentration was found to slow 
aggregation of immunoglobulin light chain (Souillac et al, 2002) and a similar mechanism 
has been proposed for SOD1 (Khare, Caplow & Dokholyan, 2004).  Thus, while increasing 
protein concentration can favour protein association reactions, it may also simultaneously 
disfavour aggregation by favouring competing association processes, such as formation of 




























Figure 2.8 Concentration dependence of holo SOD1 aggregation 
The concentration dependence of the lag phase for pWT (●) and G93V (○) is shown.  (*), 
(**), and (***) represent averages of 2, 4, and 5 independent experiments, respectively.  
Plotted values are average lag phase and the vertical error bars are the s.d. from the 
independent measurements per sample.   
 
2.3.4  Holo SOD1 aggregation is nucleation dependent. 
2.3.4.1  Self-and cross- seeding diminish the lag phase of aggregation. 
A hallmark of nucleated aggregation reactions is that the addition of preformed 
aggregates as seeds decreases or abolishes the lag phase (Chiti & Dobson, 2006; Harper & 
Lansbury, 1997).  Seeding has a central role in many diseases, such as Alzheimer’s (Harper 
& Lansbury, 1997) and prion diseases (Prusiner, 1998).  Previously, aggregation of samples 
before and after filtering with a 20 nm cutoff filter showed different lag phases, in which 
filtering increased the lag phase, suggesting that the presence of some seeds in the initial 
samples promotes aggregation (Stathopulos, 2005).  However, holo SOD1 nevertheless 
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remained capable of aggregating even when nuclei/aggregates (i.e., formed during sample 
preparation) are removed by filtration.  Seeding was examined further by adding aliquots of 
solutions that had been allowed to aggregate for different periods of time to fresh solutions of 
SOD1 (Fig. 2.9).  SOD1 exhibits both self-seeding for a given protein (pWT and A4V, Fig. 
2.9a-b), and cross-seeding between different variants (A4T, A4S and G93D with pWT, Fig. 
2.9c-e).  These findings are pertinent to understanding disease because SOD1-linked fALS is 
typically autosomal dominant, with patients having a single copy of the mutant gene as well 
as one copy of the wild type (Boillee, Vande Velde & Cleveland, 2006a), and it is not yet 
clear what roles the two forms of the protein may have in ALS (see Discussion, section 


















































































Figure 2.9 Concentration dependence of holo SOD1 aggregation   
The effects of self-seeding on the lag phase for aggregation of (a) pWT and (b) A4V and 
cross-seeding on the lag phase for aggregation of pWT upon addition of 10% (w/w) early 
seeds of (c) A4S, (d) A4T, and (e) G93D, respectively, are shown.  (a-e) Aggregation time 
courses for unseeded and 10% (w/w) early seeds of holo SOD1s are shown by (●) and (○), 
respectively.  Plotted values are average light scattering intensity and the vertical error bars 
are the s.d. from the 3 replicate measurements per sample and each measurement was 
composed of 10 runs for 30 sec.  Some error bars are smaller than the symbols.  The lag 
phase of the aggregation time course for SOD1 with seeds is significantly shorter (P < 0.001 
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at 66.5 h in (a) and at 48 h in (b), and P < 0.001 at 140 h in (c), at 60 h in (d), and at 64 h in 
(e)) than for the control samples (unseeded). 
 
2.3.4.2 Holo SOD1 undergoes heterogeneous nucleation. 
Two major types of nucleation mechanisms have been reported for protein 
aggregation: primary and secondary nucleation.  In homogeneous nucleation, only primary 
nuclei are formed, generating linear, unbranched aggregates (e.g., polyglutamine aggregation 
associated with Huntington’s disease) (Chen et al, 2002).  In secondary nucleation, additional 
nucleation sites are formed; this may occur by formation of heterogeneous nucleation sites on 
the sides of fibrillar aggregates, or by fragmentation of fibrillar aggregates, generating new 
ends for further aggregate growth.  Heterogeneous nucleation sites on the sides of fibres were 
originally described for hemoglobin in sickle cell anemia (Ferrone, Hofrichter, Sunshine & 
Eaton, 1980).  Fragmentation has now also been reported for prion propagation (Collins et al, 
2004) and β2-microglobulin amyloid formation (Xue et al, 2008).  Secondary nucleation can 
be characterized by branched aggregate structures and more rapid aggregate growth 
compared to the formation of aggregates involving only primary nucleation (Ferrone, 1999).  
The time courses of SOD1 aggregation were fit to models for primary and secondary 
nucleation (Fig. 2.10) as per Ferrone et al. (Ferrone, 1999) (see Materials and Methods, 

















































































Figure 2.10 Holo SOD1 aggregation time course is indicative of secondary nucleation. 
Data fitting to Eq. 2.3 and Eq. 2.4 (see Materials and Methods, section 2.2.5) was used to 
distinguish primary (- -) and secondary (—) nucleation mechanisms, respectively, for (a) 
pWT, (b) A4T, (c) G93V and (d) G93D.  R
2
 values for secondary nucleation fits for pWT, 
A4T, G93V and G93D are 0.972, 0.916, 0.975, and 0.984, respectively, and each of those is 
higher than the corresponding one for primary nucleation fitting.  Therefore, the rapid 
increases in light scattering are better fit by a secondary nucleation process.   
 
 
Further evidence for the occurrence of secondary nucleation was provided by analysis 
of aggregate structures by AFM.  AFM images at different stages of aggregation are shown 
in Fig. 2.11 for pWT and the fALS associated mutant, G93V.  The same types of species are 
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observed for both proteins.  During the lag phase, the predominant species is the native dimer 
(Fig. 2.12), and some globular amorphous species are also present (Fig. 2.11, yellow arrows).  
These amorphous species resemble the toxic ―oligomers‖ formed by many other disease-
associated proteins (Glabe, 2008).  There are also some elongated species that look like 
associated spherical species or protofibrils (Chiti & Dobson, 2006) (Fig. 2.11 cyan arrows).  
During the rapid growth phase, dimers are still the most abundant species (Fig. 2.12), but 
amorphous species increase in abundance and size (Fig. 2.11, red arrows).  Some of these 
immature aggregates show signs of branching (Fig. 2.11, cyan arrows), which becomes more 
pronounced in the mature aggregates from the plateau phase (Fig. 2.11 green arrows). The 
branched aggregates may become smoother with time (Fig. 2.11 e and f).  It is not clear from 
the available data whether the branched structures arise from the formation of heterogeneous 
nuclei on the sides of linear aggregates or from fragmentation; in either case, the branched or 
tangled fibrillar structures are indicative of the occurrence of secondary nucleation.  
Aggregates in ALS patients have been described as granules and tangled 15-20 nm granule-
coated fibrils (Kato et al, 2001; Shibata et al, 1994).  In addition, in mice models early 
aggregates are amorphous and later aggregates have similar fibrillar morphologies with these 
in ALS patients (Kato et al, 2001).  Thus, the structural characteristics of the holo SOD1 







Figure 2.11 AFM structural analyses show holo SOD1s gives rise to soluble oligomers 
followed by larger amorphous and tangled fibrillar species. 
Bars are 100 nm.  The AFM images are for G93V (a, c, and e) and pWT (b, d, and f) during 
the lag phase (a) and (b), rapid growth (c) and (d), and plateau (e) and (f) phases.  The 
yellow, cyan, red and green arrows point to oligomers, protofibrils, amorphous aggregates, 
and branched fibrils, respectively.  The cyan arrows also indicate possible branch points on 
the fibrils, which may arise from heterogeneous nucleation.  Samples were prepared by Y.M. 














































Figure 2.12 Quantitative analysis of AFM images shows a gradual decrease of dimer species 
and increase in larger species upon incubation. 
The symbols represent particle distribution at t=0h (–○–), lag phase (– –), and exponential 
phase (–▲–) of G93V holo aggregation.  The aggregation samples correspond to G93V in 
previous Fig. 2.11.   
 
2.3.5  Characterization of aggregate properties 
Since aggregate formation is generally highly sensitive to experimental conditions 
(Glabe, 2008), it is important to check that aggregates generated in vitro have the same 
characteristics as aggregates observed in disease.  Thus, the following sections characterize 
the aggregation with regards to tinctorial and antibody binding properties to determine the 
relevance of aggregates formed from holo SOD1 to these in ALS patients. 


























2.3.5.1 Tinctorial properties of aggregates formed from holo SOD1s 
The AFM images in Fig. 2.11 show that aggregates formed from holo SOD1 do not 
exhibit the typical morphology of amyloid fibrils (i.e., smooth and unbranched fibrils) but 
rather show tangled and granular coated fibrillar morphologies similar to those found in ALS 
patients and mice models (Kato et al, 2001; Shibata et al, 1994).  To establish further 
whether holo SOD1 aggregates have other properties typical of amyloid, binding of ThT, 
which is commonly used to detect amyloid formation, was measured upon aggregation 
(Hawe et al, 2008; Munishkina & Fink, 2007).  Fig. 2.13 shows that there is only a very 
small increase in ThT fluorescence upon aggregation (Fig. 2.13b) compared to that observed 
for other proteins that form amyloid (Munishkina & Fink, 2007).  Congo red dye is another 
dye that is typically used for detecting amyloid.  The absorption spectrum of the dye is red-
shifted upon binding to amyloid.  There was no change in Congo red absorption spectra upon 
binding to aggregates formed from pWT (P. Stathopolus and E.M. Meiering, unpublished 
data).  Additionally, ANS is commonly used for detecting exposed hydrophobic patches.  
There is no significant increase in ANS fluorescence upon aggregation (Fig. 2.13c) or during 
aggregation (Fig. 2.13d), and a blue shift in the maximum wavelength of ANS emission was 
not detected, implying that there is no significant hydrophobic area exposed during 
aggregation.  Together with AFM data (Fig. 2.11) and FTIR spectra (chapter 3), ThT, Congo 
red, and ANS dye binding data indicates that aggregates of holo SOD1s do not possess 





















































































































Figure 2.13 ThT and ANS binding by holo pWT aggregates 
(a) ThT binding assay of holo pWT; the dye alone (—), the aggregates from 3 mg/mL ( ) 
and 8.7 mg/mL (---).  (b) The intensity change at max (relative to the dye alone) in the ThT 
fluorescence is plotted as a function of incubation time for 3 mg/mL ( ) and 8.7 mg/mL (○) 
samples.  (c) ANS binding assay of holo SOD1s; the dye alone (—), with aggregates from 3 
mg/mL ( ) and 8.7 mg/mL (---) solutions of pWT.  (d) The intensity change at max (relative 
to the dye alone) of the ANS fluorescence is plotted against the aggregation time of 3 mg/mL 
( ) and 8.7 mg/mL (○) SOD1 samples.  The aggregation samples (3 and 8.7 mg/mL) for both 
ThT and ANS dye binding experiments had reached plateaus based on light scattering 
measurements (321.5 hrs incubation at 37 °C).  The samples were not separated between 
aggregates and supernatant.  The presented spectra and values are the average of at least two 
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different measurements of aliquots taken from the same samples, and the error bars are the 
s.d of the repeated measurements.  Each data point in b and d was calculated by subtracting 
the signal of the dye alone from the signal of the dye with the protein.  
 
2.3.5.2 Aggregates formed from holo SOD1 are recognized by ALS-specific 
antibody. 
Antibody binding experiments provide further evidence for the medical relevance of 
the holo SOD1 aggregates studied here.  Recently, an antibody that is specific for SOD1 in 
ALS was developed (Rakhit et al, 2007).  This antibody recognizes the SOD1 Exposed 
Dimer Interface (SEDI) by binding to a C-terminal peptide that is buried in the native dimer 
(Rakhit et al, 2007) (Fig. 2.1).  SEDI antibody specifically recognizes aggregated SOD1 in 
post mortem fALS patients and in mice models before and after the onset of disease 
symptoms, but does not bind to native holo SOD1 (Rakhit et al, 2007).  It should be noted 
that SEDI has not been found to detect SOD1 in sALS patients (Hsueh-Ning Liu et al, 
Published Online:  20 Mar 2009); however, this does not preclude a role for SOD1 
aggregation in sALS (see Discussion, section 2.4.3).  Competition ELISA experiments on 
purified unaggregated (control) and aggregated holo SOD1 show that SEDI binding increases 
upon aggregation (Fig. 2.14, P < 0.05).  The recognition of the dimer interface in the 
aggregates supports the proposed interpretation of lag phase and protein concentration 
dependence data, which suggests that formation of aggregates involved dimer dissociation to 
expose the interface (Fig. 2.2, Fig.2.5, and Fig. 2.8).  This striking finding is the first 
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Figure 2.14 SEDI antibody specifically recognizes aggregates formed from holo SOD1. 
Specific SEDI binding to aggregated (SODagg) or unaggregated (SODunagg) pWT was 
measured with competition of the C-terminal peptide epitope (see Materials and Methods, 
section 2.2.12). C represents the control of SEDI binding to the C-terminal peptide coated to 
the plate with SOD1 omitted.  The increased binding of aggregates relative to control is 
significant (**, P < 0.05), but there is no difference for unaggregated protein relative to 
control (*, P > 0.1).  The plotted values represent means ± s.d. for three independent 





This chapter has demonstrated for the first time that under physiologically relevant 
conditions holo SOD1 forms, by a nucleation dependent process, aggregates having the same 
structural as well as dye and antibody binding characteristics as aggregates observed in ALS 
patients and mice models.  Also, the aggregation appears to occur without significant levels 
of Cu-mediated aberrant chemistry.  These results have extensive implications for 
understanding disease mechanisms in ALS and other protein misfolding disorders, which are 
a growing group of devastating and prevalent diseases. 
 
2.4.1  Aggregation formed from holo SOD1 does not resemble amyloid. 
Aggregation reactions are typically complex, with competing reactions that are highly 
sensitive to solution conditions (Jahn & Radford, 2008a) and hard to characterize owing to 
sample heterogeneity (Glabe, 2008) (this is also evident here in the mixture of structures seen 
by AFM, Fig. 2.9).  Consequently, it can be difficult to compare and ascertain the relevance 
of different in vitro and in vivo studies.  A common aggregate structure formed in many 
neurodegenerative and other diseases is known as amyloid (Chiti & Dobson, 2006), and there 
has been debate as to whether or not ALS is an amyloid disease.  SOD1 has been shown to 
form amyloid under destabilizing conditions when subjected to sonication (Stathopulos et al, 
2004), low pH (DiDonato et al, 2003), or agitation (Chattopadhyay et al, 2008; Furukawa et 
al, 2008; Oztug Durer et al, 2009).  Furthermore, there is extensive evidence that all proteins 
can form amyloid under suitable, typically destabilizing, conditions (Chiti et al, 1999; Stefani 
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& Dobson, 2003).  Aggregates found in ALS patients do not exhibit the classic properties of 
amyloid, such as green-gold Congo Red birefringence (Linke, 2009; Okamoto et al, 1991) or 
smooth unbranched fibrillar structures (Kato et al, 2001; Shibata et al, 1994).  The 
aggregates studied here have high in vivo relevance because they form under physiologically 
relevant conditions and, based on multiple criteria (structure and dye and antibody binding), 
their properties match those of aggregates formed in ALS.   
 
2.4.2  SOD1 can aggregate by many pathways. 
The mechanism of aggregation from holo SOD1 likely involves both loss of metals 
and dimer dissociation.  Based on the high stability of holo SOD1 under the solution 
conditions used here, the population of the unfolded state for pWT and mutants will be 
extremely small (Rumfeldt et al, 2006), consistent with aggregation occurring from a state 
that is closer to the native state.  Previously, holo SOD1 has been proposed to be incapable of 
forming aggregates owing to its high stability (Shaw & Valentine, 2007).  However, 
aggregation could be initiated via local structural fluctuations (Chiti & Dobson, 2009), which 
are not necessarily linked to global stability (Khare & Dokholyan, 2006).  Recent 
experimental data suggest that the metal binding characteristics of SOD1 give rise to 
frustration and misfolding (Nordlund et al, 2009).  The activity and metal analysis data show 
that aggregation involves loss of some, but not all, metal (Fig. 2.6 and Table 2.1) and the lag 
phase (Fig. 2.2 and Fig. 2.5) and SEDI binding data (Fig. 2.14) suggest that dimer 
dissociation is occurring.   
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The experimental results herein support a mechanism similar to that proposed by 
Dokholyan and coworkers (Khare, Caplow & Dokholyan, 2004), modified to allow for 













Multiple pathways for pathological SOD1 aggregation.  Dholo, Mholo, DpMe/apo, MpMe/apo, Aoligo, Aamor, Afib, and 
Abranch represent the holo dimer, holo monomer, partially metallated or apo dimer, partially metallated or apo 
monomer, soluble oligomers, amorphous aggregates, fibrillar aggregates and branched aggregates, respectively.  
The expanded mechanism of Dokholyan and coworkers (Khare, Caplow & Dokholyan, 2004) is shown in solid 
lines and are supported by the data herein.  Fully metallated SOD1s may monomerize or lose metal by local 
fluctuation.  Either step may promote the other as the next step.  Dashed lines indicate additional possible 
aggregation pathways (which may include multiple steps) that are not excluded by the current data, and are 
supported by other findings from the literature.  The various aggregated species included in dashed square 
brackets may interconvert. 
 
There is considerable experimental support for Scheme 2.1 ((Khare, Caplow & Dokholyan, 
2004) and references therein).  Extensive additional data from the literature (Oztug Durer et 
al, 2009; Shaw & Valentine, 2007) (Banci et al, 2005; Banci et al, 2007b; Chattopadhyay et 
al, 2008; Stathopulos et al, 2003) can be included and rationalized by including additional 
pathways for aggregation of SOD1.  Similarly, multiple pathways have also been proposed 
for amyloid formation (Chiti & Dobson, 2006; Jahn & Radford, 2008a).  Also, a key and 
often overlooked point is that all SOD1 mutations studied to date destabilize the holo protein 
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(Hayward et al, 2002; Rumfeldt et al, 2006; Stathopulos et al, 2003), which is not 
consistently the case for the apo protein (Rodriguez et al, 2005).  In addition, the dimer 
interface for holo SOD1 is only slightly stronger than for apo SOD1 (Hornberg, Logan, 
Marklund & Oliveberg, 2007; Rumfeldt et al, 2006; Vassall et al, 2006); assuming dimer 
dissociation is required for aggregation; this means that it is certainly feasible for holo SOD1 
to aggregate.  Furthermore, fALS-associated mutations of the holo form increase dynamics, 
causing complex changes that propagate throughout the structure, as shown by NMR and x-
ray studies of G93A (Shipp et al, 2003), A4V (Hough et al, 2004a), I113T (Hough et al, 
2004a), and S134N (Banci et al, 2005).  Interestingly, the lag phase for G85R, which has 
weakened metal binding (Cao et al, 2008), is shorter than for pWT and G93 mutants (Fig. 
2.3), suggesting that loss of metal may favor dimer dissociation and hence aggregation.  This 
is reasonable because the Zn binding loop leads into the dimer interface (Fig. 2.1) (Hornberg, 
Logan, Marklund & Oliveberg, 2007). Conversely, the dimer interface mutants A4V, A4T 
and I113T have weakened Zn binding(Crow et al, 1997a).  Computational studies on many 
mutants have shown complex coupling between the dimer interface and metal binding loops 
(Khare & Dokholyan, 2006).  Thus, the proposed expanded aggregation mechanism accounts 
for our new data as well as extensive previous experimental and computational findings.  
Further support for loss of metals from holo SOD1 during aggregation is presented in 
Chapter 3.  
The Zn binding loop and electrostatic loops (Fig. 2.1) may be involved in forming 
intermolecular interactions in SOD1 aggregates.  Recently, as-isolated SOD1s that are 
partially metallated have been reported to exhibit structural and dynamic changes affecting 
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mainly the electrostatic and Zn binding loops (Molnar et al, 2009).  Although many mutant 
SOD1s are wild-type-like and appear to be predominantly properly metallated in vivo, there 
is also evidence for incomplete metallation of numerous mutants in various in vivo systems 
(Borchelt et al, 1994; Goto et al, 2000; Hayward et al, 2002; Seetharaman et al, 2009; 
Valentine, Doucette & Zittin Potter, 2005).  Common intermolecular interactions involving 
these loops and giving rise to branched assemblies have been identified in holo wild type and 
mutant SOD1 crystal structures (Hough et al, 2004a).  Also, many variations involving these 
(and various other) loops have been noted in crystal structures of partially or fully metal 
depleted wild type and mutant SOD1s, very often with formation of fibrillar assemblies 
(Elam et al, 2003).  Pertinent to the secondary nucleation observed here, the intermolecular 
interactions in the crystals may provide clues regarding possible heterogeneous nucleation 
sites on the sides of fibrils.  The above considerations together with the results presented 
herein suggest that aggregation from the holo protein may play a critical role in disease.  
 
2.4.3 Limited role for intermolecular disulfide bond formation in aggregation 
Many previous studies have focussed on the role of intermolecular disulfide bonds in 
SOD1 aggregation.  Recently, Borchelt and coworkers have shown that intermolecular 
disulfide bond formation is favoured only in the later stages of disease in mice and so it is 
likely a secondary effect (Karch et al, 2009).  In vitro studies of oxidative aggregation of 
wild-type apo SOD1 have also reported evidence for non-covalent interactions (Banci et al, 
2007b; Chattopadhyay et al, 2008; Furukawa et al, 2008; Oztug Durer et al, 2009).  Our 
studies are most pertinent to understanding non-covalent association, since the free cysteines 
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are eliminated in pWT.  This may be particularly important for the formation of pathogenic 
aggregates early in disease, and also contribute to ongoing toxic aggregation as the disease 
progresses.  
 
2.4.4 Implications for disease 
The observation of the same type of aggregation for pWT and mutant holo SOD1 
suggests that the holo protein may play an important role in both forms of the disease.  SOD1 
is a particularly abundant protein (see Introduction, section 2.1.1), placing it at high risk for 
aggregation (Rakhit et al, 2004).  Furthermore, motor neurons are particularly vulnerable to 
the toxic effects of protein aggregation (Boillee, Vande Velde & Cleveland, 2006a).  There is 
extensive evidence that many forms of SOD1 may aggregate, consistent with the general 
mechanism proposed in Scheme 2.1.  Aggregated SOD1 is generally found in fALS, but has 
only been reported for a subset of sALS cases (Hsueh-Ning Liu et al, Published Online:  20 
Mar 2009; Shibata, Asayama, Hirano & Kobayashi, 1996; Shibata et al, 1994).  This does 
not, however, rule out a role for SOD1 aggregation in additional sALS cases.  Detection of 
SOD1 in aggregates, and indeed the types of protein inclusions observed in different cases of 
ALS, vary considerably (Kato, 2008).  Also, SOD1 aggregates could be involved in early 
disease stages but do not accumulate to high levels in end-stage aggregates.  Alternatively, 
SOD1 may be present in end-stage aggregates but may not be detected due to inaccessibility 
of SOD1 epitopes, for example due to ubiquitination (Kato et al, 2001; Okamoto et al, 1991).  
It is also possible that the structures of SOD1 aggregates in ALS vary, perhaps in specific 
ways associated with different mutations (Shaw & Valentine, 2007) and disease 
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characteristics such as duration or onset, analogous to varying disease and aggregate 
characteristics in different prion strains (Prusiner, 1998).  Consistent with this, different 
mutant SOD1-mouse models have distinct phenotypes (Kato, 2008).  Further studies are 
needed to determine the characteristics of aggregates formed by different forms of SOD1 
(fALS mutations and metallation states) (Banci et al, 2005; Banci et al, 2007b; Elam et al, 
2003; Khare, Caplow & Dokholyan, 2004; Oztug Durer et al, 2009; Rakhit et al, 2004; 
Stathopulos et al, 2003), and different disease characteristics and stages.    
The seeding and secondary nucleation observed here also have important implications 
for understanding the disease characteristics of ALS.  The autosomal dominant inheritance of 
SOD1-fALS means that just one copy of the mutant SOD1 gene causes disease, and patients 
also express wild-type SOD1 (Boillee, Vande Velde & Cleveland, 2006a).  The cross-
seeding of mutant and pWT show that the two forms can co-aggregate.  This is consistent 
with results from cell culture fALS models where pWT and mutant SOD1 co-aggregate when 
co-expressed (Prudencio et al, 2009), and with fALS mice studies that found overexpression 
of pWT is required to convert A4V mice to a disease phenotype (Deng et al, 2006) and 
enhances the disease phenotype in other mutant SOD1 fALS mice models (Turner & Talbot, 
2008).  Combining different mutants with wild-type may have different aggregation (Fig. 
2.7) and hence disease characteristics.  Mutations could enhance initiation and/or propagation 
of aggregation and so favor disease.  Also, seeding and the very rapid growth of aggregates 




The aggregation observed here for holo SOD1 shares many characteristics with the 
aggregation of other disease-associated proteins, including occurrence of a lag phase (due to 
unfavorable nucleation, which can be overcome by seeding), formation of amorphous and 
fibrillar species, and very rapid aggregate growth due to secondary nucleation.  These 
findings support the hypothesis that SOD1 aggregation has common toxic effects with 
protein aggregation in other diseases.  The experimental system reported here represents a 
breakthrough for further elucidation of mechanistic details of SOD1 aggregation and co-
aggregation, and further defining key commonalities with and difference from other diseases.  
It can also be used to determine the nature and consequences of possible inappropriate 
interactions between SOD1 aggregates and other cellular components, such as chaperones, 
protein degradation machinery and membranes (Boillee, Vande Velde & Cleveland, 2006a).  
Finally, it may ultimately be useful for developing new therapeutics, such as small molecules 
or antibodies, which have shown promising initial results (Ray et al, 2005; Urushitani, Ezzi 
& Julien, 2007).  In summary, the current results provide new and potentially general insights 
into protein aggregation in disease and provide the basis for further studies to define 
aggregation mechanisms, identify inappropriate interactions, and develop urgently needed 





The role of metal loss in aggregation from holo SOD1 
3.1 Introduction 
Protein aggregation is a subject that has been extensively investigated in the field of 
biochemistry.  This is partially because protein aggregation has been implicated in the 
pathology of many different human diseases.  Importantly, aggregation can sometimes occur 
naturally with protein function (Chiti & Dobson, 2006; Ross & Poirier, 2004).  For example, 
polymerization of the muscle protein, actin controls the mobility and shape of the cells 
(Carlier & Pantaloni, 1997; Condeelis, 1993).  Thus, understanding aggregation is important 
not only in disease but also in natural protein function.  Pioneering work in understanding 
aggregation mechanisms using kinetic and thermodynamic approaches was reported by 
Oosawa and coworkers in 1959, who developed an aggregation model (Oosawa et al, 1959).  
This classical model has been used extensively over the years by other researchers.  Based on 
Oosawa and coworkers’ work, various related models and model systems have been 
developed, such as hemoglobin polymerization (Bishop & Ferrone, 1984) and prion protein 
self-replication (Griffith, 1967).  In general, however, aggregation is not yet well understood 
due to the complexity of aggregating systems.   
A general overview of aggregation is given in Fig 3.1, which is simplified from the 
scheme proposed by Roberts (Roberts, 2007).  It is important to keep in mind that this simple 
depiction is an attempt to describe protein aggregation, but aggregation reactions are much 
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more complicated than depicted in Fig. 3.1.  In particular, aggregation in vivo is far more 
complex due to the many possible modulating effects in the cellular environment, including 
crowding effects (Munishkina et al, 2004) and/or interactions of various cellular components 
such as chaperones, protein degradation machinery, and membranes (Bellotti & Chiti, 2008).  
Fig. 3.1 illustrates three stages pertinent to aggregation: pre-stage, stage I, and stage II.  Stage 
I is the reversible association of two or more reactive units, which was first introduced by 
Oosawa and coworkers (Oosawa, 1975; Oosawa et al, 1959).  Their reactive unit was the 
folded monomer of actin and therefore they did not consider a pre-stage in their work.  These 
early studies considered aggregation as a simple association reaction and usually monomers 
were the addition unit (Bishop & Ferrone, 1984; Ferrone, 1999; Oosawa, 1975).  Later, 
protein unfolding pathways (corresponding to the pre-stage in Fig. 3.1) were added to 
aggregation mechanisms as many experimental results supported the importance of 
additional monomer unfolding events proceeding the aggregation process (Andrews & 
Roberts, 2007; Arnaudov & de Vries, 2007; Kelly, 1998).  Thus, competition between re-
folding and aggregation can add additional complexity (Arnaudov & de Vries, 2007; Hamada 
et al, 2009; Wiseman et al, 2005).  In addition, many different types of unfolding 
intermediates have been proposed as the reactive units in the aggregation of different 
proteins.  A partially unfolded monomer is likely to act as the reactive unit in most 
aggregating systems, for example, for monomeric proteins such as lysozyme (Booth et al, 
1997) or β2-microglobulin (Chiti et al, 2001), and for multimeric proteins such as TTR 
(Wiseman, Powers & Kelly, 2005) and β-lactoglobulin (Hamada et al, 2009).  Generally, 
multimeric proteins are proposed to dissociate before aggregating.  It is important to note that 
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the same protein can form different aggregate structures (i.e., having different morphology) 
due to different experimental conditions that result in the formation of different reactive units 
(Khurana et al, 2001).   
Stages I and II are separated by the formation of nuclei, the least stable species in 
aggregation pathway and, therefore, the least populated species (Fig. 3.1) (Ferrone, 1999).  
Historically, nucleation-dependent aggregation was first introduced by Oosawa and Asakura 
(Oosawa, 1975) as primary (homogeneous) nucleation, whereby reactive units associate at 
the end of oligomers to form primary nuclei during a thermodynamically unfavorable 
process, generating linear, unbranched aggregates (e.g., polyglutamine aggregation 
associated with Huntington’s disease) (Chen et al, 2002).  Ferrone et al. later introduced the 
secondary nucleation mechanism, whereby reactive units add to a secondary nucleus site via 
heterogeneous nucleation (sides of an existing aggregate) or fragmentation generating new 
ends for further aggregation growth.  Aggregates formed by secondary nucleation are 
characterized by branched structure and rapid aggregate growth preceeding an exponential 
phase (Ferrone, 1999) (this is described in more detail in section 2.3.6).  After nucleation, 
thermodynamically favored additions (i.e., irreversible additions) occur during Stage II.  One 
can also include additional interactions between aggregates in stage II, such as cross-linking 





Nucleus Mature f iibrils
Native monomer
Native multimer




















Figure 3.1 General scheme for protein aggregation 
This figure was modified from Roberts et al (Lowry, Rosebrough, Farr & Randall, 1951).  (a) 
Pre-stage represents a protein unfolding event which results in the formation of reactive 
units.  Partially unfolded monomers have been proposed as reactive units, or to be closely 
related to the reactive unit.  Alternative pathways for formation of the reactive unit from a 
native multimer or monomer are illustrated here.  Stage I is the energetically unfavourable 
step of reversible association of reactive units to form a nucleus, and stage II is the 
subsequent favourable stage of irreversible addition of reactive units to form a fibrillar 
aggregate structure.  (b) Relative energy diagram for reactive units, nucleus, and mature 
fibrils.   
 
3.1.1 Theoretical aspects of protein aggregation  
This section describes the differential equations for the kinetics of aggregation 
including both homogeneous and heterogeneous nucleation.  The rate equations for the 
formation of aggregates and the disappearance of native proteins are formulated using the 
classical model proposed by Oosawa and coworkers (Oosawa, 1975) with the addition of 
heterogeneous nucleation introduced by Ferrone and coworkers (Bishop & Ferrone, 1984; 
Ferrone et al, 1985).  The equations from Eq.3.1 to Eq. 3.10 are based on Oosawa’s model, 
which is based on primary nucleation, followed by inclusion of equations for heterogeneous 
nucleation.  The heterogeneous nucleation model of Ferrone and coworkers has been used 
extensively to study the polymerization of deoxygenated hemoglobin S involved in the 
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pathophysiology of sickle cell disease (Bishop & Ferrone, 1984; Ferrone, Hofrichter & Eaton, 
1985).  This model has also been applied to other systems, including β-lactoglobulin 
(Arnaudov & de Vries, 2007) and polyglutamine aggregation (Chen et al, 2002) and is also 
applied here to demonstrate the heterogeneous nucleation dependence of aggregation from 
holo SOD1s (see Results, section 2.3.6).   
According to Oosawa’s model, the first association step in protein aggregation is 
represented as: 
 








K               Eq. 3.1 
 
where A is the monomer, A2 is the dimer, and K2 is the equilibrium constant for association.  
Prior to formation of the nucleus, association reactions are reversible and dissociation is 
favored (the length of the arrows represent the relative size of the corresponding rate 
constants).  The concentration of A2 can be expressed using K2 as: 
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The next association and equilibrium constant are shown in the same manner as Eq. 3.1: 
 



















where [A2] is replaced using Eq. 3.2.  Therefore, the concentration of Ax (for any given x-
mer) can be expressed in terms of Kx: 
 
x
xx AKKKA ][][ 32        Eq. 3.4 
 
We define i-mers (the associated species containing i units of A) as the homogeneous 
nucleus, which is the least stable species in the reaction.  Additionally, the rate constant for 
formation of Ai from A + Ai-1-mer and the reverse dissociation reaction are taken to be equal 
(Ferrone, 1999).  The equilibrium constant, Ki and the concentration of Ai, are given by: 
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where K* = K2K3····Ki-1.  The rate equations for i-mers (nucleation) and (i+1)-mers can then 





















Assuming that the total concentration of aggregates formed by primary nucleation (CP1, 
where P1 represents aggregates formed by primary nucleation) is the sum of the 
concentrations of all species of size (i+1) or larger and setting the rate constant for addition 
and dissociation of the monomer during the formation of the primary nucleus in stage 1 and 
the aggregates (P1) in stage II to be (k+) and (k-), respectively, then the rate of aggregate 















     Eq. 3.8 
 
where Cx is the concentration of aggregates at a given size.  Note the last two terms in any 
given rate equation are cancelled out by the first two terms in the rate equation of the next 
larger aggregate (i.e., with one more monomer added).  Eq. 3.8 can be simplified using the 







P         Eq. 3.9 
 










This is the general equation for growth of aggregates formed by a primary nucleation process 
with subsequent addition of monomer, A.   
Now, let us consider heterogeneous nucleation as per Ferrone et al. (Bishop & 





























Figure 3.2 Formation of heterogeneous nucleus, Pj 
(a) Pj is formed by the association of a monomer to the existing polymer, Pj-1.  (b) The 
formation of Pj is treated as an equilibrium process with two hypothetical steps (top and 
bottom): (1) the formation of j-mers first in the solution; and (2) the attachment of the j-mer 
onto the surface of an existing polymer.  
 
The first association of a monomer (A) onto the surface of an existing polymer (P1) can be 
written as: 
 








K         Eq. 3.11 
 
Using a similar model and derivation as for homogeneous nucleation but with j (instead of i) 
monomers forming the heterogeneous nucleus (instead of homogeneous, for details see 







        Eq. 3.12
 
 
where CP2 is the total concentration of aggregates (P2, any species of size (Pj+1) or larger) 
formed via heterogeneous nucleation, Pj is a heterogeneous nucleus, k+ is the rate constant for 
addition of monomer, A, to form homogeneous and heterogeneous nuclei and aggregates (P1 
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      Eq. 3.13
 
 
where P is the sum of P1 and P2, and CP is the total concentration of aggregates.  It is 
convenient to treat [Pj] as an equilibrium process taking place in two hypothetical steps: (1) 
the formation of free j-mer in solution, (2) the attachment of this j-mer onto the surface of an 
aggregate (Fig. 3.2).  In order to express [Pj] in terms of initial protein concentration [A0], the 
Langmuir isotherm derivation is considered for the equilibrium of heterogeneous nucleation.  






  Eq. 3.14
 
where [Pjt] is the total concentration of available sites for attaching a solution phase j-mer, 
is the equilibrium constant for attaching a solution phase j-mer to the polymer surface, Cj 
is the concentration of solution phase j-mer, A0 is the initial total monomer concentration of 
the protein,  is a scaling factor that determines the number of available nucleation sites per 
polymerized monomer, and jK
~
 is the equilibrium constant for formation of a j-mer in 
solution from j monomers.  Therefore, the change in concentration of aggregates with time 


















This is the general equation for growth of aggregates formed by homogeneous and 
heterogeneous nucleation processes with subsequent addition of monomers.   
 
The rate equation for loss of the native protein from solution into the homogeneous aggregate 









     Eq. 3.16
 
 
where the details are described in Appendix D.   
Since the differential rate equations (Eq. 3.15 and 3.16) become more complicated 
due to the addition of heterogeneous nucleation, the equations cannot be integrated 
analytically.  Ferrone et al. (Bishop & Ferrone, 1984; Ferrone, Hofrichter & Eaton, 1985) 
solved this problem by linearizing the rate equations as Taylor series and then truncating the 
series to first-order terms.  This method produces a simplified set of equations that can be 
integrated and applied to the initial 10-15% of aggregation reactions (Bishop & Ferrone, 
1984; Ferrone, Hofrichter & Eaton, 1985).  As a result, the concentration of protein that is 
incorporated into aggregates (Δ = A0-Afree, where A0 is the initial (non-aggregated) protein 
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concentration and Afree is the concentration of non-aggregated protein at a given time and can 
be written as:   
 
      Eq. 3.17\ 
 
, and
.  Eq. 3.17 actually corresponds to Eq. 2.4, (i.e., fractional completion = │A│ 
{cosh(│Bt│)-1}).  However, the parameters A and B in Eq. 2.4 are expressed in kinetic and 
thermodynamic terms relating to the aggregation model.  Fitting of aggregation data to Eq. 
3.17 /2.4 provides insight into the mechanism, as described in Chapter 2.  The formalism of 
Oosawa and Ferrone allows for interpretation in terms of kinetics and thermodynamic terms.  







is composed of the terms related to only primary nucleation and 




 (Bishop & Ferrone, 1984; Ferrone, Hofrichter & Eaton, 1985).  
 
      Eq. 3.18 
 




where As is soluble protein concentration at equilibrium.  Equations 3.18 and 3.19 can be 
used to gain further insight into the aggregation mechanism for holoSOD1 as a log-log plot 
of AB
2
 versus A0 can provide information about the size of the nuclei since the slope of the 
plot is (i+1). 
 
3.1.2 Methods to characterize aggregation 
A variety of techniques has been used for characterization of aggregation processes 
involving the partially unfolded reactive unit and the oligomers that form prior to fibril 
formation.  These include sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), light scattering (LS), Fourier transform infrared (FTIR) spectroscopy, atomic force 
microscopy (AFM), CD spectroscopy, analytical ultracentrifugation (AUC) (Liu et al, 2006), 
and intrinsic and extrinsic fluorescence (Alcaraz & Donaire, 2004) (reviewed in (Frieden, 
2007; Morris et al, 2009; S.E., 2006)).  In the current work, the mechanism of holo SOD1 
aggregation is further investigated using LS, FTIR, CD, ultraviolet (UV), and fluorescence 
spectroscopy.  The application of optical spectroscopies involves well established qualitative 
analyses.  The following section describes the background theory for quantitative analysis of 
dynamic light scattering (DLS) since DLS was used as a tool to analyze aggregation profiles.    
 
3.1.2.1 Dynamic Light Scattering (DLS)   
In contrast to static light scattering (SLS) which collects scattered light from particles, 
DLS measures changes in light scattering over time since the intensity of light scattering 
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from particles in a solution fluctuates due to Brownian motion.  The time-dependent 
fluctuation depends on how fast the particles move.  The rapid change of the light scattering 
intensity is commonly analyzed using autocorrelation functions.  The following processes are 
used to accomplish the autocorrelation analysis: first, the deviation of scattered intensity (Δi 
(t)) at time t is defined from the intensity (i (t)) at time t and the average intensity i as: 
 
Δi (t) = i (t) – i         Eq. 3.20 
 
Then, the autocorrelation function is defined using a fixed τ as: 
 
G(τ) = Δi (t) • Δi (t + τ)        Eq. 3.21 
 
where Δi (t + τ) is the deviation of scattered intensity at some later time (t + τ) and the bar 
means to average the product over t, using a fixed interval τ.  When τ is very small, both 
terms used in Eq. 3.21 will have the same sign, whereas when τ is large, the value of Δi (t) • 
Δi (t + τ) will be negative as often as positive, having a higher chance to be zero (Fig. 3.3) 



































Figure 3.3 Autocorrelation of two different cases with large and small  
For large , the chance that the average of Δi (t) • Δi (t + τ) over time, t in Eq. 3.21 becomes 
zero is high, whereas for small , Δ i(t) and Δ i(t + ) in Eq. 3.21 usually have the same sign. 
 
Thus, the quantity of G(τ) decays exponentially with τ according to: 
 
         Eq. 3.22 
 
where D is  the diffusion coefficient of solution, and q is the scattering vector.  The scattering 
vector is given by: 
 




where n is the refractive index of solution,  is the wavelength of the incident light, and θ is 
the scattering angle.  Using the diffusion coefficient, the hydrodynamic radius of particles 
can be determined from the Stokes-Einstein relationship with the assumption that the 
particles are hard spheres (Jachimska et al, 2008; van Holde Kensal E., Johnson W. Curtis & 
Shing, 1998): 
 
             Eq. 3.24 
 
where k is Boltzmann’s constant, T is temperature in Kelvin and η is the solvent viscosity at 
T.  When the distribution of particle sizes is narrow and monodisperse, the average radius can 
be determined by the well known method of cumulants analysis (Koppel, 1972).  However, 
when the particle distribution is polydisperse, as can occur during protein aggregation, 
cumulants analysis is no longer applicable.  In this case, Eq. 3.22 must be integrated over all 
possible sizes and corresponding diffusion coefficients using the CONTIN method 
(Provencher, 1982).   
 Although DLS has been developed as a tool for monitoring aggregation time courses 
(Nicolai & Durand, 2007), it still has weak points for applications with protein aggregation.  
For example, the hydrodynamic radius of the particles estimated using Eq. 3.24 is based on 
the assumption that the particles are hard spheres.  Often, proteins form aggregates with 
fibrillar shapes, which cannot be analyzed as described above.  There is, however, an 
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empirical equation available to convert the calculated diameter to fibril length (Lomakin et al, 
1996).   
 
3.1.3 Chapter Overview 
The results presented in this chapter show that dimer dissociation and metal loss play 
important roles in the aggregation that arises from the native, holo form of SOD1, with or 
without fALS associated mutations, under physiologically relevant solution conditions (37 
°C and pH 7.8).  Moreover, various structural probes (intrinsic fluorescence, CD, and UV 
spectroscopies) provide evidence for two aggregation pathways that differ with respect to 
dimer dissociation and metal loss.  Thus, this chapter provides additional experimental 
evidence for the aggregation mechanism proposed in chapter 2 (Scheme 2.1) and further 
supports the hypothesis that the most stable form of SOD1 can play an important role in 
pathological aggregation of ALS.   
 
3.1.4 Other contributions 
This work includes data obtained by various people, which is acknowledged in the 
following text.  I was involved in obtaining all of the data described in this chapter unless 
otherwise stated.  I would like to thank: Kristin Dimmick, who assisted in collecting 
aggregation data including light scattering measurements; and Ming Sze Tong, an MSc 
student who also assisted in collecting aggregation profiles of holo A4S and holo A4T.   
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Metal analysis for confirming Cu/Cu SOD1 was done at the ALS laboratory Group in 
Waterloo using inductively coupled plasma- mass spectrometry (ICP-MS).   
 
3.2  Materials and Methods  
3.2.1 Expression and purification of pWT and mutant SOD1 
The SOD1 proteins were prepared as described in section 2.2.1.   
 
3.2.2  Preparation of apo from holo SOD1 
Extensive dialysis was used for preparation of apo SOD1 from holo SOD1.  A 
dialysis bag (3000 Da cutoff, cellulose membrane. Spectrum Laboratories, Inc.) was 
regenerated by soaking it into water for 3 times (20 min per each time) prior to being used.  
Holo proteins were dialyzed first against 50 mM sodium acetate, 100 mM 
ethylenediaminetetraacetic acid (EDTA), pH 3.8 at 4 °C (at least 3 exchanges of 4 L, 8 hrs 
per each time).  Then, the protein is dialyzed against 50 mM sodium acetate with 100 mM 
NaCl, pH 3.8 at 4 °C (at least 3 exchanges of 4 L, 8 hrs per each time).  Lastly, the proteins 
were dialyzed against milliQ water at 4 °C (at least 3 exchanges of 4 L, 8 hrs per each time).  
The apo proteins were concentrated using an Amicon untrafiltration device (YM3 amion 
untrafiltration membrane, Millipore Ltd.).  Protein concentration was determined using the 
Lowy assay (Lowry, Rosebrough, Farr & Randall, 1951) and aliquoted into various volumes.  




3.2.3  Preparation of Cu/E and E/Zn SOD1 
To identify whether holo SOD1 loses metals during aggregation by taking UV 
measurements, Cu/E and E/Zn SOD1 (E represents empty) were prepared as following the 
procedures in a previous study (Beem et al, 1974).  Apo pWT was diluted to 0.45 mg/mL in 
Milli Q water, and then 1 eq. (per monomer) of CuCl2 or ZnCl2 (i.e., 5.6 μL of 5mM of 
CuCl2 or ZnCl2) was added.  (Note that at the end of the apo SOD1 preparation, the pH of the 
solution is 3.8; hence an additional acidification step was not needed (Beem, Rich & 
Rajagopalan, 1974)).  Since the metal reconstitution is time-dependent (Beem, Rich & 
Rajagopalan, 1974), the mixtures were incubated overnight at room temperature.  Cu/Cu 
SOD1 was prepared using a bench-top fermentor by adding excess Cu ions and the metal 
contents in the proteins was identified using a ELAN9000 (Perkin Elmer) following the 
procedure of EPA200.8.   
 
3.2.4 Static and dynamic light scattering (SLS and DLS) 
 Static and dynamic light scattering were measured simultaneously, using a 90Plus 
particle sizer (Brookhaven Instruments, Inc.) or a Zetasizer Nano-SZ (Malvern).  Comparable 
results were obtained with both instruments.  The autocorrelation functions measured for the 
protein samples are an average of 10 (5) consecutive measurements for 30 sec (10 sec) with 
the 90Plus (Nano-SZ) instrument.  The hydrodynamic diameter was calculated from the 
autocorrelation function using cumulants or CONTIN analysis, using the software supplied 




3.2.5  Attenuated total reflectance (ATR)- FTIR spectroscopy 
FTIR spectra of SOD1s were collected using a Tensor 27 FTIR spectrometer (Bruker 
Optics) at room temperature (RT).  A mercury-cadmium-telluride (MCT) detector was used 
because it can be used for a broad spectral range (400 to 4000 cm
-1
) and was operated at a 
liquid N2 cooled temperature.  The IR spectrometer was purged extensively by N2 gas prior to 
and during IR measurements to minimize interference of CO2 and H2O signals.  Protein 
samples contained 20 mM HEPES at pH 7.8, and 3 mg/mL protein.  A volume of 30 μL of 
the protein samples was placed onto the ATR sample holder.  For each spectrum, 254 scans 
were collected in single beam mode with 4 cm
-1
 resolution.  Buffer spectra were collected 
under identical conditions.  Only the spectra that met the criterion of effective water 
subtraction (flat baseline between 1700 – 2000 cm
-1
) were used for further analysis.  The 
reported spectra of SOD1 were not subjected to any further manipulation, but the reported 
first derivative spectra (Fig. 3.15) were smoothed using Origin 7.5 by a second order 
Savitzky-Golay derivative with 11 point smoothing to decrease noise (Bromba & Ziegler, 
1981).  The ATR sample holder was cleaned between sample measurements by first adding 
SDS solution (1% (w/v) SDS in MilliQ water) and then incubating for 5 min, then the SDS 
solution was pipetted for several times to remove proteins that were adhered onto the ATR 
sample holder.  MilliQ water replaced the SDS solution by pipetting, and this step was 
repeated until no more foam was created by pipetting.  The holder was then dried using a Q-
tip, according to recommendations from the instrument manufacturer.  The secondary 
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structure of the proteins was analyzed by pattern recognition algorithms using the QUANT2 
analysis tool supplied by the manufacturer.   
 
3.2.6 Temperature Ramp of ATR-FTIR spectroscopy 
The FTIR spectra were collected as a function of temperature using the same method 
described in 3.2.5, except that the number of scans was reduced to 100 scans.  Background 
spectra of 20 mM HEPES, pH 7.8, were obtained first as a function of temperature, and then 
the spectra of protein samples (3 mg/mL in 20mm HEPES, at pH 7.8) were obtained at the 
same temperatures as the background spectra.  30 μL of the protein solution was placed onto 
the ATR sample holder and a Teflon O-ring was used to prevent evaporation.  The reported 
IR spectra of protein samples were analyzed after subtracting from the background spectra at 
each temperature.  For the temperature ramp, IR spectra were obtained every 5 °C between 
30 °C and 60 °C (program 1), every 2 °C between 60 °C and 66 °C (program 2), every 1 °C 
between 66°C and 80°C (program 3), and 2 °C between 80 °C and 90 °C (program 4) 
respectively.  Program 1, 2, 3, and 4 used 30 sec, 60 sec, 30 sec, and 60 sec for equilibration 
time after reaching the desired temperature, respectively.  Temperature was controlled using 
a Thermo HAAKDC 30 water bath (Haake).  The difference spectra relative to the spectra 
obtained at 35 °C were performed from the simple calculation; the spectra at higher 




3.2.7 Holo SOD1 aggregation monitored by optical spectroscopic methods 
The samples for holo SOD1 aggregation experiments were prepared as described in 
section 2.2.2.  Aliquots were removed at various time points of incubation for various 
spectroscopic measurements including fluorescence, CD and UV spectroscopy (see below).  
At various time points, 54 μL of the aggregation solution was diluted in 1 mL MilliQ water 
(i.e., final concentration is 0.54 mg/mL SOD1 in 1.08 mM HEPES).  The diluted protein was 
centrifuged (14000 g, 10 min) using an eppendorf centrifuge), and then 700 µL of 
supernatant was removed for fluorescence, CD, and UV spectroscopic measurements.  If the 
pellet (the bottom 300 μL) was used for analysis, then it is stated.  After the measurements 
were obtained, the protein concentration was measured using the Lowry assay (Lowry, 
Rosebrough, Farr & Randall, 1951) for normalization of various data.  For unaggregated 
protein samples as a control (fluorescence and CD measurements), the proteins (0.54 mg/mL) 
were prepared in 1.08 mM HEPES, pH 7.8 after being freshly thawed from –80 °C freezer. 
 
3.2.7.1  Intrinsic fluorescence spectroscopy 
Unaggregated and aggregated protein samples were prepared as previously described 
(see Materials Methods, section 3.2.7).  The supernatant of holo SOD1 aggregation samples 
at various time points was placed into a cuvette to measure fluorescence using a Fluorolog3-
22 (Instrument SA, Edison, NJ) at 25°C.  The samples were excited at 280 nm and emission 
was scanned between 300 – 400 nm.  Excitation and emission slit widths are 1 and 2 nm, 
respectively.  To facilitate accurate measurement of wavelength maxima and intensity, the 
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raw spectra were smoothed using Origin 7.5 by a second order Savitzky-Golay derivative 
with 11 point smoothing (Bromba & Ziegler, 1981).  
 
3.2.7.2  CD spectroscopy 
Unaggregated and aggregated protein samples were prepared as previously described 
(see Materials Methods, section 3.2.7).  CD spectra for SOD1s were collected using a J715 
CD spectrometer (Jasco, Inc.) with a 1.0 mm path-length quartz cuvette at 25 °C.  The 
parameters: 1 nm for resolution, 2.0 nm for bandwidth, and 50 nm/min for speed, were used.   
 
3.2.7.3 UV spectroscopy 
UV measurements were made during aggregation time courses using a Cary 300 UV 
spectrometer (Varian, Inc.) with a 1 cm pathlength quartz cuvette at RT.  400 µL of the 
prepared protein samples (see Materials Methods, section 3.2.7) were placed in the cuvette 
and UV spectra were obtained between 230 – 400 nm spectral range.  Prior to protein sample 
measurements, the buffer (20 mM HEPES, pH 7.8) was scanned and this was subtracted 
from the sample spectrum.  In particular, the UV slope between 255 – 270 nm, calculated as: 
(A270 –A255)/15, was used as a measure of metal loss during aggregation.   
 
3.2.8 Metal analysis 





3.3.1 Common aggregation kinetics for pWT and fALS-associated mutant 
SOD1s 
The sigmoidal aggregation time courses of pWT and fALS-associated mutants of 
SOD1 that were obtained using SLS are shown in chapter 2 (see Results, section 2.3.1).  
Additional information on the size distribution of the aggregates can be obtained using DLS 
measurements.  Fig. 3.4-3.7 show the aggregation profiles, autocorrelation functions and size 
distributions for holo SOD1 samples at different time points during aggregation time courses.   
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Figure 3.4 Evolution of pWT aggregation 
(a) A representative sigmoidal aggregation profile for pWT.  The colored arrows indicate 
time at 18 h, 60 h, 108 h, 137 h, 156 h, 180 h, and 228 h.  The color code for the arrows 
matches that in (b and c) (i.e., from earlier to later; the color is black, red, green, blue, purple, 
magenta, and orange).  The broken line in (a) shows the fit of the data to the empirical 
equation (Eq. 2.1).  The plotted values and the associated error bars are normalized mean 
light scattering and s.d. from the 3 replicates of 5 measurements for 10 sec.  (b) Time 
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evolution of autocorrelation function during the aggregation shown in (a).  (c) The size 
distributions (hydrodynamic diameter, nm) during the aggregation shown in (a).  In (b and c), 






















































































































































































































Figure 3.5 Evolution of G85R aggregation 
(a) A representative sigmoidal aggregation profile for G85R. The arrows indicate time at 0 h, 
120 h, 144 h, 168 h, 240 h, 386 h, and 504 h.  The same color code as in Figure 3.4 is used.  
The broken line in (a) shows the fit of the data to the empirical equation (Eq. 2.1).  The 
plotted values and the associated error bars are normalized mean light scattering and s.d. 
from 3 replicates of 5 measurements for 10 sec.  (b) Time evolution of autocorrelation 
function during the aggregation of (a).  (c) The size (hydrodynamic diameter, nm) change 





























































































































































































Time (hrs) Delay times  (μsec)
 
Figure 3.6 Evolution of G93V aggregation 
(a) A representative sigmoidal aggregation profile for G93V.  The arrows indicate time at 18 
h, 108 h, 137 h, 180 h, 228 h, and 301.  The same color code as in Fig. 3.4 is used.  The 
broken line in (a) shows the fit of the data to the empirical equation (Eq. 2.1).  The plotted 
values and the associated error bars are normalized mean light scattering and s.d. from 3 
replicates of 5 measurements for 10 sec.  (b) Time evolution of autocorrelation function 
during the aggregation of (a).  (c) The size (hydrodynamic diameter, nm) change during the 
aggregation of (a).  In (b and c), (*) indicates the second species at t = 137 h.   
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Figure 3.7 Evolution of A4T aggregation 
(a) A representative sigmoidal aggregation profile for G93V.  The arrows indicate time at 0 
h, 43 h, 63 h, 85 h, 136 h, and 226 h.  The same color code as in Fig. 3.4 is used.  The broken 
line in (a) shows the fit of the data to the empirical equation (Eq. 2.1).  The plotted values 
and the associated error bars are normalized mean light scattering and s.d. from 3 replicates 
of 5 measurements for 10 sec.  (b) Time evolution of autocorrelation function during the 
aggregation of (a).  (c) The size (hydrodynamic diameter, nm) change during the aggregation 




The experimental conditions for aggregation were the same as in chapter 2 (see 
Materials and Methods, section 2.2.2): holo SODls (generally 10 mg/mL in 20mM HEPES, 
at pH 7.8) were incubated at 37 °C.  At t=0 h (or t=18h), the autocorrelation functions for all 
the samples show a single decay, indicating that the solutions are monodisperse (i.e., consist 
of a single species).  DLS is extremely sensitive for the detection of larger species relative to 
smaller species, because the intensity of scattered light is proportional to the sixth power of 
the radius (Lomakin, Benedek & Teplow, 1999).  By deconvolution of single-phase 
correlation functions using the method of cumulants (Koppel, 1972), the hydrodynamic 
diameters of the species were determined to be 5.38 ± 0.10 nm, 5.32 ± 0.13 nm, 5.44 ± 0.11 
nm and 4.93 ± 0.06 nm for pWT, G85R, G93V, and A4T, respectively.  These measured 
diameters agree with the calculated size of the holo SOD1 dimer using Eq. 3.24 with the 
assumption that the viscosity of the protein solution is the same as that of water at 37 °C.  
Furthermore, the measured diameter is in agreement with other published hydrodynamic 
diameters of smiliar MW proteins by DLS: β lactoglobulin (36.8 kDa, 6.27 nm (de la Torre et 
al, 2000), tetramer of insulin (23.2 kDa, 5.0 nm); and hexamer of insulin (34.8 kDa, 5.9 nm) 
(Kadima et al, 1993) .  It is interesting to note that A4T, a dimer interface mutant, has a 
smaller hydrodynamic diameter compared to the others (P < 0.0003 for A4V compared with 
pWT).  If the smaller diameter for A4T is due to its higher population of monomers, it 
supports the finding in chapter 2; aggregation of A4T has a shorter lag phase than pWT and 
G93 mutants and the proposed reason for this observation is that dimer dissociation is 
required for aggregation (see Fig. 2.2, 2.5, and 2.14).   
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DLS has been used for detecting soluble oligomers or protofibrils that are formed 
during aggregation of various proteins (Kumar et al, 2007; Plakoutsi et al, 2005; Walsh et al, 
1997).  Interestingly, it is clear that there are no detectable oligomers during the lag phase 
from the size distributions and the single-phase correlation function during this phase of holo 
SOD1 aggregation.  However, AFM reveals the presence of oligomers during the lag phase 
(see Results, section 2.3.6).  It is important to note that the practical limitation on the accurate 
analysis of particle sizes using DLS can be as high as 1 order to magnitude (Lomakin, 
Benedek & Teplow, 1999).  In order to be well resolved by DLS, the diameters of two 
different species should generally differ by 10 fold (Lomakin, Benedek & Teplow, 1999).  
Thus, for a mixture of SOD1 dimers (~ 5 nm in diameter), monomers, small oligomers (< 50 
nm in diameter), the diffusion coefficient and hence diameter determined by DLS will 
represent an average of the species.  Therefore, an increase in the polydispersity about the 
average diameter during lag phase is compatible with the presence of small oligomers (data 
not shown).    
From the beginning of the growth phase and onwards, the autocorrelation functions 
contain a shoulder (multi-phase) and the size distribution profiles show a peak around 1000 
nm (i.e., aggregates appear in the size distributions of the samples) (asterisk Fig. 3.4-3.7).  
Interestingly, the major time components for each decay (i.e., the first decay occurs between 
10 ~ 100 µsec and the second decay occurs between 100 ~ 10000 µsec) is similar for all the 
multi-phase correlation functions.  This suggests that the particle sizes of the protein are not 
changing very much with incubation time.  Moreover, since different mutants of SOD1s 
show the consistent time for each decay relative to pWT, this suggests that aggregate size 
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formed by all the different SOD1s is relatively consistent.  All holo SOD1s studied, which 
includes pWT and three fALS associated mutants; G85R, G93D, and A4T shown in Fig. 3.4-
3.7, as well as A4S, I149T, G93A, G93V, and G93S (data not shown) also show similar 
aggregation time course described above.  
 
3.3.2 Aggregation kinetics monitored using intrinsic fluorescence 
Fluorescence spectroscopy has become one of the most useful biophysical techniques 
for studying protein folding, kinetics, and assembly (D'Auria et al, 2000; Eftink, 2000; 
Hawe, Sutter & Jiskoot, 2008; Munishkina & Fink, 2007).  These applications utilize the 
intrinsic fluorescence of aromatic amino acids: Trp, Tyr and Phe.  In particular, the amino 
acid, Trp has the strongest fluorescence amongst the three aromatic amino acids and its 
fluorescence intensity and maximum wavelength ( max) are more sensitive to its 
microenvironment.  Thus, Trp fluorescence is the most widely used in protein science (van 
Holde Kensal E., Johnson W. Curtis & Shing, 1998).  Intrinsic fluorescence has also been 
used to elucidate many different types of protein aggregations (Dusa et al, 2006; 
Polymeropoulos et al, 1997).  Typically, a blue shift of the spectral maximum wavelength 
occurs when the fluorophore of interest becomes more solvent inaccessible owing to 
aggregation.  For example, an α-synuclein mutant (Y39W) in Parkinson’s disease showed a 
max blue shift, from 355 to 346 nm, and an increase in intensity during oligomerization, 
implying that Y39 participates in aggregation (Polymeropoulos et al, 1997).   
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The maximum wavelength ( max) in fluorescence emission spectra was monitored 
during aggregation in order to detect changes in the environmental polarity near the Trp 
(Fig. 3.8a).  SOD1 only has one Trp at residue 32, which is located near the dimer interface 
and partially solvent exposed.  In Fig. 3.8a, the max of the emission spectra remains constant 
during aggregation of pWT, G93D, G93V, and I149T, which indicates that Trp-32 is not 
buried in the aggregates.  The fluorescence of the insoluble fraction of the aggregated 
samples (separated via centrifugation, see Materials and Methods, section 3.2.7) was also 
measured and a significant blue shift did not appear. 
In addition, the intensity of fluorescence at max  is plotted as a function of time along 
with the corresponding aggregation profile monitored by light scattering to obtain further 
information on the relationship between aggregate formation and changes in Trp 
environment (Fig. 3.8 b-e).  Both pWT and fALS associated mutants; G93D, G93V, I149T 
and G85R (data not shown) exhibit a decrease in fluorescence intensity with time; however, 
the mutants show a greater decrease than pWT.  There is no clear correlation between the 
light scattering and the signal change in fluorescence.  The fluorescence intensity begins to 
decrease during the lag phase.  It is worth noting that the Trp fluorescence was used 
previously to monitor denaturation (unfolding) of holo SOD1s by guanidinium chloride 
(GdmCl) and a cooperative increase in fluorescence signal was observed upon denaturation 
(Rumfeldt et al, 2006).  Interestingly, prior to denaturation, the fluorescence signal decreases 
between 0 and 1 M GdmCl.  Thus, the intensity decrease in Trp fluorescence, without 
significant change in max of the emission spectrum, observed during holo SOD1s 
aggregation is most probably due to a subtle change in the microenvironment near the Trp 
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residue rather than significant unfolding (i.e., a change that is akin to the 0 to 1 M GdmCl 
partial unfolding process) (Hermann et al, 1997; Rumfeldt et al, 2006).   
























































































































(a) The max of the fluorescence emission spectrum of the Trp residue, for the supernatants 
for pWT (●), G93D (○), G93V (▲) and I149T (△ ) is plotted with time.  (b-e) The 
aggregation profile of pWT (b), G93D (c), G93V (d), and I149T (e) was monitored using the 
fluorescence intensity at max (○) and light scattering aggregation profiles (●).  The 
supernatant (see Material and Methods, section 3.2.7) from the various time points was used 
for fluorescence measurements.  (b-e) After the fluorescence measurements, the protein 
concentration was obtained using the Lowry assay (Lowry, Rosebrough, Farr & Randall, 
1951) and the fluorescence spectrum was normalized.  The presented values and the 
associated error bar for fluorescence are the average and s.d. of at least two measurements.  
The values for light scattering are the average of three measurements at a given time point 
and each of these 3 measurements is an average of 10 measurements for 30 sec.  The error 
bars are the s.d. of the three measurements.    
 
3.3.3 Aggregation kinetics monitored using CD spectropolarimetry 
The aggregation of holo SOD1s was also monitored using CD spectropolarimetry.  A 
typical CD spectrum for an α helical protein contains negative bands at about 222 and 208 
nm, whereas β proteins show a negative band at about 215 nm (van Holde Kensal E., 
Johnson W. Curtis & Shing, 1998).  The CD spectrum for holo SOD1 shows a broad 
negative band in the 225 – 200 nm range (Fig. 3.9), which is consistent with a previous study 
of SOD1 and typical for β proteins (Mei et al, 1992; van Holde Kensal E., Johnson W. Curtis 
& Shing, 1998).  Fig. 3.9 shows the CD spectra for holo and apo pWT as well as holo G85R, 
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prior to aggregation.  The spectra of the apo and holo form of pWT can be distinguished by 
differences in intensity at 209 and 230 nm (Fig. 3.9), consistent with results reported 
previously for holo and apo SOD1 (Rumfeldt et al, 2006).  It is worth noting that although 
there are some differences in the spectra of the three proteins, the estimated secondary 
structure are similar among all samples.  In other words, α helical structures in holo pWT, 
holo G85R and apo pWT are all 5 % and β structures in holo pWT, holo G85R and apo pWT 
are 40, 39, and 40 %, respectively.  These estimates were derived from the atomic structures 
(1SOS for holo pWT (Parge, Hallewell & Tainer, 1992), 1HL4 for apo pWT (Strange et al, 
2003) and 3CQP for holo G85R (Cao et al, 2008) ) using the approach described by Kabsch 
and Sander (Kabsch & Sander, 1983)).  Interestingly, holo G85R shows higher (less 
negative) intensity at 209 nm compared to holo pWT but almost the same intensity as holo 
pWT at 230nm.  As holo proteins were carefully checked for full metallation, using specific 
activity and DSC measurements, the altered spectrum of holo G85R is likely due to structural 
changes in the metal binding site (especially, Zn binding site owing to location of the 









































Figure 3.9 The CD spectra of holo pWT, apo pWT, and holo G85R, a metal binding mutant 
The region of the circle in (a) is expanded in (b).  The color code used in (b) is same as in (a).   
 
In holo SOD1 aggregation experiments, the total change of [θ] at 209 nm upon 




 for pWT, G93D, and G93V, respectively, 




 difference at 209 nm relative to holo pWT 
(Fig. 3.9 and 3.10).  The change upon aggregation is less than the difference between the 
holo and apo form of pWT.  The small change in CD spectra upon aggregation is consistent 
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with the FTIR results (see below, Fig. 3.15), indicating that there is no substantial change in 
secondary structure upon aggregation.   
CD has been used as a tool to detect conformational changes in many different 
aggregating systems (Ahmad et al, 2005; Booth et al, 1997; Kumar, Mohanty & Udgaonkar, 
2007; Lai, Colon & Kelly, 1996; Pedersen et al, 2004; Plakoutsi et al, 2005; Souillac, 
Uversky & Fink, 2003).  The conformational changes occurring during holo SOD1 
aggregation were monitored using CD spectropolarimetry in parallel with light scattering.  
Fig. 3.10 and 3.11 show the changes of mean residue ellipticity ([θ]209 and [θ]230, 
respectively) for the CD spectra and the corresponding light scattering signals for 
aggregation profiles of pWT, G93D and G93V.  Fig. 3.10 and 3.11 show that the band at 209 
nm becomes less negative and the shoulder at 230 nm becomes less positive upon 
aggregation.  It is suggested the spectra obtained during aggregation become more like that 
of apo SOD1, implying that the holo protein loses metals.   
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Figure 3.10 The time courses of aggregation monitored by light scattering and CD spectra 
The aggregation of pWT (a), G93D (b), and G93V (c) was monitored using light scattering 
(●) and CD spectra ([θ]209, (○)) in parallel.  The supernatant (see Materials and Methods, 
section 3.2.7) from the various time points was used for CD measurements.  The values for 
light scattering are the average of 3 measurements, each measurement was composed of 10 

















































































Figure 3.11 The time course of aggregation monitored by light scattering and CD spectra 
The aggregation of pWT (a), G93D (b), and G93V (c) was monitored using light scattering 
(●) and CD spectra ([θ]230, (○)) in parallel.  The supernatant (see Materials and Methods, 
section 3.2.7) from the various time points was used for CD measurements.  The values for 
light scattering are the average of 3 measurements, each measurement was composed of 10 




3.3.4 Aggregation kinetics monitored using UV spectroscopy 
The UV and visible spectra of SOD1 were commonly used during the 1970s - 1990s 
for different metal reconstitution studies (Beem, Rich & Rajagopalan, 1974; Mailer et al, 
1989).  Here, the characteristic UV spectra of the various metallated states of SOD1 are used 
to investigate the role of the metals in holo SOD1 aggregation.  
Proteins have characteristic UV spectra in the wavelength region of 250 - 300 nm 
mainly due to three amino acids: Phe (245 – 270 nm); Try (265 – 285 nm); and Trp (265 – 
295) (Lucas et al, 2006).  The maximum absorbance for proteins in this spectral range is 
typically ~280 nm; however SOD1s have distinct UV spectra with a shoulder at 288 nm and 
distinctive Phe absorption regions (Fig. 3.12a) (Mailer, Addetia & Livesey, 1989).  The 
major chromophores for SOD1 are four Phe residues and one Trp residue per monomer (i.e., 
there is no Tyr).  Three of the Phe residues are comparatively close to the Cu binding site 
while the Trp is quite distant from the Cu binding site (Mailer, Addetia & Livesey, 1989).  
Consequently, different Cu metallation in SOD1 affects the UV spectra of the protein in Phe 
absorption regions (250 - 265 nm).  The current study uses the slope between 255 – 270 nm 
(calculated as: (A270 - A255) /15) to obtain information about the Cu composition in the 
protein.  Fig. 3.12a demonstrates the different UV spectra of SOD1 in different metallation 
states.  The Cu/E (E represents empty) protein has almost the same but slightly less positive 
slope (0.00006) compared to that of the holo protein (0.00033).  On the other hand, the E/Zn 
protein has a more positive slope (0.00053) than that of the holo protein, which can be 
explained by the absence of Cu ions.   Moreover, Cu/Cu SOD1 has a negative slope (-
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0.00065).  These results are in agreement with previous studies (Beem, Rich & Rajagopalan, 
1974; Mailer, Addetia & Livesey, 1989). 
By applying the method described above, mechanistic information regarding metal 
loss can be obtained by monitoring the slope change in the UV spectra of SODs during holo 
aggregation time courses.  In Fig. 3.12b-d, the change in 255 – 270 nm slope during 
aggregation is plotted with the corresponding light scattering profile.  In particular, during 
the exponential phase, an increase of slope in the 255 – 270 nm regions is observed, implying 
that holo SOD1 loses Cu generally during this phase.  This observation is consistent with a 
decrease in specific activity during exponential phase (Fig. 2.6), since Cu ions are absolutely 
required for activity.   
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Figure 3.12 Time courses of holo SOD1 aggregation monitored by UV absorption and light 
scattering 
(a) The UV absorption spectra of holo Cu/Zn (─●─), Cu/Cu (─▲─), Cu/E (─Δ─), and E/Zn 
(─■─) of pWT were obtained.  The UV spectra of the supernatant (see Materials and 
Methods, section 3.2.7) for pWT (b), G85R (c), and I149T (d) at various time points during 
aggregation were obtained.  The slope between 255 – 270 nm was calculated and is plotted 
(○) along with the corresponding light scattering profile (●).  The reported light scattering 
values and associated error bars are the average and s.d. from 3 measurements of 10 
replicates for 30 sec.   
 
3.3.5 Two distinct aggregation profiles 
Holo SOD1 aggregation shows time courses with variable lag phase, final intensities, 
and durations even after excluding the ―pre-seeded‖ profiles (see chapter 2) (Fig. 3.13).  The 
variable aggregation profiles were observed even with the same mutant with protein samples 
that were produced from the same batch of protein preparation, implying that environmental 
factors play an important role in aggregation.  Furthermore, two samples produced at the 
same time from the same batch of protein sometimes gave quite different aggregation 
profiles, suggesting that random nucleation events affect the aggregation time course.  
Interestingly, two distinct patterns in the aggregation profiles were observed: aggregation 
with low light scattering intensity at the plateau phase and shorter duration; and aggregation 
with higher light scattering intensity at the plateau phase and longer duration (Fig. 3.13).  
This observation is not specific for a given mutant (i.e., given mutant form of holo SOD1 can 
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exhibit both patterns).  Furthermore, these two different patterns of aggregation time course 
can be related to different metal loss during aggregation (see below). 
 





















































Figure 3.13 Variable aggregation profiles 
(a) 5 different aggregation profiles for 10 mg/mL pWT show different lag phases, plateau 
intensity and duration.  The 5 different aggregation profiles are divided into two groups in (b) 
and (c).  (b) When aggregation has a shorter duration, then the total light scattering increase 
is less than the other case (c).  (c) When aggregation has a longer duration, then the plateau is 
higher than the other (b).  The plots are the fits for 5 different aggregation profiles.  The 
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arrows illustrate the duration of aggregation by pointing to the end of lag phase and the 
beginning of the plateau. 
 
3.3.6  Different metal loss during aggregation 
Chapter 2 shows that decrease in specific activity (see Results, section 2.3.2) and the 
metal content in aggregates is less than that in unaggregated holo SOD1 (see Results, section 
2.3.3), indicating that holo SOD1s lose metals during aggregation.  Additionally, CD and UV 
experimental data (see Results, section 3.3.3 and 3.3.4, respectively) and thermal unfolding 
using ATR-FTIR (see below) suggest metal loss during aggregation, as well.  The previous 
section (see Results, section 3.3.5) shows the two different patterns of aggregation profiles 
that were obtained using light scattering.  This section proposes that these two aggregation 
profiles may be related to different ratio of metals (Cu/Zn) in the aggregates (Fig. 3.14).  The 
aggregation profiles with short duration and low light scattering intensity (i.e., the case of 
Fig.3.13b) appear to be associated with aggregates that contain more Cu ions than Zn ions, 
implying that the protein loses more Zn ions during aggregation.  On the other hand, the 
aggregation profiles with longer duration and higher light scattering intensity (i.e., the case of 
Fig. 3.13c) are associated with aggregates that contain more Zn ions than Cu ions, implying 
that the protein loses more Cu ions during aggregation.  This trend is further demonstrated by 
plotting metal composition of the aggregates (as measured by ITV-ICP-AES, see Materials 
and Methods, section 2.2.8) versus final light scattering intensity (Fig. 3.14e) and duration 
(Fig. 3.14f).  It is worth noting that relative metal amounts to the total protein amounts in 
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aggregates was not achieved using ITV-ICP-AES method since the baseline for carbon 
detection was not stable to estimate quantitatively. 
A possible interpretation of the different consequences for loss of more Zn relative to 
Cu and vice versa on aggregation can be based on the roles of these metals in protein 
structure and activity.  Since the Zn ion is known to be more important for maintaining 
SOD1 structure (Potter et al, 2007; Sun et al, 1997), it is reasonable that the former pattern of 
aggregation has a shorter duration (i.e., when the holo protein loses Zn ions, the protein will 
have more unstructured regions, which can promote aggregation).  Another consequence of 
Zn loss is that the Cu ions remaining in the partially structured protein may cause oxidative 
damage, which further promotes aggregation (see section 1.3.1).  On the other hand, if the 
protein retains the Zn ions, it will be more structured, which may lengthen the duration of 














































































































































Figure 3.14 Relationship of aggregation profiles to metal loss 
A mutant of holo SOD1 can lose either Cu or Zn more than the other metal, which affects the 
aggregation profiles of (a) pWT, (b) A4V (c) G93V, and (d) G85R.  The aggregation profiles 
with a higher intensity plateau and a longer duration tend to be associated with aggregates 
with lower Cu/Zn ratios, (i.e., relatively less Cu (●)), whereas the aggregation profiles with 
lower intensity plateaus and shorter durations tend to be associated with aggregates with 
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higher Cu/Zn ratios, (i.e., relatively more Cu (○)).  The dotted lines are the fits of the data to 
Eq. 2.1.  The Cu/Zn ratio measured for the aggregates is plotted versus amplitude of intensity 
in G85R aggregation (e) and duration from aggregation profiles using pWT and different 
mutants of holo SOD1s (f).  The metal analysis was performed as described in Materials and 
Methods, section 3.2.8.  (e and f) the fits were performed in Origin 7.5 and the reported r 
values were from the fitting.   
 
3.3.7 Characterization of the aggregates formed from holo SOD1s 
3.3.7.1 Structure analysis using ATR-FTIR 
Generally, the shape and location of the amide I band in an FTIR spectrum are used 
to predict the predominant secondary structure of the protein (Dong et al, 1995) 
(Bhattacharjee et al, 2005; Chiumiento et al, 2006; Dong, Huang & Caughey, 1995; 
Dupeyrat et al, 2004; Elliott & Ambrose, 1950; Jahn et al, 2008; Leone et al, 1998; Lo & 
Rahman, 1996; Meersman et al, 2002) (Jackson & Mantsch, 1995).  In the following 
experiments, the amide I band was also used to analyze structural changes upon aggregation 
of holo SOD1s.  Fig. 3.15 shows the FTIR and first derivative spectra between 1750 and 
1300 cm
-1
 of both unaggregated and aggregated pWT in 20 mM HEPES at pH 7.8.  
Shoulders for peaks in the FTIR spectrum were identified using first derivative spectra (Fig. 
3.15b).  The spectra of unaggregated SOD1s were very reproducible, whereas the spectra of 
aggregated SOD1s showed slight, but not significant, variability between independent 
experiments.  The spectrum of unaggregated pWT, shown in Fig. 3.15a is in good agreement 
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with previous studies (Chiumiento et al, 2006; Dong, Huang & Caughey, 1995; Lo & 
Rahman, 1996).  The maxima for the amide I, II, and III bands of unaggregated pWT are at 
1640, 1540, and 1390 cm
-1
, respectively.  The amide I and II bands include shoulders at 1680 
and 1619 cm
-1
, and 1522 cm
-1
, respectively.  The secondary structure analyses for the 
unaggregated pWT FTIR spectra were performed as proposed by Jackson et al. (Jackson & 
Mantsch, 1995) (see below).  The most prominent amide I band at 1640 cm
-1
 can be assigned 
to disordered structures, while the shoulder at 1619 cm
-1
 can be assigned to β-sheet structures 
(Jackson & Mantsch, 1995).  The other shoulder at 1680 cm
-1
 is also assigned to β-sheet 
structures, based on the assignments of Bhattacharjee and coworkers (Bhattacharjee et al, 
2005) and Dong and coworkers (Dong, Huang & Caughey, 1995).  The assignments are 
consistent with previous IR studies of other proteins (Chiumiento et al, 2006; Dong, Huang 
& Caughey, 1995; Lo & Rahman, 1996).  From a comparison the FTIR spectrum of 
unaggregated pWT to that of aggregated pWT, no significant changes of secondary structure 































































































Figure 3.15 FTIR spectra comparison for pWT before and after aggregation 
The aggregated sample was taken from the plateau phase.  The FTIR spectra (a) and the first 
derivative spectra (b) of unaggregated (—) and aggregated (- - -) pWT are shown in the 
amide I, II and III regions.  The arrows in the first derivative spectra (b) point to the 
corresponding shoulders in the FTIR spectra (a).  Amide I band in (a and b) are expanded in 
and shown in(c and d), respectively.  
 
Furthermore, the quantitative estimate of secondary structure was obtained using 
QUANT2, a tool provided by the manufacturer and the results (Table 3.1) agree with the X-
ray crystal structure reported for pWT.  Table 3.1 confirms that there is no significant 
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difference (P > 0.5) in secondary structure estimations between aggregated and unaggregated 
SOD1s.  Assuming that SOD1 dimer dissociation and partial metal loss (see Discussion, 
2.4.1) initiate aggregation of holo SOD1, one can expect that the aggregating species will 
undergo dramatic structural changes.  However, since dimer dissociation and partial metal 
loss can be accomplished by two external loops, loop IV and the electrostatic loop, it is 
possible that the protein retain much of their α and β structure.  Also, it is possible that the 
difference in secondary structure before and after aggregation is below the detection limit of 
ATR-FTIR since the aggregates correspond to a small percentage of the total protein.    
 




The values are  from the RCSB PDB website (www.rcsb.org/pdb) using pdb code 1SOS (Parge, Hallewell & 
Tainer, 1992) and the secondary structure analysis by pattern recognition process (Kabsch & Sander, 1983).   
b
 For pWTunagg, the values are means ± s.d. from the same batch of the protein as for aggregation and the three 
different measurements at different days.  The s.d. of A4Tagg was calculated from the three measurements from 
one aggregation experiment.   
c
 The values are means ± s.d. from 2 (for pWTagg), and 5 (for pWTseeded) independent aggregation experiments, 
for which samples was analyzed at least in duplicate.   
P values indicate statistical significance of the estimation of secondary structures with respect to that of 
pWTunagg.   
α helix β sheet
pWT a 5 40
pWTunagg
b 3.47  0.42 45.56  1.55
pWTagg
c 3.13  0.83 46.87  1.56 P > 0.5
A4Tagg 
b 4.63  1.12 45.91  0.32 P > 0.5
pWTseeded




Additionally, FTIR studies have been used to identify structural differences between 
native β-sheet proteins and cross β-sheets in amyloid fibrils ((Zandomeneghi et al, 2004) and 
references therein).  Typically, amyloid fibrils show a lower amide I band wavenumber 
compared to the native β-sheet structure.  For example, the amide I band of the native form 
of TTR is 1630 cm
-1
, whereas the amyloid form has the amide I band at 1615 cm
-1
.  Amyloid 
formation also causes a downshift in the amide I band in the case of prion propagation in 
prion disease (Jones & Surewicz, 2005), polyglutamine aggregation in Huntington’s disease 
(Thakur et al, 2009), and β2 microglobulin in dialysis related amyloidosis (Jahn, Tennent & 
Radford, 2008).  Currently, it is widely accepted that the band at 1620 cm
-1
 represents 
amyloid, although the amide I band downshift varies between proteins (Zandomeneghi, 
Krebs, McCammon & Fandrich, 2004).  To support this notion, FTIR microspectroscopy and 
ATR-FTIR identify amyloids from Alzheimer’s patients with the band at 1620 cm
-1
 (Choo et 
al, 1996; Jahn, Tennent & Radford, 2008).  Fig. 3.15 (a and b) shows no significant 
difference between the spectra from aggregated and unaggregated pWT and the band at 1620 
cm
-1
 did not appear in the aggregated SOD1s.  This supports the hypothesis that holo SOD1 
aggregates do not possess the classical properties of amyloid fibrils (see Discussion, section 
2.4.1). 
 
3.3.7.2 Thermal unfolding of the aggregates using ATR-FTIR 
The structural changes of unaggregated and aggregated pWT during thermal 
unfolding were investigated by ATR-FTIR spectra at different temperatures in the range of 
35-90 °C.  Overall, the shape of the spectra at various temperatures remains similar.  Fig. 
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3.16 (a and b) illustrates the differences between the unaggregated and the aggregated pWT 
during thermal unfolding using difference FTIR spectra, which were calculated as the 
spectrum for a given temperature minus the spectrum obtained at 35 °C.  As temperature 
increases, the intensity at 1663, 1644, 1536, and 1392 cm
-1
 increases in the difference FTIR 
spectra of both unaggregated and aggregated pWT.  The increasing absorbance at 1644 cm
-1
 
reflects increased amounts of unstructured regions upon thermal unfolding (Jackson & 
Mantsch, 1995).  The difference spectrum of unaggregated pWT shows very little change 
between 35 and 75 °C but dramatic changes in the range of 80-90 °C, consistent with a 
cooperative change in secondary structure upon thermal unfolding.  These changes are 
roughly as expected for holo pWT, which has a melting temperature in solution of ~92°C 
(Stathopulos, 2005).  In contrast, Fig. 3.16b shows that the spectrum of aggregated pWT 
begins to change at 66 °C, implying some species in the aggregated sample are more 
vulnerable to thermal unfolding.  Fig. 3.16c shows the change in the band height at 1644 cm
-1
 
with increasing temperature.  Since the melting temperature for apo pWT is ~60 °C 
(Stathopulos et al, 2006), and part-metallated SOD1s have melting temperatures between 
those of holo and apo (Rodriguez et al, 2002), the species in the aggregated sample are 
probably not apo, but most likely are part- or mis- metallated or aggregated (Potter et al, 
2007).  Although the overall secondary structure of this species remains very similar to 
native SOD1, the FTIR results are consistent with the CD (Fig. 3.10) and UV (Fig. 3.12) data 
as well as activity and metal analysis data (see chapter 2); all indicate holo SOD1s lose 










































































Figure 3.16 Thermal unfolding of unaggregated and aggregated pWT monitored by ATR 
FTIR 
The ATR-FTIR difference spectra of unaggregated pWT (a) and aggregated pWT (b) were 
obtained from the simple calculation; the spectra at higher temperature (90, 80, 75, 70, 60, 
50, and 40 °C. from top to bottom) minus the spectra at 35 °C.  The ATR FTIR spectra of the 
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 show the most change during thermal unfolding.  The aggregated pWT was 
obtained from the plateau phase.  (c) The change of the band height at 1644 cm
-1
 illustrates a 
loss of structure above 80 °C for the unaggregated pWT (●) and above 66 °C for aggregated 
pWT (○).  
 
3.3.7.3 AB2 and B2 comparison between the various mutants of holo SOD1 
Log-log plots of AB
2
 versus A0 and B
2
 versus A0 were made for pWT and 9 fALS 
associated mutants: the dimer interface mutants, A4V, A4T, A4T and I149T; three G93 
mutants, G93D, V, and S; and the metal-binding mutant, G85R.  All data were obtained at 





values among the proteins.  The time courses of all SOD1 aggregation were fit to models for 





 (Ferrone, 1999).  Fig. 3.17 shows that the values of log (AB
2
) for pWT 
and fALS-associated mutants are not significantly different (P > 0.1), except for A4V and 
A4T (P =0.017 and 0.073, respectively, compared to pWT).  The high tendency of A4V and 
A4T to monomerize may contribute to its large log (AB
2
) value ((Stathopulos, 2005) and 
Vassall, K.V. and Meiering, E.M. unpublished data for dimer dissociation constant of apo 
SOD1s).  In detail, assuming that pWT and fALS-associated mutants form the same sized 
primary nuclei (i) and share the same values of As, then pWT and all the mutants, except for 
A4V and A4T, have similar k+ and Ki values.  On the other hand, A4V and A4T would have 
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a larger value for k+ and Ki, in that the association rate of reactive unit onto aggregates and 
the equilibrium constant of primary nucleation are larger than the other proteins.   
The log B
2
 values for pWT and the fALS-associated mutants are compared in Fig. 
3.17b.  The dimer interface mutants, A4T, A4S and I149T, and the metal binding mutant, 
G85R, have higher values for B
2
, suggesting that dimer dissociation and metal loss may play 
an important role to promote heterogeneous nucleation.  In particular cases of A4S, I149T 
and G85R, it can be deduced that the values for  should be larger than the other 
proteins since k+, Ki, As and i could be the same as these of pWT and three G93 mutants of 
SOD1 (see above).  Thus, larger AB
2
 values of A4V and A4T and larger B
2
 values of A4T/S, 
I149T and G85R support the lag phase comparison results (Fig. 2.5), where the dimer 
interface mutants (A4V/T/S and I149T) and G85R tend to have shorter lag phases than the 


















































Figure 3.17 Comparison of log (AB
2
) and log (B
2
) for pWT and the fALS associated mutant 
SOD1s 
The presented values are mean ± s.d. for 14, 5, 5, 3, 4, 3, 3, and 3 independent experiments at 
10 mg/mL for pWT, A4V, A4T, A4S, G85R, G93D, G93V, and G93S, respectively.  In a, (* 
and **) indicates statistically significant difference for the log (AB
2
) value for A4V and A4T 
with respect to pWT (P = 0.017 and 0.073).  (†) indicates error estimate from the fitting 
parameters for this single measurement.  In the case of G93S in (b), the error bar is too small 
to be seen on the plot.  In b, (***) and (‡) indicate statistically significant difference of log 
(B
2
) values for A4T, A4S, and G85R with respect to that of pWT (***, P < 0.06 and ‡, P = 
0.1).  (a and b) For the remaining data, there is no significant difference between the values 
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) for pWT in order to easy to compare with other mutants. 
 
3.4 Discussion 
3.4.1 A4V aggregate property 
The lag phase in aggregation occurs because the initial nucleation event is 
thermodynamically unfavorable (Fig. 3.1) (Harper & Lansbury, 1997).  Aggregation profiles 
obtained from different mutants of SOD1 are fitted better to the double nucleation 
mechanism (Fig. 2.10).  The double nucleation mechanism consists of a combination of 
homogeneous and heterogeneous nucleation.  In other words, homogeneous nucleation 
initiates polymerization, followed by heterogeneous nucleation on the surface of existing 





 values of A4V in disease.  A4V shares a similar B
2
 value with pWT and 
G93D, V, and S (P > 0.1), although A4V is a dimer interface mutant.  However, A4V has  
higher AB
2
 values than the other mutants, suggesting that A4V forms primary nuclei faster 
but heterogeneous nuclei slowly.  This suggests that there is a higher population of 
aggregates without branches (before participating in heterogeneous nucleation).  This may be 
why A4V has a particularly short disease duration of ~1 year (Wang, Johnson, Agar & Agar, 
2008), since the soluble oligomers have been found to be more cytotoxic than mature fibrils 




3.4.2 Aggregation mechanism 
There is increasing evidence suggesting that partially folded intermediates are 
involved in protein aggregation (Arnaudov & de Vries, 2007; Booth et al, 1997; Chiti et al, 
2001; Fandrich et al, 2003a; Khurana et al, 2001; Lai, Colon & Kelly, 1996).  For example, 
several α-helical proteins have been shown to undergo significant conformational changes to 
predominantly β-structures, before forming amyloid; these include lysozyme (α + β protein ) 
(Fandrich et al, 2003a) and apo-myoglobin (α-protein) (Yamasaki, Li, Johnson & 
Huntington, 2008).  However, some proteins form aggregates under physiological conditions 
without significant structure changes but via thermal fluctuations; these include serpins (Chiti 
& Dobson, 2009), TTR, and β2-microglobulin (see more examples in (Chiti & Dobson, 
2009)).  Similarly, the holo SOD1s can form aggregates under physiologically relevant 
conditions (37 °C and pH 7.8) without significant structural change, which is supported by 
observation: no λmax change of fluorescence spectra; and no significant CD and FTIR spectra 
change during aggregation (Fig. 3.8, 3.10 and 3.11).  This finding suggests that the 
aggregates retain most of their native structure and/or extremely small amounts of aggregates 
are formed from holo SOD1s.  The former is possible if dimer dissociation and loss of metals 
disrupt mainly two loops (loop IV and loop VII) but the main structure of the protein, 8-β 
sheets, remains intact.  The latter is consistent with visible observation.  Nevertheless, it is 
important to determine how the aggregation process is initiated with regards to dimer 
dissociation and metal loss.  Here, detailed analyses of kinetics of aggregation monitored 
using different structural probes provide some insights into the molecular basis of 
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aggregation.  The following section separately discusses into the lag phase and the 
exponential phase and discusses the findings with regard to the aggregation mechanism.   
 
3.4.2.1 Early events during lag phase  
In order to elucidate the underlying aggregation mechanism during the lag phase, 
several key observations were considered.  First, the intrinsic fluorescence decreases during 
the aggregation and the absence of a lag phase in the observed kinetics of the intrinsic 
fluorescence suggest that the change in microenvironment near Trp-32 occurs almost 
spontaneously during the lag phase (Fig. 3.8).  Since aggregation profiles monitored using 
light scattering have at least 50 hrs lag phase, the change in microenvironments near Trp-32 
must be related to the very early aggregation (Fig. 3.8).  The max of the emission spectra 
does not blue-shift during aggregation, which suggests the Trp-32 does not become buried 
(Fig. 3.8).  Taken together, the decrease in the intrinsic fluorescence implies that the dimer 
interface is disrupted, which probably lead to dimer dissociation.  The decrease in the 
intrinsic fluorescence can be caused by the quenching effect of the intramolecular disulfide 
bond formed between C57 and C146 or solvents.  For the former, when the dimer interface 
becomes more flexible, the disulfide loop (residues C57-C146) can interfere with 
fluorescence of Trp-32 since both are located near the dimer interface.  For the latter, Trp-32 
becomes partially exposed when the dimer interface becomes more flexible and, therefore, 
solvents can quench the Trp fluorescence (Qiu et al).  It is not clear from the available data 
whether the decrease in intrinsic fluorescence arises from the former reason or the latter; in 
either case, the results indicate that the dimer interface is disrupted during the lag phase.   
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The various kinetics of the holo protein aggregation monitored using CD and UV 
spectroscopy suggest multiple pathways of aggregation are possible during the lag phase.  
There is an interesting observation of aggregation profiles; Fig. 3.10a and 3.12b, which are 
different analyses on the same aggregation of pWT (i.e., the same samples were subjected to 
two different experiments, CD and UV as well as light scattering measurements).  In Fig. 
3.12b, the UV slope (255 – 270 nm) remains constant during the lag phase, which suggests 
either no metal composition change or Zn loss.  It is probably due to the latter reason because 
the increase in [θ]209 (Fig. 3.10a) indicates a conformational change in the protein similarly to 
apo SOD1.  The disrupted dimer interface can affect loop IV, since loop IV encompasses 
three different regions: the dimer interface region (residues 49-54); the disulfide bond region 
(residues 55-61); and the Zn binding region (residues 62-82) (Hornberg, Logan, Marklund & 
Oliveberg, 2007).  Thus, the disrupted dimer interface and loop IV can promote Zn loss 
during the lag phase.  This coupled interaction between dimer interface and metal binding 
loops is supported by a recent study on the molecular dynamics of SOD1 (Khare & 
Dokholyan, 2006).  In addition, Zn has lower affinity to SOD1 than Cu, implying that SOD1 
may be more prone to lose Zn ions (Crow et al, 1997b).  Moreover, a previous study on holo 
SOD1 unfolding kinetics indicated preferential Zn loss during unfolding (Rumfeldt et al, 
2009).  It is important to mention that when holo SOD1 loses Zn ions, the protein contains 
Cu ion in the partially structured protein, which can cause oxidative damage, which promote 
aggregation, as well.  This sequential events can be one of many aggregation pathways.  
From the limited data available, it seems likely that there are more than one universal 
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aggregation pathways, which may be related to different duration, final intensity and metal 
amounts in the aggregates (Fig. 3.13 and 3.14) (see below). 
 
3.4.2.2 Cu loss during exponential phase  
The exponential phase begins with the appearance of a second peak in the 
hydrodynamic diameter distribution, corresponding to the size of the aggregates (~ 1000 nm), 
and a shoulder in the autocorrelation function (Fig. 3.4 – 3.7).  Since protein association is 
thermodynamically favored during the exponential phase, the rapid growth in aggregation 
profiles is observed during this phase.  The details of aggregation mechanism during the 
exponential phase are discussed below.   
From the lag phase and onwards, the intrinsic fluorescence of Trp-32 decreases 
continuously without a change of max in the emission spectra (Fig. 3.8), which indicates that 
the microenvironments near Trp-32 change continuously due to aggregation but the residue 
does not become buried.  A decrease in the UV slope (from 255 – 270 nm) is detected during 
the exponential phase regardless of different pathways observed from the lag phases, which 
indicates that the proteins lose Cu ions during the exponential phase (Fig. 3.12).  Importantly, 
the decrease in the specific activity (Fig. 2.6) during the exponential phase supports the loss 
of Cu in this phase, as well.  In summary, during the exponential phase, the dimer interface is 




3.4.2.3 Multiple routes for the holo SOD1 aggregation 
The experimental results in this chapter further support the proposed aggregation 
mechanism from holo SOD1 in chapter 2 in terms of the involvement of both metal loss and 
dimer dissociation (Scheme 2.1).  In addition to a lag phase comparison among mutants of 
SOD1 and SEDI binding data in chapter 2 (Fig 2.2, 2.5 and 2.14), SOD1 aggregation 




 comparison with various 
mutants of SOD1 (Fig. 3.8 and 3.18, respectively) indicate that dimer interface disruption 
and the dimer dissociation occur during holo aggregation.  In addition to specific activity and 
metal analysis in chapter 2 (Fig 2.6 and Table 2.1), CD data, UV slope (255 – 270 nm) 
change data, the B
2
 comparison and the thermal unfolding of the aggregates (Fig. 3.10, 3.11, 
3.12 and 3.16) indicate that aggregation from holo SOD1 involves metal loss.   
 In order to ascertain the underlying kinetic scheme to explain all the observation: (1) 
the two different aggregation profiles including two distinct patterns for duration in the 
exponential phase and final intensity in plateau (Fig. 3.13); (2) Cu loss in the exponential 
phase indicated from UV data (Fig. 3.12); and (3) metal contents in final aggregates (Fig. 
3.14), Scheme 3.1 is proposed.  The model shown in Scheme 3.1 is the simplest version in 
which a dimeric species dissociates in the lag phase.  In one model, the protein species 
proceeds to have a shorter duration and a lower plateau, and produces aggregates containing 
more Cu ions.  On the other hand, the dimer is dissociated and this species proceeds to have a 
longer duration and a higher plateau.  The final aggregates are with more Zn ions.  In both 
cases, the proteins lose Cu ions during the exponential phase.  Other studies have observed 
similar effects with metal loss on the aggregation profiles of SOD1, in which E/Zn shows a 
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longer duration and higher plateau, whereas Cu/E of SOD1 shows a shorter duration and 
lower plateau (Chattopadhyay et al, 2008).  It seems likely that the various kinetics observed 
during the lag phase might be related to the different aggregation profiles (Scheme 3.1).  The 
particular aggregation mechanism described above (see Discussion, section 3.4.2.1) 
suggested that Zn loss during the lag phase and interestingly the final intensity of light 
scattering was relatively low, implying the final aggregates have less Zn than Cu ions.  From 
the limited data, it can be speculated that specific metal loss during the lag phase affects the 




Multi-pathway of holo SOD1 aggregation.  Red circle and blue half circle represent dimer SOD1 and monomer 
SOD1.  The black line and red line represent two different aggregation pathways with regard to metal loss as 
well as duration and final intensity.  In both pathways, proteins lose Cu during exponential phase. 
 
Aggregates Cu/Zn  <1,  
Higher final  intensity  
Aggregates Cu/Zn  >1,  
Lower final  intensity  
Lag phase 
Scheme 3.1 
Cu loss during exponential phase 
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3.4.3 Disease implications 
The experimental system presented herein proposes mechanistic details of SOD1 
aggregation for the first time with regard to metal loss, in that holo SOD1s can lose more of 
either metal (Cu or Zn).  How this mechanism is actually related to in vivo is not clear to date 
since there are no experimental results of metal contents in aggregates from ALS patients 
(Hayward et al, 2002).  However, it is interesting that fALS patients with the H46R mutation, 
a Cu binding mutant having only Zn cofactor in the protein, have the longest disease 
duration, which is consistent with the proposed mechanism.  A large number of fALS- 
associated SOD1 mutants, regardless of location, have shown decreased metal affinity 
(Hayward et al, 2002) or dimer interaction (Stathopulos, 2005).  Since metal binding and 
dimer interface are coupled (Hornberg, Logan, Marklund & Oliveberg, 2007), one can affect 
the other.  Thus, the proposed multi-pathway aggregation could explain how unrelated 
mutations in SOD1 cause the same fALS pathology.  Furthermore, despite its stable 
structure, fully metallated pWT also follows the same mechanism of aggregation as the fALS 
associated mutants (monomerization and metal loss) and this may be the link between fALS 
and sALS as supporting the hypothesis of common disease mechanism of fALS and sALS 
(Boillee, Vande Velde & Cleveland, 2006a).   
The aggregation mechanism observed here for holo SOD1 shares a characteristic with 
those of other disease-associated proteins, namely the dissociation of multimeric proteins.  
This has been implicated in many other diseases as a critical step (Foss et al, 2005).  For 
example, in TTR linked familial amyloidosis, it is found that mutants of the tetrameric 
protein, TTR, promote amyloidosis when enhancing dissociation of the native tetramer (Foss, 
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Wiseman & Kelly, 2005).  Similarly, this chapter also proposed that dimer interface 
disruption is an early event in aggregation.  Also, the holo SOD1 aggregation has unique 
properties.  Unlikely to other protein aggregation processes that are related to amyloidosis, 
subtle changes can induce aggregation as seen by the agitation effect, implying that small a 
local pH change or subtle abnormal interactions with membranes in cells can initiate 
undesired interactions to disrupt the dimer interface and/or loop IV or electrostatic loop (loop 
VII).  Also, since aggregation does not require significant structural changes from the native 
structure, proteasomes and/or chaperones can miss these species, which can initiate 
aggregation, especially, in old age.  This might be why ALS is a late onset disease.  
Furthermore, if the cell defense mechanisms fail to remove initial aggregates, then successive 
aggregation is much easier due to the seeding effect, which may be related to the fast disease 
progression in ALS.  In summary, the current results provide new and potentially general 
insights into SOD1 aggregation and therefore, ALS.  The system can be used for a model 
system for ALS to develop urgently needed therapeutic strategies against toxic protein 
aggregation.  To do this, several key elements such as the metal content of patient aggregates, 
how the different aggregation pathways are related to the disease, how the different 
intermediates interact with proteosomes and/or chaperons and which intermediates are more 






Sonication, and its damaging mechanisms on proteins 
 
4.1 Introduction 
Sound is a travelling wave that is transmitted through a medium and sound beyond 
the human hearing threshold is termed ultrasound (Timothy J. Mason & Peters, 2002).  
Typical frequencies of ultrasound are between 20 kHz and 1
 
MHz (Joseph et al, 2009).  The 
action of applying ultrasound, known as sonication, has been used in a wide variety of 
processes in chemistry laboratories and industries.  The effect of sonication is induced not by 
interaction of sound waves with molecules in solution, but by the process of cavitation: the 
formation, growth and implosive collapse of microbubbles in solution (Suslick, 1990).  More 
specifically, cavitational collapse generates enormous local temperatures (roughly 5000 °C) 
and pressures (approximately 500 atm) and an extraordinary heating and cooling rate (10
9
 
K/s).  Cavitational bubbles are formed when the inter-molecular distance exceeds the critical 
distance necessary to hold the liquid intact due to the negative pressure of an expansion wave 
(rarefaction) (Suslick, 1990; Timothy J. Mason & Peters, 2002).   
The effects of sonication are divided into physical and chemical effects from 
cavitation.  The physical effects of cavitation are shock waves and microstreaming from 
frequent creation and collapse of microbubbles.  These two effects combined are called shear 
stress.  Chemical effects of cavitation involve the formation of highly reactive intermediates 
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such as hydroxyl radicals and hydrogen peroxide which are formed inside bubbles (Suslick, 
1990; Timothy J. Mason & Peters, 2002).  There are many factors that influence cavitation, 
including frequency of ultrasound, solvent conditions (e.g., viscosity and vapor pressure), 
and external factors (e.g., temperature and pressure).  For example, it is harder to create 
cavitation at higher frequencies because the time to produce cavitation during rarefaction is 
too short, which is why higher frequencies are used for medical application of sonication 
(Timothy J. Mason & Peters, 2002).   
 Sonication has been used in various fields including: biotechnology, food industries, 
medical fields, and chemistry laboratories.  For example for biotechnology applications, 
sonication assists in biofuel production with effectively mixing natural oils and methanol 
(Rokhina et al, 2009).  Additionally, sonication is used for biosensor preparation, in which 
sonication enhances immobilization of enzymes onto spectroscopic grade graphite (Rokhina, 
Lens & Virkutyte, 2009).  These applications make use of the shock wave properties of 
sonication.  In the food industry, sonication has been utilized for a wide variety of 
applications from grading beef to sterilization.  In the case of sterilization, sonication is 
combined with other preservation methods such as high pressure or heat (Butz & Tauscher, 
2002; Piyasena et al, 2003).  For medical applications, ultrasound imaging and dental 
descaling are common; however, ultrasound with microbubble contrast agents has been under 
recent investigation for drug delivery and imaging purposes (Ferrara et al, 2007).  In 
addition, sonication is being investigated for diagnosing the presence of extremely low levels 
of prion infectious agents.  In this case, minute amounts of the infectious prion are amplified 
by cycles of sonication. This procedure is called protein misfolding cyclic amplification 
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(PMCA) (Saborio et al, 2001).  Lastly, sonication is used in chemistry laboratories as part of 
preparative procedures.  For example, the degassing of buffer for chromatography can be 
done by sonication (Timothy J. Mason & Peters, 2002).  Although sonication has been 
considered as a useful tool for many different fields, the potential damage to biological 
materials (e.g., proteins) caused by sonication has received little attention (Stathopulos et al, 
2004).  Since proteins maintain their native structures mainly by weak non-covalent 
interactions such as hydrogen bonds and hydrophobic interaction, the effects of sonication 
(local heating, sheer stress, and free radical reaction) can affect protein native structure.  
Moreover, since the functions of proteins are dependent on correct folding, a loss of function 
can occur when undesired cavitation occurs and alters protein structure during the application 
of sonication.  Stathopulos et al. have found that sonication of proteins can cause amyloid-
like aggregation (Stathopulos et al, 2004).  This finding has significant implications because 
amyloid has been implicated in the pathogenesis of many different human diseases (Dobson, 
2001a).  Furthermore, since amyloid aggregates can act as seeds to promote further amyloid 
formation (Harper & Lansbury, 1997), the use of sonication for food and medical processes 
should be reconsidered due to the potential undesirable consequences of amyloid formation.     
 
4.1.1 Chapter overview 
The experiments described in this chapter characterize protein damage induced by 
sonication with a set of structurally diverse proteins.  The damage includes: aggregation and 
amyloid formation, protein unfolding, and free radical-mediated modification.  Thioflavin T 
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(ThT), a dye commonly used for detecting amyloid, trypsin digestion, mass spectroscopy 
(MS), and SDS-PAGE were used for detecting protein damage.  Additionally, this chapter 
shows protein damage induced by sonication can be reduced by altering the experimental 
conditions to use low temperatures and addition of the free radical scavenger, glutathione 
(GSH).  The characterization of sonication-induced protein damage and its mechanism 
provide valuable information on the effects of sonication on proteins in solution and these 
findings have implications for medicine, industry and basic research laboratories as 
sonication is a possible cause of the aggregates that resemble amyloid.   
 
4.1.2 Acknowledgments 
I would like to thank a former student in our lab, Peter Stathopulos who initially 
showed me how to use sonication for the study of proteins.   
 
4.2  Materials and Methods 
4.2.1  Materials 
ThT, horse heart myoglobin, hen egg white lysozyme, trypsin and β-lactoglobulin 
were purchased from Sigma (Sigma Chemical Co.).  HEPES, SDS and BSA were obtained 
from Bioshop (Bioshop Canada Inc.).  Recombinant SOD1 was prepared as described in 
section 2.2.1, and recombinant hisactophilin was obtained from a previous colleague in our 
lab, Joe Meissner.  Briefly, recombinant hisactophilin was expressed in E. coli and purified 
 
 170 
using affinity and size exclusion chromatography (Hammond et al, 1998).  Ultrapure water 
deionized using a Milli-Q system (Millipore) was used throughout. 
 
4.2.2  Sonication 
Protein samples were prepared at 3 mg/mL in 20 mM HEPES, pH 7.8, and were 
filtered using a 20 nm cutoff filter (Anatop 10, Whatman Ltd.).  Sonication was performed 
using a W 225 probe sonicator (Heat Systems, Ultrasonics, Inc.) at room temperature (RT, 
unless otherwise stated) and the tip of the sonicator was fixed at the 100 µL level in a sample 
container to prevent foam formation.  If the protein solution was turned into a complete foam 
during sonication, the sample was not further analyzed.  Sonication was conducted with a 
sample volume of 500 µL.  Prior to sonication, the tip was cleaned with sandpaper and then 
dried by ethanol.  Solutions were sonicated for either 20 cycles or 40 cycles, in which each 
cycle was composed of 5 pulses of 1 s followed by a 1 min incubation period (Fig.4.1).  For 
all sonication experiments, the frequency used was 20 kHz and the power output was set to 
30 W.   
For sonication of heterogeneous samples, each protein in solution was prepared at 
1.5mg/mL and the remaining procedures for sonication were the same as described above.  
Moreover, when evaluating the effect of temperature on sonication, sonication was 
conducted at different temperatures such as RT, approximate temperature 4.5 °C in an ice 
bath, and 40 °C in a water bath.  The temperatures during sonication (except for RT) were 
controlled by a water bath (VWR) during sonication.  Temperature change was measured 
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using a thermocouple (Temperature controller, Barnat), in which voltage was converted to 
temperature using a standard curve created prior to experiments.  The standard curve was 
generated using a temperature controlled water bath (VWR). 
 
 
5 pulses of  1 sec
3 mg/mL of  protein
20 mM HEPES
pH 7.8
1 min incubation at RT
20 or 40 cycles
 
 
Figure 4.1 Cyclic protein sonication 
Filtered protein solutions were sonicated for 5 pulses of 1 sec (20 kHz, 30W) and the protein 
solution was subsequently incubated at RT for 1 min.  The procedure was typically repeated 
20 or 40 times.  For experiments monitoring temperature effects on sonication, the procedure 




4.2.3 Light scattering measurements 
For the cycle dependence of lysozyme aggregation, light scattering was measured for 
the estimation of aggregation.  Two protein samples (2 x 500 µL) were prepared for 
sonication.  One was sonicated for a different number of cycles (as described in section 
4.2.2).   Immediately after sonication, without dilution, static light scattering was measured 
using a Zetasizer Nano ZS (Malvern).  For the control, the other sample was used and light 
scattering was measured in the same way as the sonicated sample.   
 
4.2.4  ThT enhancement 
Protein samples (3 mg/mL in 20 mM HEPES, pH 7.8) were diluted to 1 mg/mL in 
75µM ThT, 20 mM HEPES (pH 7.8).  Fluorescence emission spectra were acquired 
immediately using a Fluorolog3-22 spectrofluorometer (Jobin Yvon-Spex, Instruments S.A. 
Inc.).  The excitation wavelength was 440 nm and the emission data was collected between 
445 – 600 nm.  The slit widths for excitation and emission were 1 and 5 nm, respectively.  
The reported spectra of protein samples are the result of the ThT spectrum of the protein 
subtracted from the spectrum for corresponding samples with no ThT.  For example, ThT 





4.2.5 Denaturing gel electrophoresis 
Sonicated samples were spun down (13000 g for 4 min) and pipetted to obtain well 
mixed samples (aggregates and soluble fraction).  20 µL of sonicated samples were mixed 
with the same volume of gel loading buffer, consisting of 1.25 mL of stacking gel buffer (see 
below), 1.95 mL of 10 % SDS solution, 1.0 mL of glycerol, 0.2 mL of bromophenol blue, 
and 0.1 mL of H2O made for a total of 5 mL.  The mixed solution was then boiled for 10 min 
and subjected to gel electrophoresis.  The reducing agent, β-mercaptoethanol was used (4 % 
v/v, final concentration in loading buffer) during the characterization of higher molecular 
weight species.  SDS-PAGE was performed as described by Laemmli (Laemmli, 1970).  
Briefly, gels were prepared with 6 % (w/v) acrylamide in the stacking gel buffer and 15 % 
(w/v) acrylamide in the separating gel buffer.  The separating gel was made from: 3.75 mL of 
40 % (w/v) polyacrylamide solution, 3.55 mL of MilliQ water, 2.25 mL of 1.5 M Tris buffer 
(pH 8.8), 100 µL of 10 % (w/v) SDS, 100 µL of 10 % (w/v) ammonium persulfate  (APS) 
and 5 µL of N, N, N', N'-tetramethylethylenediamine (TEMED).  The stacking gel was made 
from: 0.75 mL of 40 % (w/v) polyacrylamide, 2.575 mL of MilliQ water, 0.625 mL of 1 M 
Tris buffer (pH 8.8), 50 µL of 10 % (w/v) SDS, 50 µL of 10 %  (w/v) ammonium persulfate 
(APS) and 5 µL of N, N, N', N'-tetramethylethylenediamine (TEMED).  Running buffer 
contained 14.4 g of glycine and 1g of NaSDS dissolved in 25 mM Tris buffer, pH 8.8 to final 
volume of 1L.  Gels were run at 150 V (constant voltage).  Gels were stained using 




4.2.6  Trypsin digestion 
For evaluating the cycle dependence of aggregation, the samples with different 
numbers of sonication cycles were subjected to trypsin digestion.  Trypsin was prepared in 
MilliQ water (1.5 mg/mL).   Sonicated protein samples (3 mg/mL) were vortexed and 25 µL 
of protein samples before and after sonication were mixed with 5 µL of the trypsin solution 
to give a trypsin: protein ratio (w/w) of 1: 10.  The mixture was then incubated for 12 min at 
RT for digestion, after which 30 µL of gel loading buffer for SDS-PAGE was added and the 
sample immediately boiled in order to stop the digestion reaction. 
For different ratios of trypsin digestion, different concentrations of trypsin (1.5, 0.6, 
0.3, and 0.15 mg/mL), were prepared by diluting a stock solution (6 mg/mL in MilliQ water).  
25 µL of protein samples (before and after sonication) were obtained after vortexing and then 
mixed with 5 µL of the various concentrations of trypsin in order to make the following 
trypsin: protein ratios (w/w): 1: 2.5, 1: 10, 1: 25, 1: 50 and 1: 100.  The rest of the procedures 
were the same as described above.  Typically, SDS-PAGE was conducted directly after 
boiling the samples.   
 
4.2.7 Mass Spectrometry (MS) 
Sonicated samples were centrifuged (13000 g for 5 min) in order to obtain soluble 
species.  Protein samples were diluted to 1 µM in 50/50 of MeCN in water containing 0.2 % 
(v/v) FA.  Each sample was incubated for 1.5 min and then applied to electrospray ionization 
using a Micromass Q-TOF Ultima Global (Waters).  The capillary voltage and cone voltage 
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were 3 kV and 80 V, respectively.  The signal was accumulated for at least for 1 min and the 
average of m/z data from the accumulated signal was reported.  Prior to mass measurements, 
a 1 % phosphoric acid solution in 50/50 of MeCN in water was used for m/z calibration.   
 
4.2.8 Effect of glutathione (GSH) on protein sonication  
Stock GSH solution (50 mM) was prepared fresh for each experiment by dissolving 
glutathione in degassed MilliQ water.  Prior to sonication, 10.2 µL of the stock GSH solution 
was added to each protein solution (500 µL of 3 mg/mL protein in 20 mM HEPES, pH 7.8, 
prepared as described above) to give final concentrations of 1 mM GSH and 2.94 mg/mL 
protein.  The mixed solution was subjected to sonication for 20 cycles as described in section 
4.2.2.  Following sonication, the ThT fluorescence enhancement of the samples was 
measured as described in section 4.2.4.    
 
4.3 Results  
The experimental conditions used herein for sonication were similar to those in the 
previous work of the Meiering lab (Stathopulos et al, 2004), which were initially based on 
conditions developed by Saborio et al. for PMCA (Saborio, Permanne & Soto, 2001) (see 
Materials and Methods, section 4.2.2 ).  One modification from earlier experiments was that 
the position of the sonicator tip was fixed at the 100 µL level in order to minimize foam 
formation, which can contribute to additional protein unfolding.  When the position of the 
sonicator tip was varied during sonication, samples occasionally turned completely into 
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foam.  Such samples were not further analyzed.  In order to correlate protein damage caused 
by sonication with characteristic protein properties, proteins with varying physicochemical 
properties were selected for study.  These include: BSA, myoglobin, lysozyme, β-
lactoglobulin, hisactophilin, and holo SOD1 (Fig. 4.2 and Table 4.1).  All proteins are 
monomeric except for holo SOD1 and β-lactoglobulin which are dimeric.  The protein 
structures range from mainly α helical (myoglobin and BSA), to mixed α helical and β sheet 
(lysozyme and β-lactoglobulin), and mainly β sheet (hisactophilin and holo SOD1).  Free 
radicals commonly target Cys residues (Stadtman & Levine, 2003), hence the cysteine 
content of the proteins was also chosen to vary, from zero (myoglobin) to 17 (BSA) (Fig. 4.2 
and Table 4.1).  Melting temperatures, total number of amino acid residues and the numbers 
of Arg and Lys residues, which is important information for trypsin digestion (see below) are 
also listed in Table 4.1.  The following sections describe sonication-induced protein damage 








































Figure 4.2 Structure of myoglobin, human serum albumin, lysozyme, β-lactoglobulin, 
hisactophilin, and holo SOD1 
Ribbon and helical structure represent monomeric myoglobin (a), monomeric human serum 
albumin (b), monomeric lysozyme (c), dimeric β-lactoglobulin (d), monomeric hisactophilin 
(e) and dimeric holo SOD1 (f).  The pdb codes for the proteins are 1WLA for myoglobin, 
1AO6 for human serum albumin (as the structure of BSA has not been reported), 1E8L for 
lysozyme, 2AKQ for β-lactoglobulin, 1HCE for hisactophilin, and 1SOS for holo SOD1.  In 
(a), the bound heme is shown as black sticks and in (f) Cu and Zn ions are colored orange 
and blue, respectively.  Cys residues are shown in black with space filling representation and 
residue numbers indicated within the figure. If the cysteine residue is involved in 
intermolecular disulfide bonding, this is also indicated by a dash notation (for example, C57-
C146).  (a and d) were made using ViewerLite 5.0 and (b, c, e, and f) were  made using 
MolMol (Koradi, Billeter & Wuthrich, 1996). 
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( C)α (%) β (%)
Myoglobin 17.0 0 0 19 2 153 73 n.ac 76.7
BSA 66.4 17 1 59 23 581 48.7 0d 59.0
Lysozyme 14.6 4 0 6 10 129 34 3 61.5
β-lactoglobulin 36.8 4 2 28 6 324 15 40 69.1
Holo SOD1 f 31.8 2 0 22 8 306 5 40 92.0
Hisactophilin 13.7 0 1 9 1 118 2 52 61.7
 
a
 Molecular weight is for the native proteins, which are all monomers except for β-lactoglobulin and holo SOD1. 
b
 Number of disulfide bonds, free thiols, Lys residues, Arg residues, total amino acid residues and native secondary structure (Kabsch & Sander, 1983) are 
from the RCSB PDB website (www.rcsb.org/pdb), except for BSA (Brown, 1976). 
c 
 not available 
d 
Percent secondary structure is from the work of Oberg et al. (Oberg & Uversky, 2001). 
e
 References for melting temperature: Kelly et al.(Kelly & Holladay, 1990) for myoglobin at pH 9.87; Arakawa et al. (Arakawa & Kita, 2000) for BSA at pH 
7.2; Wray et al. (Wray et al, 2000) for lysozyme at pH 7.4; Fessas, et al. (Fessas et al, 2001) for β-lactoglobulin at pH 6.8; Stathopulos (Stathopulos, 2005) for 
holo SOD1 pH 7.8; and Liu et al. (Liu et al, 2001) for hisactophilin at pH 6.25.  
f
 A well established pseudo wild type (pWT) background was used for holo SOD1, in which the free cysteines at positions 6 and 111 are mutated to alanine 





4.3.1 Cycle dependence of aggregation 
The formation of aggregates due to sonication was investigated as a function of the 
number of sonication cycles and characterized using static light scattering, trypsin digestion, 
and ThT fluorescence enhancement.  Fig. 4.3 shows that light scattering intensity of 
lysozyme increases linearly with sonication cycles.  A similar linear relation was reported 
previously by Stathopulos et al. (Stathopulos et al, 2004) using BSA.  The previous work 
reported that the distribution of particle sizes measured by dynamic light scattering (DLS) 
did not change significantly above 5 sonication cycles (Stathopulos et al, 2004).  Thus, the 
observed light scattering results suggest that the number of aggregates induced by sonication 
is proportional to the number of sonication cycles. 
 To further investigate the dependence of aggregation on the number of sonication 
cycles, lysozyme after sonication was subjected to trypsin digestion (Fig. 4.3b).  Trypsin 
cleaves at two positively charged amino acids: Lys and Arg.  One can expect that if 
sonication causes the protein to unfold in some way, then sensitivity to protease digestion 
should increase.  When lysozyme was sonicated for greater than 5 cycles (Fig. 4.3b lane 3-7), 
it became more sensitive to digested by trypsin, resulting in an additional band slightly above 
the main band in the SDS PAGE gel (Fig. 4.3b, arrow).  In contrast, unsonicated lysozyme 
shows no intensity of this digested band (Fig. 4.3b lane2).  When trypsin cleaves at a site 
between the two Cys residues to form a disulfide bond (Fig. 4.3c), the protein can 
nevertheless remain intact but run more slowly on the gel due to a more expanded structure.  
Lysozyme contains 6 Lys residues, 10 Arg residues and 4 intramolecular disulfide bonds 
(Table 4.1) and 5 Lys residues, 8 Arg residues are located between the two Cys residues to 
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form a disulfide bond.  The intensity of the digested protein band (Fig. 4.3b, arrow) is not 
dependent on sonication cycle (i.e., the band intensity does not change significantly above 5 
sonication cycles).  Overall, it can be concluded that sonication destabilizes lysozyme so that 
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Figure 4.3 Cycle-dependence of aggregation 
(a) Light scattering intensity of sonicated lysozyme solution is plotted against the number of 
sonication cycles.  The data were fit to a straight line obtained using Origin 7.5 and showed a 
strong correlation (r = 0.937).  (b) Trypsin digestion of unsonicated and sonicated lysozyme.  
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The number of cycles of sonication is 0 (lane 1, lane 2, and lane 8), 5 (lane 3), 15 (lane 4), 25 
(lane 5), 30 (lane 6) and 35 (lane 7).  Samples in lanes 2-7 were digested at 1:10 ratio of 
trypsin: lysozyme.  Symbols (*, **) represent lysozyme without trypsin digestion and trypsin 
by itself, respectively.  (c) Scheme of lysozyme digestion by trypsin.  If trypsin cleaves 
lysozyme between two residues that form a disulfide bond, then the molecular weight of the 
protein is not changed but the species is expanded and so runs slower on the gel (indicated by 
the arrow in (b)) and is located just above the undigested species shown in lane 1.    
 
4.3.2  Amyloid formation upon sonication 
ThT is a fluorescent dye that is commonly used for the detection of amyloid 
(Lindgren et al, 2005).  Typically, when ThT binds to amyloid species, its fluorescence is 
enhanced and λmax of the spectrum is shifted from 440 to 482 nm.  Sonication has been 
shown previously to induce the amyloid formation of numerous proteins, including BSA, 
myoglobin, lysozyme, hisactophilin, holo SOD1, β2-microglobulin and TTR (Misumi et al, 
2008; Ohhashi et al, 2005; Stathopulos et al, 2004).  Since the experimental criteria used here 
is different from the previous works (see Materials and Methods, section 4.2.2) (Stathopulos 
et al, 2004), it was necessary to confirm amyloid formation by ThT fluorescence herein (Fig. 
4.4).  Under more restricted experimental conditions (i.e., by ensuring no foam formation), 
sonication also promotes amyloid formation.  Fig. 4.4 and Table 4.2 compare the 
enhancement of ThT fluorescence for various proteins at two different sonication cycles (20 
and 40 cycles).  The intensity of ThT fluorescence tends to be less than that observed in the 
previous work of Stathopulos et al. (Stathopulos et al, 2004), which is not surprising since in 
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the current experiments, samples were discarded when the sonicated solutions completely 
foamed.  The ThT data supports the finding that increasing sonication cycles results in 
increased formation of amyloid aggregates, although the degree of amyloid formation varies 
among the examined proteins.  It is worth noting that the heme cofactor in myoglobin has 
significant absorbance at 410 nm, resulting in an underestimation of ThT fluorescence 
enhancement (Stathopulos et al, 2004) (Marden et al, 1986; Neves-Petersen et al, 2007).  
However, myoglobin did demonstrate non-physiological dimer formation on a gel (see 
below) as well as a significant increase in light scattering upon sonication (269 fold), 
indicating that it produces significant amounts of aggregates when subjected to sonication.   
 



















































Figure 4.4 ThT fluorescence enhancement of sonicated BSA with 20 and 40 cycles 
ThT fluorescence emission spectra are shown for solutions with no added protein (—), BSA 
at 1 mg/mL before sonication ( ), or 1 mg/mL sonicated BSA (—), for 40 cycles (a) and 20 




Table 4.2 Summary of ThT fluorescence enhancement for proteins subjected to 20 and 40 
sonication cycles 
Protein          
# of








BSA 20 1.3 α 17/1
Myoglobin 20 1.0 α 0/0
β-lactoglobulin 20 1.2 αβ 2/1
Lysozyme 20 1.4 αβ 4/0
Hisactophilin 20 2.8 β 1/0
BSA 40 3.9 α 17/1
β- lactoglobulin 40 2.0 αβ 4/2
Holo  SOD1c 40 8.0 β 2/0
 
a
  The fold increase in ThT fluorescence is obtained from the ratio of the of ThT intensities at λmax between 
native protein and the sonicated protein, after subtraction of the background fluorescence of the 
corresponding protein solution without ThT.   
b
  The native secondary structure (Kabsch & Sander, 1983), number of disulfide bonds and free thiols were 
obtained from the RCSB PDB website (www.rcsb.org/pdb), except for BSA (Brown, 1976).  
c
  A well established pWT background was used for holo SOD1, in which the free cysteines at positions 6 
and 111 are mutated to alanine and serine, respectively.  The pWT has very similar structure, dynamics, 





4.3.3  Non-physiological dimer species and fragments formation upon 
sonication 
To further investigate the properties and the amount of the aggregates formed by 
sonication and the possible occurrence of fragmentation, light scattering and denaturing gel 
electrophoresis (SDS-PAGE) were used.  Additionally, the nature of high molecular weight 
species was investigated using β-mercaptoethanol on an SDS PAGE gel (Fig. 4.5), which can 
reduce intermolecular disulfide linkages.  Fig. 4.5a demonstrates that all three proteins, 
myoglobin, lysozyme, and β-lactoglobulin, exhibit non-physiological dimers on the gel under 
non-reducing conditions after 40 cycles of sonication (see lanes 1-3).  Also, the dimer 
formation of β-lactoglobulin was also detected using MS (see below).  However, Fig. 4,5b 
shows that only myoglobin forms a non-physiological dimer under non-reducing condition 
after 20 cycles of sonication (see lanes 1-3).  The latter is additional experimental evidence 
supporting the notion that aggregation from sonication is cycle dependent.  Also, it is 
concluded that sonication-induced aggregates are mainly formed via hydrophobic interaction 
since the size of the aggregates was  > 100 nm by DLS (Stathopulos et al, 2004), which is 
larger than that of dimers of the proteins.  Fig. 4.5 (a and b) demonstrates that most dimers 
disappear upon addition of -mercaptomethanol (compare lanes 1-3 and lanes 4-6), 
suggesting that dimerization occurs via Cys residue cross-links.  The observed dimer 
formation is probably caused by free radicals due to cavitation, since free radicals commonly 
target Cys residues (Stadtman & Levine, 2003).  Formation of intermolecular disulfide bonds 
can be another mechanism of expanding aggregation, as well, as seen previously in β-
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lactoglobulin fibrils under thermal unfolding conditions (Prabakaran & Damodaran, 1997) 
(see Discussion for details) and amyloid formation of metal free SOD1 (Banci et al, 2007b).  
However, decreases in intensity of non-physiological dimer formation of myoglobin by 
addition of the reducing reagent should be understood as experimental errors such as 
contamination of Cys containing proteins since myoglobin does not contain any Cys residues 
(Fig. 4.5b).  Nevertheless, the low intensity of the band corresponding to the dimer of 
myoglobin resulting from being unaffected by the reducing agent is still observed in Fig 4.5a 
(see lane 5), implying that this dimer is formed via non-Cys residue cross linking.  
Myoglobin dimerization has been reported, in which the highly reactive oxygen species, 
hydrogen peroxide can mediate non-physiological dimerization via linkage of Tyr residues, 
Tyr 103 and Tyr 151 (Tew & Demontellano, 1988).  It is possible that the observed 
myoglobin dimers may be formed by the same mechanism since cavitation can produce 
hydrogen peroxide (Timothy J. Mason & Peters, 2002).  The non-physiological dimer species 
formed after 40 cycles of sonication also appears to contain protein fragments, which become 
apparent upon the addition of the reducing agent as broad and weak bands below the main 
bands (Fig. 4.5 a, lanes 4-6).  In other words, fragments are attached to other protein species 
via intermolecular disulfide bonding.  However, protein fragments were not detected by MS 
(see below), suggesting that the presence of fragments upon sonication should be minimal, if 
at all. Sonication induces protein modifications such as non-physiological dimerization and 


















Figure 4.5 Higher molecular species and fragments from sonicated proteins shown by 
denaturing gel electrophoresis 
Samples in panel (a) and (b) were subjected to 40 and 20 sonication cycles, respectively. In 
both panels, lanes 1-3 do not contain 4 % (v/v) β-mercaptoethanol and lanes 4-6 do contain 4 
% (v/v) β-mercaptoethanol.  The protein samples are as follows: lysozyme (lane 1(a) and 
lane 2 (b)), myoglobin (lane 2 (a) and lane 1 (b)) and β-lactoglobulin (lanes 3 (a and b)).  
Two pieces of each gel (a and b) were originally from one gel, but for ease of comparison of 
the effect of the reducing agent on dimer species, sections of the gel involved in this analysis 
have been cut out and placed beside each other.  Non-physiological dimer species are 
indicated by an asterisk symbol (*).  Molecular weight markers are shown at the left side of 
the gel.  
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4.3.4 Protein unfolding upon sonication 
4.3.4.1 Mass spectroscopy (MS) 
Previously, Stathopulos et al. reported that > 90 % of the protein remained in solution 
after sonication (Stathopulos et al, 2004).  Also, the bulk of sonicated proteins in solution are 
not significantly modified since differential scanning calorimetry thermograms of sonicated 
protein solutions and unsonicated solutions are not considerably different (Jessica Rumfeldt, 
Jimes R. Lepock and E.M. Meiering, unpublished data).  Thus, it is important to characterize 
properties of protein remaining in solution after sonication.  The increased sensitivity of 
sonicated proteins to trypsin digestion suggests that sonication induces protein unfolding 
(Fig. 4.3).  Partially unfolded proteins are known to be particularly prone to aggregate (Booth 
et al, 1997; Chiti et al, 2001; Hamada et al, 2009; Wiseman, Powers & Kelly, 2005).  
Therefore, protein unfolding induced by sonication was further investigated using ESI-MS 
since unfolded proteins can accommodate higher net charges than native proteins in ESI-MS 
(Chowdhury et al, 1990).  This gives complementary information to denaturing SDS-PAGE, 
which cannot distinguish the native form of a protein from unmodified unfolded forms under 
non-reducing conditions.  Fig. 4.6 shows that sonication of holo SOD1 for 40 cycles gives 
rise to a second m/z envelope at lower m/z ratios; regardless of incubation temperature (the 
effect of temperature is discussed in section 4.3.8).  The envelope of higher m/z peaks 
corresponds to protein with lower net charge (mainly ―9+‖ charged, Fig. 4.6a) indicates a 
more folded protein state.  Additionally, the observed charge state (9+) agrees with the 
expected charge state of a folded protein with 18 kDa MW (Heck & Van Den Heuvel, 2004).  
With sonicated SOD1, the envelope of lower m/z peaks corresponds to proteins with higher 
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net charge (mainly ―11+‖ charged, Fig. 4.6 b-d), which indicates that the protein is more 
unfolded.  This finding implies that the sonication destabilizes SOD1 to unfold compared to 
the unsonicated protein SOD1.  In the case of SOD1 the different m/z peaks correspond to 
species with the calculated monomer holo SOD1 MW (15879 Da); however, it should not be 
precluded that small mass changes, such as chemical modifications due to  random free 
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Figure 4.6 MS m/z spectra of unsonicated and sonicated holo SOD1 
m/z spectra are shown for holo SOD1 before sonication (a) and sonicated (40 cycles) at 4.5 
°C (b), RT (c), and 40 °C (d).  All the samples were treated in the same way (see Materials 
and Methods, section 4.2.7).  The charge state for the corresponding peak is given as the 
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number above the peak.  A charge state and the m/z peak are related as: i.e., for +9 of SOD1 
(15879 Da): m/z = (15879+9)/9 = 1765.    
 
When 40 cycles of sonication were performed on β-lactoglobulin, an additional set of 
peaks corresponding to the dimeric form of the protein are observed (Fig. 4.7), consistent 
with the results obtained by SDS-PAGE (Fig. 4.5).  Only the soluble species in the 
supernatant of sonicated samples was analyzed by MS.  Thus, the soluble fraction contains 
considerable amounts of damaged proteins, non-physiological dimer species, which 
contribute to formation of amyloid aggregates via hydrophobic interaction and/or 
intermolecular disulfide bonds (Fig. 4.5).  
 The MS spectra were also inspected for evidence of fragmented species since Fig. 4.5 
indicates the possibility of the presence of fragments induced by sonication, but these were 















































Figure 4.7 MS m/z spectra of unsonicated and sonicated β-lactoglobulin 
m/z spectra are shown for β-lactoglobulin solution before sonication (a) and sonicated (40 
cycles) at RT (b).  All the samples were treated in the same way (see Materials and Methods 
section 4.2.7).  The arrows indicate peaks corresponding to a dimer of β-lactoglobulin.  The 
charge state for the corresponding peak is given as the number above the peak, in which red 
and blue numbers represent a charge state assuming that the β-lactoglobulin remains 
monomeric and dimeric, respectively.  For example, a charge state and the m/z peak are 
related as: i.e., for +12 of monomeric β-lactoglobulin (18365 Da): m/z = (18364+12)/12 = 




4.3.4.2 Trypsin digestion 
Fig. 4.5b demonstrates that no detectable change upon 20 cycles of sonication of 
lysozyme, β-lactoglobulin and myoglobin, although ThT fluorescence enhancement results 
indicate that 20 cycles of sonication can also induce amyloid formation (Table 4.2).  Trypsin 
digestion was conducted with protein samples sonicated for 20 cycles without separation of 
aggregates to further detect protein unfolding induced by sonication.  Samples were 
sonicated and then digested by different amount of trypsin.  For trypsin digestion, the band of 
trypsin in SDS PAGE decreases as the trypsin to protein ratio decreases.  The intensity for 
the main band (corresponding to native protein) for lysozyme and hisactophilin does not 
change significantly upon addition of trypsin, whereas the main band for BSA decreases in 
intensity as the amount of trypsin is increased.  This may be explained by the relatively 
higher number of Arg and Lys residues in BSA (Table 4.1).  Thus, a decrease in the total 
amount of stained BSA at higher trypsin to protein ratio (see the lanes 3, 4, 5, and 6 in Fig. 
4.8b) is likely due to extensive degradation to short peptides which may not be well fixed in 
the gel and/or stained by Coomassie Blue.  From the comparison of digestion patterns before 
and after sonication, the main difference between the sonicated samples and the unsonicated 
control for lysozyme, BSA, and hisactophilin (Fig. 4.8 a - c) is a decrease in intensity of the 
main protein bands, suggesting that sonication destabilizes the proteins so that they become 
more sensitive to trypsin digestion (compare lanes 3 and 4 in Fig. 4. 8a-c).  Some non 
physiological hisactophilin dimers may show resistance to trypsin under the experimental 
condition.  However, larger molecular weight species of hisactophilin (  in Fig. 4.8c) are all 
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digested.  Additionally, lysozyme shows the formation of the slower migrating species 
having same MW indicated by the arrow in Fig. 4.8a, which is also seen in Fig. 4.3, likely 
resulting from a cleavage of the protein backbone by the attack of free radicals.  To 
summarize these results, although 20 cycles of sonication does not result in the formation of 
substantial quantities of high molecular weight species except for hisactophilin, protein 
unfolding and backbone cleavage does occur.   
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Figure 4.8 Trypsin digestion of lysozyme, BSA, and hisactophilin subjected to 20 cycles of 
sonication at RT 
Sonication increases sensitivity to digestion by trypsin for (a) lysozyme, (b) BSA, and (c) 
hisactophilin.  Gel electrophoresis was conducted without a reducing agent.  The numbers 
and (+ and -) symbols on the SDS-PAGE gels represent sonicated and unsonicated protein, 
respectively.  The ratio represents trypsin: protein (w/w).  Thus, ―0‖ indicates no trypsin 
digestion.  The location of trypsin on the gel is indicated by asterisk symbols.  The arrow 
( ) in (a) indicates the protein species that results from a cleavage of the lysozyme 
backbone by the attack of free radicals.  The arrow ( ) in (c) represents a high molecular 
weight species of hisactophilin that resulted from sonication.  Molecular weight markers are 
shown at the left of the gels, corresponding to 96.0, 66.0, 45.0, 30.0, 20.1, and 14.4 kDa from 
top to bottom.   
 
4.3.5 Additional aggregate formation upon further incubation of sonicated 
samples  
Since trypsin digestion and MS experiments suggest that sonication results in the 
formation of various levels of unfolded species, the process by which unfolded proteins may 
contribute to further protein damage was investigated.  This was studied using BSA samples 
which were sonicated and then incubated at RT and monitored for changes in ThT 
fluorescence.  Fig.4.9 shows clearly that ThT fluorescence increases upon further incubation, 
suggesting amyloid formation continues after sonication.  This suggests that destabilized 
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forms of the protein will continue to aggregate and/or the aggregates formed by sonication 
can also recruit soluble protein (seeding), as was shown in the previous study (Stathopulos et 






































Figure 4.9 Post-sonication amyloid formation by BSA 
ThT fluorescence enhancement is shown upon incubation of BSA solution (1 mg/mL) that 
has not been sonicated ( ), and that has been sonicated at RT for 40 cycles (○) and sonicated 




4.3.6 Effect of temperature on aggregation induced by sonication    
Local heating is one of the mechanisms by which sonication can damage proteins 
(Timothy J. Mason & Peters, 2002); thus, the effect of temperature on sonication-induced 
aggregation was investigated.  The temperature in solution was determined by measuring the 
thermocouple voltage and determining the corresponding temperatures using a calibration 
curve (see Materials and Methods, section 4.2.2).  A calibration curve was generated for the 
temperature range, 1 – 80 °C (Fig. 4.11a).  The temperature is linearly related to the 
measured voltage over the experimental temperature range.  The temperature of sonicated 
samples was determined by measuring the voltage immediately after 5 pulses of the 
sonication and at the end of the 1 minute incubation period by immersing the thermocouple 
in the sonicated solutions (Fig.4.1).  The sonication procedure was conducted at different 
incubation temperatures, such as 4.5 °C (ice bath), RT, and 40 °C (water bath) (see Materials 
and Methods, section 4.2.2).  For experiments at 40°C, the Eppendorf tube was immersed in 
a water bath throughout the sonication procedure and for experiments at 4 °C, the Eppendorf 
tube was immersed in an ice bath.  Fig. 4.11b shows temperature change during 40 cycles of 
sonication at RT, in which the solution temperature reaches 65 °C after 11 cycles of 
sonication and plateaus.  This high temperature is significant because it is in the range where 
many proteins are thermally unfolded (Table 4.1).  The pattern for the change in temperature 
is very similar for the other incubation conditions; however, the absolute temperature 
difference between post-cycle and pre-cycle (ΔT) varies.  Table 4.3 summarizes the 
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differences and clearly indicates that temperature is regulated better when immersed in water 
or an ice bath, instead of at ambient temperature.  
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Figure 4.10 Temperature changes during sonication at RT 
(a) A calibration curve that was obtained using a thermocouple.  The presented values are 
data points and data were fit to a straight line using linear regression (Origin 7.5); however 
the fitting line is not shown since the line is coincident with the data points.  (b) The 
temperature of sonicated solutions is shown immediately after 5 pulses of sonication and at 
the end of the following 1 minute incubation (i.e., just before the next 5 sonication pulses) 
(Fig.4.1).  Measured voltages were converted to temperature using the standard curve in (a). 
 
The extent of aggregate formation was also monitored using ThT fluorescence.  Fig. 
4.11 shows that incubating protein samples of BSA, hisactophilin, β-lactoglobulin, and 
lysozyme in an ice bath, with approximate temperature of 4.5 °C, during sonication markedly 
decreases aggregate formation as measured by ThT compared to higher temperature (RT).  
There is still a small increase in ThT fluorescence for BSA and hisactophilin, but not for β-
lactoglobulin and lysozyme.  However, Fig. 4.9 indicates that the sonicated BSA solution in 
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Figure 4.11 Effect of temperature on aggregate formation caused by sonication 
(a) ThT fluorescence enhancement after 40 sonication cycles for β-lactoglobulin (█) and 
BSA (▨).  (b) ThT fluorescence enhancement after 20 sonication cycles for lysozyme (█) and 




4.3.7 GSH effects on amyloid formation  
Free radical mediated oxidation of free amino acids and amino acid residues in 
proteins has been studied and these modifications are recognized as a form of protein damage 
(Stadtman & Levine, 2003).  The involvement of free radicals in protein damage upon 
sonication was investigated further here using the free radical scavenger, GSH, a tripeptide 
antioxidant.  GSH plays an important role in guarding against ROS in living cells by acting 
as an electron donor to reduce ROS (Hayes & McLellan, 1999).  After reduction, GSH is 
oxidized to form GSSG (Owens & Belcher, 1965).  As a strong free radical scavenger, GSH 
was therefore added to the protein samples, BSA, hisactophilin and β-lactoglobulin, prior to 
sonication in order to examine the involvement of free radicals in protein aggregation.  Fig. 
4.12 shows that amyloid formation, as monitored by increased ThT fluorescence for BSA, β-
lactoglobulin, and hisactophilin, is completely inhibited by the presence of 1 mM GSH 
during sonication.  This is clear evidence that free radicals from cavitation are significantly 



























































































Figure 4.12 Effect of GSH on sonication-induced aggregate formation for BSA, β-
lactoglobulin, and hisactophilin 
(a) Fluorescence intensity of ThT alone (—), ThT with unsonicated BSA (—), ThT with 
BSA sonicated for 20 cycles at RT (—) and ThT with BSA and GSH mixture sonicated for 
20 cycles at RT (—).  (b) Fluorescence intensity of ThT alone (—), ThT with unsonicated β-
lactoglobulin (—), ThT with β-lactoglobulin sonicated for 20 cycles at RT (—) and ThT with 
β-lactoglobulin and GSH mixture sonicated for 20 cycles at RT (—).  (c) Fluorescence 
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intensity of ThT with unsonicated hisactophilin (—), and ThT with hisactophilin and GSH 
mixture sonicated for 20 cycles at RT (—).   
 
4.3.8 Sonication of mixed protein solutions 
When sonication is used for food processing, for example for mayonnaise preparation 
and meat processing, different proteins exist together during sonication.  In order to 
investigate the possible effects of these processes and the way two different proteins behave 
was studied when they are sonicated together.  Lysozyme was chosen as a primary protein 
since Fig. 4.8 shows evidence for substantial modification (cleaved backbone polypeptide 
chain) induced by sonication, which may promote interaction with another protein.  Fig. 4.13 
shows that when lysozyme is sonicated for 20 cycles with myoglobin and BSA, there is no 
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Figure 4.13 Sonication of mixed protein solutions 
Lysozyme and myoglobin (a), lysozyme and BSA (b) were sonicated for 20 cycles at RT and 
then analyzed by SDS-PAGE.  In (a), bands are observed for lysozyme and myoglobin before 
sonication (lanes 1 and 2, respectively), and sonicated lysozyme with myoglobin (lane 3).  In 
(b), the samples are BSA before sonication (lane 1), sonicated lysozyme with BSA (lane 2), 
and lysozyme before sonication (lane 3).   
 
4.4 Discussion 
The use of sonication has received increased attention over the last decade for 
enhancement of various processes in a range of different fields including biotechnology, 
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medical application and food industry.  On the other hand, possible damage induced by 
sonication had been received less attention.  Stathopulos et al. (2004) studied the effects of 
sonication on proteins for the first time systematically and reported that sonication of 
proteins can cause formation of amyloid-like aggregates (Stathopulos et al, 2004).  The 
results presented in this chapter can advance the findings of Stathopulos et al. (Stathopulos et 
al, 2004), in that sonication of proteins results in amyloid formation, free radical mediated 
modifications, including non-physiological dimer formation, fragmentation, and chain 
cleavage, and protein unfolding.   
 
4.4.1 Sonication induces amyloid-like aggregates. 
Previously, sonication has been shown to induce the amyloid formation of BSA, 
myoglobin, lysozyme, hisactophilin, holo SOD1, β2-microglobulin and TTR (Misumi et al, 
2008; Ohhashi, Kihara, Naiki & Goto, 2005; Stathopulos et al, 2004).  For current work, a 
more controlled sonication procedure was used to investigate if sonication is a sole effect on 
amyloid formation and the result confirms that sonication of structurally diverse proteins, 
BSA, myoglobin, lysozyme, hisactophilin, holo SOD1 and β-lactoglobulin, cause amyloid 
formation (Fig. 4.4 and Table 4.2).  Additional evidence of amyloid formation upon protein 
sonication was provided including aggregate morphology, increase in β components in 
secondary structure, dye binding assays using amyloid specific dyes, ThT and Congo Red, 
and seeding effects (Stathopulos et al, 2004).  It is important to note that Stathopulos et al. 
observed a mixture of morphologies for aggregates by TEM, some of which are clearly 
amyloid-like smooth fibrillar structures, but others are amorphous (Stathopulos et al, 2004).  
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Observation of amorphous aggregates implies another possible toxic mechanism of 
sonication as such aggregates are more related to toxic species than mature aggregates (Chiti 
& Dobson, 2006).  Interestingly, none of the proteins used in current work are associated 
with amyloidosis, except for lysozyme; two mutants of lysozyme are known to be amyloid 
precursors that are implicated in the pathogenesis of non-neuropathic amylodosis (Pepys et 
al, 1993; Zalin et al, 1991).  This is consistent with the observation that any protein is able to 
form amyloid in vitro under destabilizing conditions (Chiti et al, 2003b).  Remarkably, the α 
helical proteins, BSA and myoglobin can also form amyloid by sonication, such that the α 
helical structure in the proteins are converted to β structure upon sonication.  Together, these 
findings confirm that sonication can promote amyloid-like aggregates of various proteins, 
unrelated to amyloid disease and having diverse sequences as well as structures.   
This chapter shows ways of decrease initial amyloid formation, in that the use of 
more controlled sonication procedure, less cycles of sonication (Table 4.2), lower incubation 
temperature (Fig. 4.11), and GSH addition (Fig. 4.12) can decrease amyloid formation.  
However, post-sonication amyloid formation is an issue of using sonication, which can be 
promoted by unfolded proteins by sonication and/or initial aggregates (seeding) (Fig. 4.9).  
Partially unfolded proteins are considered to be responsible for many different protein 
aggregation processes (Booth et al, 1997; Chiti et al, 2001; Hamada et al, 2009; Wiseman, 
Powers & Kelly, 2005).  Thus, extreme sample conditions (e.g., increased temperature, 
extreme pH, and addition of chemicals to induce oxidizing condition) have frequently been 
associated with protein aggregation.  For example, myoglobin and lysozyme can form 
aggregates at high temperature (Fandrich et al, 2003b; Morozova-Roche et al, 2000) and 
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SOD1 can form aggregates in Cu medicated oxidizing solution conditions (Rakhit et al, 
2004) and in low pH (Stathopulos et al, 2003).  In fact, MS data and trypsin digestion pattern 
of sonicated proteins provide evidence that there are proteins unfolded even if there is no 
sonochemical modifications observed.  Therefore, sonication enhances formation of unfolded 
protein species that may more readily unfold and the protein species are responsible for post-
sonication aggregation.  Thus, addition of stabilizing agents to help refolding after sonication 
can be considerate to prevent post-sonication amyloid formation. 
 
4.4.2 Free radical effects on protein damages upon sonication 
The experimental results herein support the notion that free radical mediated reaction 
can cause protein modifications upon sonication.  Free radicals can be produced during 
sonication due to hydrolysis of water molecules by extremely high temperature and high 
pressure that are created by cavitation.  Sonochemistry is the field making use of free radicals 
from cavitation (Timothy J. Mason & Peters, 2002).  However, reactions involving free 
radicals are known to cause diverse chemical modifications on proteins.  These include 
peptide bond cleavage, site-specific metal-catalyzed oxidation, oxidation of aromatic amino 
acid and methionine, and protein-protein cross-linking using tyrosine and cysteine (Stadtman 
& Levine, 2003).  Thus, it is conclusive that non-physiological dimer formations of 
myoglobin and β-lactoglobulin, fragmentation of myoglobin, lysozyme and β-lactoglobulin 
(Fig. 4.5 and Fig. 4.7), and chain cleavage of lysozyme (Fig. 4.3) are mediated by free radical 
reactions.  In particular, non-physiological dimer formation occurs via cysteine and tyrosine 
cross-linking.  A previous study showed that non-native disulfide bond formation during 
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thermal unfolding of β-lactoglobulin can lead to polymerization of the protein.  During 
heating, the native dimer was first dissociated, and then partial unfolding monomer exposes 
the free thiol group (Cys 121) to solvents (Prabakaran & Damodaran, 1997).  The thiol group 
in a monomer of β-lactoglobulin started to form intermolecular disulfide bonds (Prabakaran 
& Damodaran, 1997).  Thus, if sheer stress, local heating, and/or free radical reactions can 
dissociate dimer of β-lactoglobulin and unfold the monomers, then the free thiols (Cys 121) 
can be exposed and then form intermolecular disulfide bonds.  However, it is not precluded 
that free radical can attack the solvent exposed intramolecular disulfide bond (C66-C160), 
resulting in thiyl radicals, which can form intermolecular disulfide bond with a thiyl radical 
on another monomer.  Myoglobin has been shown to facilitate two Tyr residues, Tyr 103 and 
Tyr 151 for non-physiological dimer formation (Tew & Demontellano, 1988).  Typically, 
solvent exposed Tyr 151 is a primary target by free radicals (Tew & Demontellano, 1988).  
Thus, it is possible that the observed non-physiological dimer of myoglobin upon sonication 
is formed by these two Tyr residues (Tyr 103 and Tyr 151).  Moreover, backbone cleaved 
lysozyme (Fig. 4.8) and fragments of proteins (Fig. 4.5) are more evidence of protein damage 
induced by free radicals from sonication (Stadtman & Levine, 2003).  However, currently 
available data cannot provide site specific information of chain cleavage and fragmentation 
of the proteins.  Importantly, such modifications can promote amyloid formation via newly 




4.4.3  Possible sonication mechanism of protein damage 
Cavitation generated by sonication is mainly responsible for protein damage.  When 
microbubbles collapse, sheer stress from shock waves and microstreaming is induced as well 
as free radicals, extremely high temperatures and pressure (Timothy J. Mason & Peters, 
2002).  The net effects are sufficiently powerful to alter protein structure.  For example, as 
seen in Table 4. 3, sonication at RT and 40 °C can increase solution temperatures up to 65.5 
°C, which can induce protein unfolded, for instance, lysozyme with a Tm of 61.5 °C.  
Therefore, local heating by sonication can damage protein, since high temperature itself can 
induce amyloid formation (Fandrich et al, 2003b; Morozova-Roche et al, 2000).  Sonication 
at a 4.5 °C can increase the temperature of a solution only up to 30 °C (Table 4.3) and 
decrease in amyloid formation is observed (Fig. 4.11).  The sheer effect has been recognized 
as the main mechanism of breaking existing aggregates (Chatani et al, 2009).  Breaking 
existing aggregates can induce further aggregation indirectly by generating seeds (Saborio, 
Permanne & Soto, 2001).  Importantly, addition of free radical scavenger can inhibit amyloid 
formation almost completely (Fig. 4.12).  Therefore, free radicals appear to play an important 
role for the induction of amyloid formation.  However, it is not clear whether the free radical 
scavenger can completely prevent protein unfolding, which can be induced by sheer stress 
and local heating without free radical reactions.  Nevertheless, at least adding a free radical 
scavenger can inhibit initial aggregation.  Taken together, high temperature, sheer stress, and 
free radical reactions all affect initial amyloid formation induced by sonication. 
The results presented here show that protein damage induced by sonication varies 
among the examined proteins, however, there is some correlation.  By comparison of ThT 
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fluorescence enhancement among different proteins (Table 4.2), β components in a native 
structure play an important role with amyloid formation, in that the most ThT enhancements 
by sonication are observed by β-structure rich proteins, holo SOD1 (40 cycles) and 
hisactophilin (20 cycles) regardless of melting temperature of proteins.  Also, the number of 
Cys residues contributes to protein damage by sonication, since BSA forms significant 
amounts of aggregates although the protein contains all α-helical structure but BSA has 17 
disulfide bonds and 1 free Cys residue.  This is probably because free radicals target Cys 
residues, resulting in promoting amyloid formation.   
 
4.4.4 Potential risks of sonication 
Although sonication is commonly used in various fields, there has been very little 
investigation of the detailed effects of sonication at the molecular level on proteins with the 
exception of a few studies (Krishnamurthy et al, 2000; Ohhashi, Kihara, Naiki & Goto, 2005; 
Stathopulos et al, 2004).  The observations reported here including amyloid formation, 
protein unfolding, post-sonication amyloid formation, and free radical mediated modification 
provide important new data concerning the effects of sonication on proteins.  The findings 
further support that caution is warranted when applying sonication to food and the human 
body (Stathopulos et al, 2004) even though prion aggregate is the only amyloid form that is 
known to be infectious to date, the relation between sonication for any medical purpose and 
amyloidosis has not been reported, and sonication equipment for diagnostic imaging is not 
designed for cavitation.  In particular, ultrasound contrast agents have been developed 
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whereby gas or fluorinated compounds are encapsulated in sonicated spheres of serum.  
These agents have applications for imaging blood flow (Ferrara, Pollard & Borden, 2007).  It 
is possible that formation of amyloid may occur during generation of the contrast agents, but 
not be detected, and perhaps subsequently grow by seeding effect in blood.  Therefore, 
further examination of the influence of sonication on protein in the living body with respect 
to protein aggregation and/or amyloid formation is warranted.  The findings provide useful 
information to prevent amyloid formation directly and indirectly such as addition of free 
radical scavenger agents, decrease incubation temperature, use minimum cycles of 
sonication, and addition of stabilizing agents after sonication.  In summary, experimental 
results reported here advance further understanding of sonication and controlling the 





Summary and future work 
5.1 Key findings of this thesis  
5.1.1 Aggregation from holo SOD1 
Pathological aggregates formed from the native, holo state of SOD1, with or without 
ALS-associated mutations, under physiologically relevant solution conditions (37 °C and pH 
7.8) were characterized in chapter 2 and chapter 3 using light scattering techniques.  In 
particular, the free-thiol free form of holo SOD1 (pWT, C6A and C111S) was used as a 
reference state (control) to avoid formation of non-physiological intermolecular disulfide 
bonds during aggregation, which has been shown to be a secondary effect in the progression 
of ALS (Karch et al, 2009).  The aggregation profiles of pWT as well as ALS-related mutant 
SOD1s in this background showed a sigmoidal profile having a lag phase, an exponential 
phase, and a plateau phase, implying that the aggregation is nucleation dependent (Fig. 2.2).  
Lag phase comparison showed that dimer interface mutants and metal binding mutants tend 
to have shorter lag phases than pWT (Fig. 2.5).  Moreover, ALS associated mutants of SOD1 
did not aggregate more readily than pWT, which may explain that why 90% of ALS cases are 
sALS and sALS have similar onset and duration of the disease with some of fALS cases.  
Mechanistic details of aggregation (dimer dissociation and partial metal loss, scheme 2.1) 
were elucidated, based on experimental results including the observed lag times for different 
holo SOD1s (Fig. 2.5), the moderate protein concentration dependence of lag time (Fig. 2.8), 
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binding of the dimer interface-specific antibody, SEDI, to the aggregates (Fig. 2.14), 
decreases in specific activity during aggregation time courses (Fig. 2.6), and metal analysis 
of aggregates (Table 2.1).  In addition, seeding and cross seeding was found to decrease the 
lag phase for aggregation analogous to what has been observed for aggregation of other 
proteins associated with misfolding diseases (Harper & Lansbury, 1997; Prusiner, 1998).  
The data fitting using the hyperbolic cosine function as well as AFM images indicates that 
heterogeneous nucleation is the underlying mechanism for holo aggregation (Fig.2.10 and 
2.11).  This may explain the relatively quick disease progression of ALS.  AFM revealed a 
range of aggregate morphologies, including oligomers, protofibrils, amorphous aggregates 
and fibrillar aggregates.  Also, it appears that Cu mediated aberrant chemistry is not an 
important factor in promoting the aggregation (Fig. 2.7).  Most importantly, the data in 
chapter 2 show that the aggregates have common structural, tinctorial (distinct from amyloid, 
Fig. 2.13) as well as immunological characteristics as aggregates formed in ALS patients 
(Fig. 2.14), supporting that the observed aggregation is medically relevant.   
Chapter 3 provided further experimental evidence for the findings in chapter 2 that 
dimer dissociation and/or metal loss promote aggregation from holo SOD1s.  Various 
structural probes (intrinsic fluorescence, CD, UV absorbance and FTIR) were used in this 
chapter.  Aggregation profiles monitored using intrinsic fluorescence suggest that there is no 
major change in the environment of the single solvent exposed Trp residue during 
aggregation (Fig. 3.8).  CD and UV absorbance measurements at various time points during 
holo SOD1 aggregation revealed multiple pathways of aggregation (Fig. 3.10, 3.11, and 
3.12).  In particular, the UV measurements suggest that the proteins lose Cu during the 
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exponential phase.  In addition, the proposed heterogeneous nucleation described in chapter 2 
was investigated further by comparing log (AB
2
) and log (B
2
) among different mutants of 
SOD1 (see Eq. 3.17 and 3.18).  The comparison indicated that dimer interface mutants and 
metal binding mutants have bigger log (AB
2
) and log (B
2
) values, implying that dimer 
dissociation and metal loss are required for the nucleation events.  Unlike aggregation of 
other proteins whose structure changes significantly upon aggregation (Booth et al, 1997; 
Fandrich et al, 2003a; Padrick & Miranker, 2002; Ruschak & Miranker, 2007), FTIR 
measurements of plateau phase SOD1 aggregates (Fig. 3.15) show no significant structural 
change (i.e., the aggregation does not occur from unfolded protein).  Similar aggregation for 
other proteins from a native-like state is increasingly being recognized (Chiti & Dobson, 
2009; Yamasaki, Li, Johnson & Huntington, 2008).  However, the comparison of FTIR-
monitored thermal unfolding of aggregated and control samples revealed destabilization of 
the aggregated sample, likely due to altered metal binding (Fig. 3.16).  Based on the 
combined intrinsic fluorescence, CD, and UV experimental results (Fig. 3.8, 3.10, 3.11 and 
3.12) as well as metal analysis of final aggregates, analysis of aggregation profiles in terms 
of duration, and final light scattering intensity (Fig. 3.14) two different aggregation pathways 
was propsed (Scheme 3.1).  In one pathway, the aggregation profiles exhibit shorter 
durations, lower final intensities, and aggregates with more Cu ions than Zn ions.  The other 
aggregation pathways exhibit longer durations, higher final intensities, and aggregates with 
more Zn ions than Cu ions.  However, the trigger(s) that direct the aggregation to different 




Due to the high stability of the holo form of SOD1s, it has been thought to be 
incompatible with aggregation (Shaw & Valentine, 2007).  Also, previous in vitro 
aggregation studies have failed to report aggregation from holo SOD1s (Banci et al, 2007b; 
Chattopadhyay et al, 2008).  The results presented here can be considered to be different 
from the previous studies; however, various experimental factors are found to be reasons for 
the different observation of aggregation (see Results, section 2.3.1.1).  Nevertheless, there is 
some evidence of aggregation from the holo state found in the NMR study (Banci et al, 
2005) and other studies (Oztug Durer et al, 2009; Rumfeldt et al, 2006).  More interestingly, 
many previous studies have shown that loss of metals, either Cu or Zn ions, can promote 
aggregation by various pathways (DiDonato et al, 2003; Estevez et al, 1999; Rakhit et al, 
2002; Roberts et al, 2007).  Taken together, the results obtained here are consistent with 
previous studies.  Furthermore, specific antibody binding to aggregates formed by purified 
SOD1 and in the disease (see Results, section 2.3.5) was demonstrated for the first time, 
suggesting the aggregation from holo SOD1 is closely related to disease mechanism(s) of 
ALS. 
 
5.1.2 Sonication-induced aggregation 
Chapter 4 described damage induced by sonication of structurally diverse proteins.  
The experimental conditions were changed relative to previous studies in the Meiering lab 
(Stathopulos et al, 2004) in order to minimize denaturation caused by foaming (see Materials 
and Methods Section 4.2.1).  This chapter showed that sonication of proteins can induce 
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amyloid formation, which was detected by enhancement of ThT fluorescence (Fig. 4.4 and 
Table 4.2). The ThT fluorescence enhancement upon sonication, i.e., amyloid formation, 
decreased when sonication was performed at lower temperature (4.5 °C, Fig. 4.11) and with 
addition of free radical scavenger (GSH, Fig. 4.12).  These results suggest that local heating, 
sheer stress and free radicals created by cavitation are the main cause of damage due to 
sonication.  The involvement of free radical-induced damage was further indicated by 
observation of free radical-mediated modification (non-physiological dimerization, 
fragmentation, and backbone cleavage) and protein unfolding detected by MS, SDS-PAGE 
and trypsin digestion (Fig. 4.5, 4.6, 4.7, and 4.8).  The observation of additional aggregate 
formation after sonication indicates that the initial aggregates and/or unfolded proteins 
formed during sonication may promote further amyloid formation (Fig. 4.9).  Thus, addition 
of stabilizing agents after sonication may be useful to prevent post-sonication amyloid 
formation.  Proteins having a higher proportion of native β structure and/or more free thiols 
(or disulfide bonds) are more vulnerable to sonication-induced damage.   
Although use of sonication has been received great attention, very little is known 
about sonication and sonication-induced protein damage.  Here, chapter 3 extends previous 
studies from the Meiering laboratory (Stathopulos et al, 2004), with aim of better 
characterization of the mechanism of sonication-induced aggregation and effects on different 
proteins.  The experimental results in this chapter can provide reasons why caution should be 
taken when using sonication, in particular for medical and food industrial applications, and 




5.2 Medical implications 
The aggregation studies in chapter 2 and 3 have shown that aggregation is formed 
from holo SOD1s, is facilitated by dimer dissociation and involves changes in metal 
bindings.  These findings provide possible strategies to prevent the aggregation, and, 
therefore, the disease.  First, the holo form of SOD1 is newly recognized in this thesis to be 
important species in the disease progression.  Thus a possible strategy is to stabilize the holo 
state of the protein.  For example, finding small molecules to stabilize the SOD1 dimer 
and/or two metal binding loops would be one of possibilities.  A previous study found 15 
drug-like molecules out 1.5 million molecules from commercial databases to inhibit in vitro 
aggregation of partially metallated SODls by stabilizing the dimer of SOD1 (Ray, Nowak, 
Brown & Lansbury, 2005).  Unfortunately, there are no subsequent studies; however, these 
findings can provide possible compounds to try into the aggregation system.   
Aggregates formed from holo SOD1s possess very similar properties from those 
observed in the patients such as morphologies and tinctorial and antibody binding 
characteristics (see Discussion, section 2.4.1).  This implies that the aggregation system 
developed in chapter 2 and 3 has a great potential for a model system to better understand 
disease mechanism(s) of ALS.  Readily available potential toxic species can be used for 
antibody development(s).  Previously, an immunization using purified anti-human mutant 
SOD1 antibody showed promising initial results with alleviating disease symptoms and 
prolonging the life span of G93A SOD1 mice.  If finding the toxic species from the system is 
successful, the outcome would be more promising.  However, caution should be followed 
when considering an immunotherapy for ALS patients.  When immunotherapy was applied 
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to Alzheimer’s disease patients, the side effect, T-lymphocyte meningoencephalitis, was 
reported (Nicoll et al, 2003), although vaccination with amyloid-β results in clearance of 
amyloid plaques in patients and the mice models (Bard et al, 2000; Morgan et al, 2000; 
Nicoll et al, 2003; Schenk et al, 1999).   
 Although the studies of aggregation formed from the holo state provide significant 
potential and different avenues for ALS research and/or general aggregation fields, 
aggregation parameters (e.g., lag phase or final plateau intensity) obtained from the 
experimental results herein did not clearly correlate to disease characteristics (e.g., disease 
onset and/or duration).  It seems likely that many different states of SOD1s (with regard to 
metallation and/or intramolecular disulfide bond formation) can be involved in progression 
of ALS and these states of SODls have different effect on different hSOD1 mutants 
associated with fALS.  Thus, further research with more mutants and/or different metallation 
of SOD1s will advance understanding of SOD1 aggregation in ALS. 
 
5.3 Future directions 
5.3.1 Aggregation from holo SOD1 
There are a number of avenue for future research that are important to pursue in order 
to better understand aggregation arising from holo SOD1.  An initial objective is to find more 
direct evidence to support or disprove the proposed aggregation mechanisms involving 
various modes of metal loss (Scheme 3.1).  First, aggregation can be investigated with 
partially metallated states, more mutants, for example for ones that alter metal binding or the 
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dimer interface, more disease associated mutants and non-disease associated mutants.  In 
particular, metal binding site mutants (e.g., the Zn ligand mutation, H80R, and the copper 
ligand mutation, H46R) could be used to analyze effects of altering different metal binding.  
For example, if the proposed aggregation mechanisms (Scheme 3.1) are correct, H46R 
aggregation should exhibit long duration and high final intensity as a consequence of loss of 
Cu binding.  In the proposed aggregation mechanism, the electrostatic loop and the Zn 
binding loop play important roles in dimer dissociation and metal loss.  Additional studies 
with structure-specific antibodies (such as SEDI) could be very valuable. For example, it 
would be interesting to analyze antibody binding throughout the aggregation time course.   
Investigating aggregation from the holo state of SOD1 in reduced conditions would 
be another reasonable experiment since the cytosol is a reducing environment.  All the 
experiments described in chapter 2 and 3 were performed on pWT, free-free cysteines 
(C6A/C111S).  Thus, a comparison of the aggregation behavior of wild type to that of pWT 
would provide useful information of a role for intermolecular disulfide bonds.  Comparing 
the in vivo results (i.e., formation of intermolecular disulfide bonds is the secondary effect on 
disease process) would be useful as well.  Another avenue for investigation is the effect of 
solution agitation, and whether mechanical stress and/or air/water interface modulate 
aggregation.   
Since the SOD1 can exist in various forms that differ in metallation as well as 
disulfide status (reduced or oxidized, cross-seeding of different aggregates formed from 
different SOD1 species can provide useful information for understanding complexity in ALS.  
Some of these studies are ongoing in the Meiering lab.  In addition, experiments assessing 
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the toxicity of the different species formed during aggregation (e.g.., from the lag phase or 
exponential phase) can provide insight into the roles of different species in initiating or 
propagating disease.  From these findings, urgently needed therapeutic strategies for ALS can 
be developed to target the critical species to inhibit or reverse protein aggregation.   
 
5.3.2 Sonication 
 Future experiments on sonication- induced protein damage could be aimed at 
determining details of sonication-induced damage mechanism between free radical mediated 
reactions, shear stress and local heating as well as additional ways to inhibit damage.  
Sonication of proteins under different solution conditions such as different pH, ionic strength 
and/or adducts can provide more information on the mechanism of the sonication effect.  In 
addition, seeding experiments using the aggregates formed by sonication and soluble proteins 
may have significant consequences on the use of ultrasound in medicine and industry.  It 










This is a sample Appendix. Insert additional appendices with the ―Start New Appendix‖ command. 
Some of initial sequential addition; monomers attach on the surface of an existing aggregate for the 
heterogeneous nucleation, can be written in the group of chemical reaction and formulas: 
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           Eq. A1 
 
where Px (x > j, j is the size of heterogeneous nucleation) A and Kx represent an existing aggregate 
with association of x-mers on its surface, the monomer and the equilibrium constant of the formation 
of Px, respectively.  Before the nucleation, the reaction is reversible and, therefore, favored to 
dissociation (i.e., the length of the arrows represent relative size in the rate constants.).  Now, let us 
assume that j-mer (the association of (j-1) numbers of A) is the heterogeneous nucleation.  Therefore, 
the chemical reaction, Kj and the concentration of Pj can be written as: 
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If we define a heterogeneous polymer (CP2) as any species of size (j+1) or larger with the assumption 
that the rate constant of additions and dissociations of monomers during the formation of aggregates 
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Heterogeneous nucleation 2  
The two hypothetical-equilibrium processes are considered as the alternative pathway of formation of 
Pj: (1) the formation of free j-mer in solution; (2) the attachment of this j-mer onto the surface of an 
aggregate.  Fig. 3.2 illustrates the first step in the chemical reaction: 
 
jA                  Cj         Eq. B1 
 
where A and Cj represent the monomer and j-mer in solution phase, respectively.  The equilibrium 
constant (
~
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      Eq. B3
 
 
where  is a scale factor that determines the member of available nucleation sites per a polymerized 
monomer, [Pjt] is  the total concentration of available sites for attaching a solution phase j-mer, and  
is the equilibrium constant for attaching a solution phase j-mer to the polymer surface.  Also the last 
term is simplified with assumption; 1 >> ][ jj CK .  Therefore, [Pj] can be rewritten using Eq. B3 as: 
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where  is a scaling factor that determines the number of available nucleation sites per 
polymerized monomer and A0  and A are the protein concentration initially and during aggregation, 
respectively.   
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Langmuir isotherm derivation from equilibrium consideration 
 
V-*       +        G(g)                                            V-G 
Where, V-* represents vacant surface site and G(g) represents gas.  The equilibrium of chemical 







         Eq.C1 
 
However, using the new term, ( , the surface coverage), defining another equilibrium constant b is 







          Eq.C2 
 
where [V-G] is replaced by (θ) because it is proportional to the surface coverage of adsorbed 
molecules, [V-*] is replaced by (1-θ) because it is proportional to the number of vacant sites,  and [G] 






Eq. 3.16 simplification 
The rate equation for the disappearance of the native proteins from the solution phase into 
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